var title_f5_34_5664="6-MP metabolism";
var content_f5_34_5664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    6-mercaptopurine metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 447px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial metabolism of 6-mercaptopurine occurs along the competing routes catalyzed by thiopurine methyltransferase (TPMT), xanthine oxidase (XO), and hypoxanthine phosphoribosyltransferase (HPRT). Further metabolism of the thionucleotide is catalyzed by inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase (GMPS). The diphosphates and triphosphates are formed by their respective monophosphate (MPK) and diphosphate (DPK) kinases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cuffari C, et al. Gut 1996; 39:401. Copyright 1996 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5664=[""].join("\n");
var outline_f5_34_5664=null;
var title_f5_34_5665="Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction";
var content_f5_34_5665=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"TIMI_UA_NSTEMI_form\" name=\"TIMI_UA_NSTEMI_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Age &gt;=65 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           3 or more CAD risk factors (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Known CAD with more than 50% stenosis (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Aspirin use in the past 7 days (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe angina in the preceeding 24 hours (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Elevated cardiac markers (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"TIMI_UA_NSTEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           ST deviation greater than 0.5 mm (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          TIMI Score and 2 week Death / MI Risk ** Death / MI / Urgent Revasc Risk Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-1 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           3% ** 5%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           3% ** 8%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           5% ** 13%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           4 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           7% ** 20%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           5 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           12% ** 26%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_6\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           6-7 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           19% ** 41%",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Antman EM, Cohen M, Bernink PJ, et. al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.",
"        <i>",
"         JAMA",
"        </i>",
"        . 2000 Aug 16;284(7):835-42.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"TIMI_UA_NSTEMI_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5665=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function TIMI_UA_NSTEMI_fx() {",
"with(document.TIMI_UA_NSTEMI_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 1)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 2) && (Score <= 2)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 3)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 4) && (Score <= 4)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 5) && (Score <= 5)){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"if ((Score >= 6) && (Score <= 7)){ document.getElementById('rr1_6').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"document.getElementById('rr1_6').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f5_34_5665=null;
var title_f5_34_5666="Patient information: Tachycardia (The Basics)";
var content_f5_34_5666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/40/19075\">",
"         Patient information: Sick sinus syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/17/33042\">",
"         Patient information: Vagal maneuvers and their responses (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tachycardia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tachycardia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10515875\">",
"      <span class=\"h1\">",
"       What is tachycardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Tachycardia&rdquo; is the medical term for a heartbeat that is faster than normal. Sometimes, a fast heartbeat is a normal response to exercising or feeling very worried. But other times, a fast heartbeat is a sign of another problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515890\">",
"      <span class=\"h1\">",
"       What causes tachycardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Exercising or feeling worried, stressed, or afraid can all cause tachycardia.",
"     </p>",
"     <p>",
"      Other things that can cause tachycardia include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having too many drinks with caffeine, such as coffee, tea, or soda",
"       </li>",
"       <li>",
"        Smoking or using chewing tobacco",
"       </li>",
"       <li>",
"        Taking certain illegal drugs, such as cocaine",
"       </li>",
"       <li>",
"        Having a fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Problems with your heart&rsquo;s electrical system can also cause tachycardia. Some people are born with these problems. Other people get them because of high blood pressure, a heart attack, or other heart problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515907\">",
"      <span class=\"h1\">",
"       What are the symptoms of tachycardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with tachycardia have no symptoms. But they might notice that their heart is beating fast, beating hard, or seems to skip a beat. These kinds of heartbeat changes are called &ldquo;palpitations.&rdquo;",
"     </p>",
"     <p>",
"      Sometimes, a fast heartbeat makes it harder for your heart to pump blood to your body. This can cause symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Fainting",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515922\">",
"      <span class=\"h1\">",
"       Is there a test for tachycardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will probably do a test called an electrocardiogram. This test, also known as an &ldquo;ECG&rdquo; or &ldquo;EKG,&rdquo; measures the electrical activity in your heart.",
"     </p>",
"     <p>",
"      You might also need other tests to see if another condition is causing your fast heartbeat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515937\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have trouble breathing or have chest pain that lasts for more than a few minutes, call 9-1-1 for an ambulance.",
"     </p>",
"     <p>",
"      If you do not have these problems, but you often feel your heart beating fast or irregularly, talk to your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515952\">",
"      <span class=\"h1\">",
"       How is tachycardia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the cause of the tachycardia. When your heartbeat is very fast, your doctor might suggest ways to slow it down. He or she might have you cough, or bear down as if you&rsquo;re having a bowel movement. He or she might also put an ice pack on your face. Doing these things can affect the nerve that helps control your heartbeat.",
"     </p>",
"     <p>",
"      Other treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to control the speed or rhythm of your heartbeat",
"       </li>",
"       <li>",
"        A treatment called &ldquo;cardioversion&rdquo; that involves applying a mild electrical current to the heart to fix its rhythm",
"       </li>",
"       <li>",
"        A device called an &ldquo;implantable cardioverter defibrillator&rdquo; (&ldquo;ICD&rdquo; for short) that the doctor can put in your body. The ICD can help make your heart rhythm normal using mild electrical currents.",
"       </li>",
"       <li>",
"        A device called a pacemaker that the doctor can put in your body. The pacemaker sends electrical signals to your heart to control your heartbeat.",
"       </li>",
"       <li>",
"        Treatments called &ldquo;ablation.&rdquo; Ablation treatments use heat (called &ldquo;radiofrequency ablation&rdquo;) or cold (called &ldquo;cryoablation&rdquo;) to destroy the small part of the heart that is sending the abnormal electrical signals.",
"       </li>",
"       <li>",
"        Surgery to create scar tissue in the heart. This will block the flow of the electrical signals that make your heart beat abnormal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515967\">",
"      <span class=\"h1\">",
"       Can tachycardia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If drinking too much caffeine or smoking caused your tachycardia, stopping those habits can prevent the problem.",
"     </p>",
"     <p>",
"      Heart disease can increase your chance of having tachycardia. Doing things that keep your heart healthy can help. This includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eating lots of fruits and vegetables and low-fat dairy products, but not a lot of meat or fatty foods.",
"       </li>",
"       <li>",
"        Walking or doing a physical activity on most days of the week.",
"       </li>",
"       <li>",
"        Losing weight, if you are overweight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515982\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"       Patient information: Sick sinus syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"       Patient information: Vagal maneuvers and their responses (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/34/5666?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16998 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-E02CFC2FE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5666=[""].join("\n");
var outline_f5_34_5666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515875\">",
"      What is tachycardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515890\">",
"      What causes tachycardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515907\">",
"      What are the symptoms of tachycardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515922\">",
"      Is there a test for tachycardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515937\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515952\">",
"      How is tachycardia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515967\">",
"      Can tachycardia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515982\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=related_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5667="Glomus tumor subungual 1";
var content_f5_34_5667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Subungual glomus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: Red flush of the nail bed induced by a subungual glomus tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5667=[""].join("\n");
var outline_f5_34_5667=null;
var title_f5_34_5668="Fat emulsion: Patient drug information";
var content_f5_34_5668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fat emulsion: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=see_link\">",
"     see \"Fat emulsion: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=see_link\">",
"     see \"Fat emulsion: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to aid diet needs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fat emulsion or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eggs or soybeans, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Irritation of the pancreas or very high cholesterol.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12433 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5668=[""].join("\n");
var outline_f5_34_5668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026078\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026077\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026082\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026083\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026085\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026080\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026081\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026086\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026087\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=related_link\">",
"      Fat emulsion: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=related_link\">",
"      Fat emulsion: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5669="Insulin glargine: Patient drug information";
var content_f5_34_5669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin glargine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     see \"Insulin glargine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"     see \"Insulin glargine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2114346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lantus&reg;;",
"     </li>",
"     <li>",
"      Lantus&reg; Solostar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lantus&reg;;",
"     </li>",
"     <li>",
"      Lantus&reg; OptiSet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix this insulin in the same syringe with other types of insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699214",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened cartridges and pens at room temperature. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11545 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5669=[""].join("\n");
var outline_f5_34_5669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186124\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018680\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018679\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018684\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018685\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018687\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018682\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018683\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018688\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018689\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=related_link\">",
"      Insulin glargine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=related_link\">",
"      Insulin glargine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5670="Topotecan: Patient drug information";
var content_f5_34_5670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Topotecan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     see \"Topotecan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20822?source=see_link\">",
"     see \"Topotecan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;;",
"     </li>",
"     <li>",
"      Topotecan For Injection;",
"     </li>",
"     <li>",
"      Topotecan Hydrochloride For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to topotecan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3445783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low white blood cell count, low platelet count, or very bad anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up after taking this drug, do not repeat the dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11171 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5670=[""].join("\n");
var outline_f5_34_5670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229294\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028359\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028361\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028360\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028365\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028366\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028368\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028363\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028364\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028369\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028370\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=related_link\">",
"      Topotecan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20822?source=related_link\">",
"      Topotecan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5671="LS SCC 1";
var content_f5_34_5671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71222%7EOBGYN%2F50192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71222%7EOBGYN%2F50192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus (LS) and squamous cell cancer (SCC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severely itchy vulvar LS with scarring, loss of vulvar architecture and thick indurated areas of SCC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus (LS) and squamous cell cancer (SCC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular plaque of LS around the vulva with periclitoral thickening and painful erosions on the left side. Biopsy site visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5671=[""].join("\n");
var outline_f5_34_5671=null;
var title_f5_34_5672="EPS tracing AVNRT dual AVN pathways I";
var content_f5_34_5672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 448px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHAAkEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivP7f4q6PdRu9npHii5WOVoJDFotwwSVW2tGTtwGDcEev0oA9Aorgz8TLHzCg8O+MWIGeNBufb/AGfcfnSJ8TrJ0DL4a8ZlSMgjQLjp6/d5oA72iuGPxKsF27/D/jBSxwAdAuuT+Cexp0PxJ0yUsBo3iwBSRn/hH7wjI6jiM98j8KAO3orjE+I+iugcWXiXYSBn/hHr4jnp/wAse+Rj6ipl+IGjMcLa+Izxnjw7qH/xj3H50AdbRXKf8J9o+SPsniTIGT/xTmocf+QKjl+IehwxmSaDxDHGCF3v4e1ADJOAM+R68fWgDr6K45PiNocjzJFa+I5HhYJKqeHr8lGKhgrfueDhlOD2YHvSH4iaWDgaV4qJ9B4dvv8A41QB2VFcSnxI0qRd0WleKpBgHK+Hr09ef+eXpg/jTz8RdLAy2leKlHqfDt7/APGqAOzorix8R9KO7bpfik7euPD179P+eXsfypD8RtNH3dG8Wt9PDt7/APG6AO1orhj8TNL3BU0fxY7HoB4fu+RxzzH7j8xR/wALJsj93w74wY+n9g3IPb1X3FAHc0VwE3xQsYYxJJ4c8XqhyATo0oyQGJGDzwFY/h9Ke3xJjBI/4RHxmcemkMc8kevtQB3lFcCPiZDgH/hEvGgB450ZxyenU+4/P2OFi+JltIoZPC/jMqQCD/YsuDkZ/l/nNAHe0VwTfEy1VGd/C/jJUXOSdEm4Azk9PY/5Iyn/AAs6zxkeGPGZ+bbxoc55zjrjHUGgDvqK89/4WnY7tv8AwjXjLIIUg6JN8pOMA8dfmX86c3xS09I1eXw54yjDsFXdoNxyT0A+XvQB6BRXBL8UNNIm3aD4uXyTiTOhXPycZ5wvpz9MetSr8SLA5zoHjBcevh+7/olAHcUVxA+JOll9h0jxWG9P+EfvM9v+mfuPzFJ/ws3Q/tEcBsvEnnyI0scf9g3m541KhnA8rJUb0ye29fWgDuKK4v8A4WNpeRnSvFQLHaAfD16MnBOB+69jUVp8TtFvbaK4sdP8S3VvNGssckOhXbq6N91gRHgg+vSgDuaK4g/EjTguToni0cgYOgXfU9P+WfuKUfEfTiSP7D8Xcdf+Kfu//jfuKAO2orh2+JFgN/8AxIfF529f+JBde/8Ase1R3PxR0i1tJrq60nxRDawK7yzSaJcqkarncWbZgAbTk9sUAd5RXDn4kWIOP7A8X59P7Auv/iKYfiZp4JzoHi7AYLk6Fcjk4wPu+4/P60Ad3RXn918U9MtLaa4u9C8WQW8EZmmll0SdFijAJLsSvAABJ+lTN8SLYOyDwz4vZkGWA0aXIHPt/smgDuqK4YfEaA52+F/GBAyMjR5OoOMfof8AOKYfiTCGAPhTxkAeQTpDgdQPX1I/P2OADvKK4NPiXbO5RfDHi8uDhlGkSZU4U4Ppwyn8fY4WT4k28asz+F/GIVQST/Y0uBjmgDu6K4CX4n2cK7pPDPjBVyRk6LKOgJP5BT+XHapx8RoM4/4RfxjuzjH9jS/z6dqAO4orgX+JtunLeFfGIXcqZOkOOWxgcn3H5/WkHxMiYZTwj41bp00d/QH19x/nNAHf0VwY+JMRVifCfjJSo3FTpLZxz7+x/L3GRPiVC2T/AMIp4yABIz/Y7nkHB6E9waAO8orhR8SrPcA3hzxgpPTOhXHsP7vuP85pE+JuntGH/wCEf8Y7TyD/AGBdHI9eE6UAd3RXCH4maeHdDoHi7ei72X+wrnIHOCfl6Ha35fSlPxJtQM/8I14x64/5AVxzzj+7QB3VFcJ/wsq0yijw14w3uCyqdEnBIGMnBHuPz+tMX4nWhXP/AAi/jUD/ALAM/pn0oA76iuEf4l2SDMnhzxiijqToVxgDnn7vsf8AOKF+Jdgc/wDFPeMQQcY/sC6Pt2T6/lQB3dFcQfiTpo+9oni5RnGT4evPw/5Z/T86F+JGmsqsui+LWU8gjw9ecj1/1dAHb0VxI+I+nf8AQD8Xf+E9ef8Axuum8P6xZa/otpqulytLZXcYkidkZCR7hgCPxoA0KKKKACiiigAooooA4zx945PhC+0a2Oh3+pNqtwLS3a2khUGY52od7rjIBOenvXZ1wnxJ8E6n4t1Hw/c6frltpi6PdrfRpLYG43zLkAk+any4J4/Wu7oAKKKKACiiigArzb4JOJbXxsrYIj8WamP/ACKD/WvSa8h+DGlabqn/AAsA6lptjdPH4v1FA01ujnG5GHJHPX+XpQB655ab9+1d/I3Y55xn+Q/IU2WCOWB4WXEbjaQpK8fUViv4O8OyB1l0aylidSjQyRB4iOnKH5enHTpUVx4W8OWlvcTtoltJBHGWNslv5iYUfwQgFd2Bj5VyaANy8uLW2jWS9lhiQNgNKwUZPHU9+cfjWbH4j8PK+2LWdJDNzhbqPJyc+vcn9a8+074geEbbwPqniiw8NvaxW+oHTBaizjhnnm3KoXbxjJYcNgjBz6Vbk+Llj/Zssc2i3w1wauuhnSS8ZdrhxkfPnZ5ZXJ3Z7UAekLaW/wAhWJAqABQB8o+7jjpxtXB7Y4qRY0D7gihxxnbz2/wH5Vwngm48N+LNEn1iw02XR5oppbW9jgkNrIkkTYZZGhYb8dQSTw3bJrKX4g/DSNJJB4vcqiqSf7Uu2yGOAR83PTkjOOc4oA9S2rk/KOeDx1/zmud1C2hfXNJ06IfKsk2ozbjuyBkBT3GXn3DpwjDpxWFr3i7wbo9//Z154ubTNQ/dqGN4zlA43Ix8zcmCOdzAjkc9KueHde8NnQNZ8V2OsvqltErfbL2QjciwKx8vaFULt3MQNozvJ5zmgDWJGneLsOES31aIBDnGbmIEkYxyzRYPXpAa2Wt4m/gAO4NleCSMY5H+6PyxXBav4x8PXnhXSG8XTNot3qMEWoxWqu0k9ttKuknyLkbTtyWG3OVORkHrLTSw6CW41PUL3eAUZpvKAHXgRBAfXJBPvigDSSGKMYSNFHHAUDpgD+Q/IU50V1w6qw9CM+1ZcmgWcjMzTamCwwdup3Kj8AJOPwqNfDGl4xLHc3C4xtubyaYHjHR3I7n6ZNAF5LNIr+4uSy+VLEkfl7QApDSEtn38z9PeornWdJtFBudRsIFbkeZOig988n3zXnsWt+FLPxf4h0vUPDCiXS5oYYbmz0Se8aVXt45TuaOJsEFjwTkgA47nch8Z+F7c74NN1mIn5sp4Zv1z78QUAbkWv+GzMPK1bSDL90bbmPPbjr/sj/vkela8KRqgMQUrj7wOc8Ade/QflXLt460aRWV7LxGyngg+G9QI/wDRFZc2r+C55fNn8M6lJL13v4RvWP5m3oA72SOIriREK56MBjJ4/XJ/OlCrwVAHfjv/AJzXnkt/4Gl2iXwrfuFYMqt4QvSAwOQcfZ8ZyAc9aqatrXhGAWjWPhVzdXGoWlsGvPDdzbIPOuY42YySQKoYCQkZIyeO9AHot9fWOnwmS/ura1iGCWmkVFHpyfp+lUh4l0BIkca1pSxPjY32qMBvTHNaFtY2lrj7NawQ4/55xhf5V5RqHxT1nw5rPiCx8UaJYn+ztHbV0Om3bS7Bv2JDKWQbWY9xnjnnsAerW62lxm5tzFKsg270YMpALfh1ZqnEaDOEUZOTx3zn+fNfP+p/ES1tNP8AEE/ibwdpL67Z2djd2/2R8idbkqqK0hUMpQkZPcA49+u+HH2fWtS8SaTqlnc2Gr6JcpBcfYdYu2gkWRN6smXBHGRjHb3oA9QEEIZiIowWIYnaOSMYP/jq/kPSsS8t4pdc0PT4og0Ngr3hLHeY9qGKMHPILeY5BPXym9685f4geD7fUmtrePxrPcB7iCExSXsqzSwcSRpmQh2Ay2cbcDJNaGmfErwnY3Vh9hbVtX1TWrSK9aVYA87QklUDD5QADvAjjHBLHGWJIB21yEs/F0bTRq0GrW4ttzEYEsW91XbjnfG8pyTgCHHO6te8heSJFh2giVHPbgOCf60zVtPg1SwktLsN5TlWBRirIysGVlI5DBgCD2IFVY9FUgG7v9SupQc+Y1y0XHpti2L+maANLyYsk+WmSck7R14/wH5CuVv40T4oeHURFVP7F1IbQMDHnWA/lWsfD9mRjztT9ONTuf8A45XKat4c06b4neG45xdzIulajMBLezP8yzWIxy5+UhmBXowJDAjigDu7h7e1R7m4eOFFA3SSMFVevc8D7x/OuJ+Fmqafa/DHwaiFpJDpForC1geYqfJXO/ywdvJPXHOfeuutdF0u0nE1rptlBMP444EVvzArE+E//JLPBv8A2BbL/wBEJQBrTavZpt8yC9O4gjFhO2O4JwnHQdasaVd2F5bbtKuba5gQ7N8EokAIA4JBPOMVcqhqOjaZqUqSajp9ndSRjCPNCrsoznAJHAoAusisrKygqwwQR1Fcl8W4I3+F3i1mUZi0i9dMcYY28gJ/Jj+dax8NaZ0jjuYV3BgsF3NEoI6YCsAK5r4qaJaR/DLxdKsuolo9HvCA2oXDKcQueVL4P4igDvSATyAaasUartVFUcHAGOmMfyH5VlP4csHcsW1DceARqFwNo44XD/L0HTHSon8KaOyugtpUik4khjuZUjlHo6KwVgehDAggkHqaAF8NrFe2F7fMBJDqk7zgGTzY3i2iONl7bXjjR8dMufWjwpMv2N9OnbdqGmEWs2/77Ko/dSE4wd6ENxwCWXqrAbgGBgdKoX2kWd7ci4mWZJ9nlF4J5ISy5yA2xhuAOcZzjc2MbjkAvY4wOPpUdvAsMEMZ+YxoEDEcnGP8KzIvDlhDEI4Wv441G0KmoXAAHoMPxSjw/Zg587U+uf8AkJ3P/wAcoA1gqhiQoBPJOOv+cCkdFdcOMr3B6H6+tZDeGdKfHnwS3OOn2m4lm2/Texx0H5Uo8MaADkaHpefX7JH/AIUAWNR1PSbAhNRvrG2P3gs8qJ14zye+f1p2n6tpuou407ULO7dfvCCZZCPrg+9TWVjaWMZjsbaC2jJyVhjCA/gKLyxtL1Nl5awXCf3ZYw4/WgBy20KvKwQEyOJGzzlgFAPPT7q/lUoAHQAfSsZ/Cnh2TG/QdJbHTNnGcfpSx+FvD8ahY9C0pVGSAtnGBz17UAalzbxXNtNBMm6KZDG4BxlSCCMjnuaeqKv3VUc54Hf/ACTWSfDGgbs/2HpecAZ+yR9B07dqUeGNAAAGh6XgdP8ARI+P0oA1Qigk7RknJOOvT/AflTDbxHyxsAWMFVUcKBjGMdOlZY8L6IC5XS7Vd/3tqYBGMEcdjjkdCeetDeF9EZyzaXak/wAOUGE/3R/D36YoA1fJi3OfKTLjax2j5hycH1HJ/M1JWMnhnSI2LR2YjJOfkkdcfTB4HqBwaQ+F9HJy9oXHO0PK7BCepUE4U9eRg8n1oA0reFkuLmSQJ88mYyOoXYoOfxU/pVjAxjAx0xWKPC2iAKBptuNpyCAQfoT1I7Y9OOlKfC+h+YHGk2asO6RBc+ucdc989cDPQUAal1bxXdvJBcJvikUowyRkEEHkcjgnpUgULnAA+grIbwxobgiTSrORSMFXiDA855B6n39OOlOXw1oStuXRdMDZzkWkf+FAE19rGlWWBfajY2+eQJp0Tpznk/jUtulnctb31s0coEbJFLE+VKMVJxg4P3F/Kp4LeG3DCCKOMMcnYoGT+FUrvQtIvJjLd6VYTyk5Ly26MxPrkigDRrgvgL/yRzwl/wBeKfzNdIfC+iBlaDTbe1dSCHtB9nYYOR8yYP8A9YkdzXK/s9uZPgx4UYnOLTb+TsP6UAeh0UUUAFFFFABRRRQAUV4j+0PqGl2WveBkv9Yn0/z9TSO8WLUZbYNZnO8sEdcDOPm6j1o8Bahpc37Q3jazh1iefyY4za2rajLIizEN9pCxlyvDcEYwvQYoA9uooooAKKKKACvL/gWpWT4ig/8AQ4X56Y/hir1CvJPhFqkGnT/EIXCXkm7xdfEG2s5Z8fJD18tWx+NAHrdRXSzPazJaypFcMjCOR03qjY4JXIyAe2Rn1FZGoeJrOz0u4vfsmrT+Um4QRadN5sp7Kiso3Mc9PqegJp1v4l0+QmOcz2dwOsFzCySYPRgMcqcgbhkZO04bIoA85s/g7eDwjrehal4ljnF/qP8Aa8FxBp3lNbXW8OWwZWDrwBt44zz6Tv8ACB5LWS6k18nxK+tpro1AWYEQlQbRH5O//V7cjG/PvXoLeIIDMsNvZarPM3RRYyxr+LyKqD8WpU1a8YjdoGqIDjJL2xx+Up/SgDJ8C+C08K+FrvSvtz3lzezz3V1dNGE8yaU5ZggJ2jpxk9OtcbB8F/K0hLH+3s7fDMvhzf8AY/78ok87HmdsY2fjur0JvFmiwkDUL5dNdiVVNRU2hcjrs8wLvx6rke9TweJNCnkVINa0yV2DEKl1GSQoyxwD2yM+lAHAah8Ivtn9tf8AE72f2j/ZP/Lpny/sP/A+d/4bf9qqnibwFdJp154dgumubLxd4ma/1F0Tymt7UxiR4wcnOfIVd3H+s6evqkmqafFEJZb61SMruDtMoGPXOelZem3MOteIjqNjKZrCztmto7iJ8wzySOrSAHo2zykG4ZGXdc5VgADhvFnw/ufiJBpGpPq8el31tbm0mlis2E8cquRIYpElQr8ykANvXjOOTn1W3i8m3iiMjyFFC75DlmwOpPrWBpsqaN4gu9MuFeKDUZ2urB2cskkjKWmiXP3XBV5dvcOxXOx9vR0AFFFMeWNGCvIisxAAJAJJ6UAVbLSrKy1DUL61gEd1qDpJcuGJ8xkQIpwTgYVVHGOlXaxrzxV4espmhvNe0m3mU7WSW8jRgfQgmlbxDZlwkEGozu33PKsZij/SQqE/EsBQBsUVjtq96CceHdVYAEgiS25/OanHXI4jtu7DU7d+yi0ebt/eiDr+tAGtVbUbC21GBIb2ISxJNFcKpJGJI5FkRuPRlU/hWRdeKI0ES2Oka5fzPJ5flx2Lw7R3YtP5aBR/vZPYGrDeIbVCyzWuqpIp2so06d8H/eRCp+oJHvQBsV5lovwc0nTV1qKfXPEOpW2spIt/De3ETC4LjG9mWNWLD+E7uK7k6tIy7rbS9RnX1CJF+kjKaj/ta9wD/wAI9qfPYSW3H1/e0AcdD8HPDv8AY+sWF/c6rqLanBBbSXV1Opmjjgx5SxlVULtIBzgkkc5rpPBng+x8Kf2lLb3N7fX2pTi4u7y9dXlmYLtGdqqoAA4AArR/ty3USfaLe/geMAyB7SRguf8AbUFD7kEgd6gn8W+HraISXWt6bboW2ZnuUjw3907iMHnp1oA56x+F+i2d9p93FdaiZLK8vr2MNImC92pWQH5OgDHbjBHcmuX1/wCDmgXEfhTQ5L/UZrC2AtzbyyQlmhjV5C6t5e9G3mNWMZThq9Hj8YeHJpRDba5p1zOTtEVtcLNIT6BUJJP4UmlNNqmuy6o9vLBYwQfZrTz4jFLIWYNK5VgGVcpGoyASVY4wVJALfhu8lvdEtZbmRJbtAYLlo1KqZ42Mcu0HtvVsVp1zlndnSPEdzp17lLXUJvP0+U/cLlMyQez7leUZ+8HbH3Gxr6jqun6aYhqV/aWhlJEfnzLHvPoMkZ6j86ALlcrqX/JU/D3/AGBdT/8AR9hWsPEWikgDWNOJJwP9JTk8nHX2P5Vx+v8AijRrT4m+HJWvknVtM1G2AtEa5bzGmsSFKxhiCdp6igD0SuV+E/8AySzwb/2BbL/0Qlaw1/S3B+z3a3TDbuS0Vp2XPQsqAlR7kVy/wrutRk+F/hFLXTgm3SLNRJdTKqsPJT5lCbifXB2/hQB3lFZxXV0UuJbCc44i8t4sn/f3N/6DUSatNCuNT027t3BxugQ3Mbn/AGSgLY92VaANauV+LH/JLPGX/YFvf/RD1rrrdqyswi1HCsFOdPuAc/TZyPeuW+Keu6TL8MvF8MepWbTvo14Fi85d5JhfA25z2oA7yistfEOktKYo7+CWbbv8qJt8hXswUZJX3xio7zXo4lKWtjqV1dFN0cS2ciBz2BkdQi/8CYUAZl3czprzalLdSJZWt5FpwhVm2OsqqC20HDN50ka5I+URsARuYHq6xU0iaTwxNp0ty1veXMcjPcW53eTPIWcvHuH8LsSuRxgUmneIrSXRzd6lLDp88DrBeQSyjNvOcDyyTjOSy7Tj5wyFchhkA26Kw5/F3h22nEF3rmm2lyRu8i6uFhlAxnlHIYfiKc3izw6qoza/pIVxlSbyP5h7c80AbVFYjeLfDiKrP4g0hVcZUm9jAI9R81P/AOEk0t0V7WeW9ibOJLG3kuk47Fo1YA89M0AbFFY51t5IRLY6Rql2hOP9UsDZ/wB2Zkb8cUsOr3jl/M8P6pCqrnLvbtn2AWUnP4UAa9FY8viG0i3ebbaqCvULptw//oKHP4Un/CSWO3d5GrY3bf8AkFXWc/Ty+nv0oA2aKyB4hsif9Rqnr/yDLn/43R/wkFnnHk6p/wCCy5/+N0Aa9FZS67aEqBDqXPrp1wP/AGSnDWrU7v3WocED/kHz9/8AgHNAGnRWc2sWiMFZbwE8D/Q5v/ifx+nNOGrW5GRHeEf9ec3/AMTQBforKbXrIDIj1Bh6pp9ww/RPaga9ZkkeVqII9dOuBn6fJzQBq0VkP4gs0jLmHUyvXA0y5J/IR5pzatO8KyWek6hOGIC7gkPXuRIysB68Z9j0oA1aKx5bjxACfK0zSmGON2oyLn/yAfamjxAsKf8AEw03VbSXBPlraPc5AzyGhDrzjgEhvYZoA2q84/Z1BHwW8LA5yLdxz/11euvPibR4whur6OzLjKreq1sx5x92QKa5X9n5dvwc8MDIP+jsQR3HmNzQB6FRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmPwP/wBd8Rev/I333X/chr06vMfged03xFP/AFN98P8AxyGgD00kKCWIAHJJ7UtZfinZ/wAI5qXmhSnkPwwyM44/WtSgAooooAKjlghlOZYo3PH3lB6dKkooAqRabYxSmSKztkkJ3FliUHPrnFW6juZ4rW3luLmVIoIkMkkjsFVFAySSegArB8MavqF7cSQavDBBLLbxX0CR8FI5CwMTAsdzptG5xgHeAAMZIBsapp9rqljJZ30XmwSYJAYqVYEMrKwIKsrAMrAgqQCCCAazh4X0qWQzanbR6pdN1uL+NJXA9FGNqD2UAdT1JJ26KAMlfDWhKQV0XTFI6YtIxj9KnGjaYFKjTrIKckgQLg569qv0UAMghigjEcEaRRjoqKAB+Ap9FFABRRRQAySWOIoJZEQu2xNzAbm9B6ng0+ue8WMgvPDauM79UUKfQiGU/wBK6GgAooooAKKKKACimTSxwwvLM6xxRqWd3OAoHJJPYVheGdWv76eWPUrdYllhjvbVliaMeVJuHlMGJJkTaCxwo/eKMdaANi/s7e/tXt7yJZYWIbaezKQysD1DAgEEcggEYIqHS9Ks9LWX7HCVklIMssjtJLKRwN8jEs2BwMk4HA4q9RQAzyoyMFFx9P8APoK5W+jSP4peHhGioP7F1LhRj/lvYV1tcF4omki+MfgNI5GVJbHVUkA/iXFs2D+Kg/hQB3tcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJQB1VFFFABXK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9AHVUUVn63qDadZq8EH2m7mkWG3g3bRJI3TJwSFAyzEAkKrHBxigDQqs9hZvqEd89pbtfRoY0uDGDIqnqobGQPajTL2LUdPt7y33CKdA6hhhlyOhHYjoR2IqzQAUUUUAIABnAAzzS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwHwEBHwh8Nbs7jAxOfeRjXf15/8AAJt/wg8NN2MD4+nmPQB6BRRRQAUUUUAFFFFAHkXxu1q98Ca34c8bwvdzaTbmWw1Kzjc7HWRSYn29AQ46+4FcV4+n1Hwp8JvBsuteKdQsvEF3fx3l3AbrZ5/mSo8qtkbtsQZVwpCjPIPGPpKigCCxu7e/sre8spkntbiNZYpYzlXRhlWB7ggg1PRRQAUUUUAFeO/BVNTlufiI2nXdlBAPGGoBkntWlYsPLydwkUAdOMfjXsVeV/AP/mo3/Y56l/7ToA2PiBa69a+CNZlh1m3nkS2fatzZjY3UfMUYEdRyvQgHB5U74g8TSgv9v0e1JmJEP2OScLF/d3+ahL9920AZxtOMmt8S8DwHrWc4+znODjAyM1e8M3l1dw6gl/JE9xbX88P7tdu2PeWiB9/LaPJ70AI9jrTyLIdZhQrwI47ICNhnPzBnLZ4xwwGCeM4IigvdegJtrzSo7ufDFLy1lWK3YZG0OrsZEY5OQokAAzuydtb1FAGGtz4ly27SdHABG3GqSnIzzn/R+OPr+HWnwz+IWiUzadpKSEfMq38jBTk9D5IzxjsPxrZooA57ULPWdXgWyvEsrOzeVDcPBcPK8sQOWjAKKFD42nk/KWA5IIm1Vhb+JtCnKITN59kGP3l3IJeP/AetusTxdEx0yK6iiMktjcw3Q2hiyorjzSoUEsfKMg2gEnOByaANusS88SWsdzcWmnwXOq3tuP30FiqsYzjO1nZlRW6fKWDcg4xzVKG31jX1kuZr+40zTJ3KxWkdv5Vw1vgcu5O+ORiuRgKyI5UqJMOnQafZW2nWcVpYwpBbRDCRoMAdz+JOST3JoAyv7Z1NmAXwzqQB2kl57YYB69JT8w546H1pTrGpq7/8U3qDJjKFZ7fcT6MDIAPbBPvjpW5RQBgLrupeXGZPC2sCRvvKstowU7c9fOHGeM+vpTX8Q3sal5vC2uJEFLMwNtIVwM42pMWY9sKDXQ0UAc8dd1SYMtl4Y1HewzFJdzQQxNwCCxV3kUc4/wBWTkHipJY/Esq7ornR7RmONjW8twIxjru3x7uccYXr1OMHdooA4HxfF4kjvvCxS40W9k/tdPkeCa2G37PPuIYPJ82M4yuM9a6NIfEjHc9/pEQbnyhYySeX/s7/ADl346btq5xnAzgR+KGQal4ZEhYZ1I4IxwRbTnn24xVjwjqF1qvhnTb3UYkhv5YF+1RopVUmHEgUHnAYNjPOMUAMEPiJDuN/pMuOfL+wyR7uOm7zm25PfacehoXVtRDeVJ4fvjMANzxzQGHOP4WLqxXPGSoPcqK2qKAMRrvxC7M0OkacseflE+oMshH+0FhYA/RmHv6Oa48QZO3S9KIxxnUZBk/9+K2aKAOX1Oz1/W7X+zr6206x0+dtt1Jb30ksrQ/xIoMSYLfdJzwpJHOMXtVVYfEuhXZDtJJ59gAD8qh0ExYj/t2A/wCBGtqsbxY72+ki9iDFrKeK4Yh9uI1ceaff92ZOO9AGzWVqmu21jeJYxxz3upSRmVLO1UNIVH8RJIVB6F2UE8Ak8VnwajqfiGCV9HNvZ6VK+2DU/M8yWWPjMkUZTZg87HLMpGH2spAOzpWmWmlW7Q2UbKrNvd3dpJJGwBud2JZ2wAMsScADtQBn/wBtX+7H/CM6xjJGfNtMfX/X/wCc155431l4fjH8N573TtRs41h1YFTGszOPIiPCws5PT0z04r1+vHvjDcSWnxT+HdxE/ltFZ65JvHVcWikEe+QKAPSIdZu5duPD+qqp53O1uuPwMue/p9a5T4ZeIFsPhb4VfUNN1O3tYtGs8XCweergQoMhYi7gd8so4rsPCwdfDunxTSzzTQQrBLJOcyO6DYzMe5LKTnvWT8J/+SWeDf8AsC2X/ohKANq61rTLWwS9nv7ZbWRQ8cgkBEgPTZj72cjAGc5GKrLqep3MqfYdGZYCN3nX04gyOcbVUO2TgHDBSAeeQVrQtbCztJp5bW0t4JZ3MkrxxqrSMepYgcn3NWaAMT7P4jMrN/aekJGWysf9nSMVHHBbzxk9edoz6Cud+KcGrr8M/Fpk1CyeAaPeGRfsbBmH2d+FbzMKc85IPf8ADva5X4sf8ks8Zf8AYFvf/RD0AarW+uFoduo6aFBPm5sHJbjjb+++XnnnPHHvS2+lyNqEV9qV0bq4iQpEiJ5cMRP3nVMk7yONzMcDIXbufdqUUAY/hzZENTs0laVrW+l3s3UGXE+PoBMB+FSap4g0jSZxDqWpWtrKUEhWWQKQmcbj6LkHk8cH0NZOtahLompatLE0LSXVnHJZWzZ/fXKuYjnHYmS1WtnQNIt9F09ba3G52O+eY5LzykANI5JJLHA5JPAA6AUAV4tda6SKXTdL1C8tpFJW4VUiQ4OOkjKxB6hgpBHIJyMuiu9ZIJm0q1XCDhL0sS/ccxgbfQ5ye6iteigDIl1S+jkCjQdQkVsYaOW34H+1ulHPXpnjH0CNqmosdkOgXwc4w000Cxj6lZGb8lNbFFAGPNqt/CyL/wAI/qMxI+ZoJbcoD3wWlUkfh+FN+363OY2ttFhhjJ+cX16I5FGewjWRT/30P8NqigDDf/hJZFjkQ6NbNsw8BEs43ZHIk+TgDIxs5yDkYwXO/iONX2W+kXDF/lzPJCAmO/yPk5+mR6VtUUAZEsevOzeVc6XECMKGt5JNp9Sd65+nH1qJLbxKMh9V0c/MSGGmyjAzwMfaOuO+fwrcooAy1bWo3cNFp1wpyVIkeEr6Aja+e5zkemO9RyHX3ieONNKgkJ+W4Z5JQoz3iwueOPvj19q2KKAMpZ9c2tu0/Td2TjF++COx/wBTx9OfrUS3PiLeQ2laSEzwRqUhJGPT7P8A1raooAxhP4h+0c6dpIgCn/l/kLFu3/LHAH55z2xyS3HiEK3laXpLNuAAbUpFyuRk/wCoPPXjvgcjPGzRQBkNLr8ilVtNLtyTgSm6km2j12eWm76bh9artpviC4yl14ght4+SG06wWKTOTjJleVcYx/CDkde1b9FAGCt3rlgoiutOGqYfAuLJ0iLJg8tHI4wwOBgMQRluPuU/+0danx9k0HycEbv7QvEi477fKEuT7HH1rbooAyhd6ufl/suANkctd/L78hCfpxz321yX7PuP+FM+FSpJBtc8+u9s16FXnn7Pf/JGPCnI/wCPTt/vtQB6HRRRQAUUUUAFFFFABRXlvxT8U6/oPxG+H1loFtPqEWof2h9o02KSKM3XlwoV+eTAXbkt1GcY54rymf4keK38OeGrm71HWke61XVIruPTY4HufKhUMqLuUodvP1GepxQB9UUV86618RfES/BrwUItegHirXt0j6haweaI4Y9zMSiqfm/1UbDHDFvSvUvh542XX/hTZ+J7iOaa4is3e8hgj3SmaIESKqDncWU4X3FAHcUV4L8IviR4g1bxN45j1yDUtSmto7O6s9KtbIxPbrID5kQMojGV3oPnYFwjMuRVv44eJNVsvDEWuaTrWp6BqUEccjaVLcWiNChlIMssZ3mQHBAVG5x9RQB7fXlfwEGD8RhjH/FZaif/AEXXp1jOtzZW86PvSWNXDbSu4EZzg8j6V5P8JX1i3vviCul2FhcQnxZeszXN68DAlITwqxPkYxzkfSgDrvi3I0fw/wBTKsVJaBMj0aeMH8OefapvCF0G1C6g8tgZrO1vXlPAlkbzI2/ELDHn/eFcz8X9S1m1+HupS6tpmmRWgntFLwag8rDN1EAdrQKMDOevat6GCe207wxrdhay3b2tkLeeFDmVoJUQkoCwBYPHEeT93fjJIBAOyorD+3eIJYkkg0SziDDPl3eoFJE9mEcci5+jEZ7nrUv2jXsD/iWaZu7/APEwfH5+T/SgDXorINxr2D/xLdLzjj/iYScn/vxSfaPEH/QM0rr/ANBGTp/34oA2KKx/tHiDI/4lmlY7/wDExk/+MUpuNexxpul5/wCwhJ/8YoA16KxBc+JMDOlaRnvjU5P/AJHpBceJcknS9Hx2A1KX+fkUAblFYbXPiXB26To5PbOqSj/23oNz4l4xpOj+/wDxNJf/AJHoA3KKw1ufEuTu0nRxzxjVJTx/4D0G58S8Y0nR/f8A4mkv/wAj0AblFYv2nxHgf8SvSM+n9pSfz8inifXsHOnaYPT/AImEnP8A5BoA5v4qTvA3hZo3ZP8AiZTZI/7B14fUdwD9QK3vDDPFda3YySiT7Pfu8eRhgkqrNz6jdI4B9F9q4r4rT6in/CIm/htI1bWWQeRMzEFrK6UDlRnqeeOnTnjstVjv9P1+PUtNsJNQW7iSzuYkkRDFsLtHLlmA2AySBwNzHchUfKQQDoKKx/P1/JP9naUAOg+3yHd+Pk8frSG48Q540vScYz/yEpOvp/qOnvQBs0VjGfxCxwNP0lBn7326R+Pp5I/nQ0viDJC2mlDphjdSH1zx5f070AbNFYpk8RjpbaQ//bxIv/sh+n6+1Bm8RLgCw0mT1P22RMfh5RoA2qKypP7cVgIzpsgI5LB02n0xzntzx9BTn/thRuT+z5CcZQ702/8AAuc/kKANOvEPj5vbx94GjRmXzNN19Ttzz/oI7d+cflXrTS65yVs9NznhTdvyPr5f9K8f+Mb3jfEz4d/b4raJjba2q+TI0nWzA7qPwoA9d8Nuy/2raPKJXtb+VSwGMCTE6r+CzKPwrN+E/wDySzwb/wBgWy/9EJU+qXN3o+umaCyku7XUI1iVYImJjulOFMhUHCOh5dgFTyQOS4FY3wuk1dPhj4OFvb2E8R0azId7h4iP3K4G0I2eMc5HfgUAd5RWWJtaI5sdOUkkZ+2O2PQ/6oZ78frSkazuADaeFyAWKucDucZ5+mfxoA065X4sf8ks8Zf9gW9/9EPWyyauPuzWD89TC68f99GuY+KEepD4YeMGuLmzKf2Nebkjt2B/1D9GL/0oA7iis7Zq27InsQMH5fJfr253f0pzJqmCVnssgjCmF+R3538fkaAJLzTrW9uLOe5hEktpIZYWJI2sVK9uvB6HIyAeoBFusuH+2pCwmOnW4U8Mgebf+B2bcfVs+1Pkh1ct+7vrBR/tWbn/ANqigDRorOEWrA/Ne2B+lo4x/wCRad5eqf8AP3Zdf+fV+n/fygC/RVAR6mNu65sm9cW7Ln/x80xE1gL881gzYHAhcc/XcaANKissJrW3mfTt2P8Ani+Cf+++lGzWmUnz9ORuy+S7frvH8qANSistY9aJy1zpygdhbuc/jvGO3Y0qR6yfv3Wnr7i2ds/+RBQBp0VnGLV9pAvLDd2JtHx+Xmf1pHTV8jZPYHPcwuMf+Pc/pQBpUVmBdZVzmXT5F7funQ/X7x/z+VGNZCZ36ez56bHAx9cn/PpQBp0VnrHqvG65seozi3fp/wB9/wCf5MEWsHlrvT1z/CLV2x+PmDP5CgDToqgI9UOM3VkuOv8AoznP/kQY/Wk8rVSwIu7ELnkfZXPHPfzPpQBoUVmMmtRqWWfTp2AyIzC8W4+m7e2367T9KozWXiJy16mpwR3SEGPTlQfZWXukkhUyFjziRdoX5T5bYYOAdDRWWJtad2/0PT4k/hJundj9QIwB+Zp5GrgZDWDnj5cOufXnJ/l+VAGjXnP7OziT4K+FSoIAtmHJzyJGH9K7VYtX43Xdh15AtX/n5lcN+zewb4KeGNoxiKVce4mkB/lQB6VRRRQAUUUUAFFFFAFW502xub+zvrmztpr2z3/ZriSJWkg3jD7GIyu4cHGMjrVS38OaHbSWz2+jabE9tK88DJaopikf77qQPlZu5HJ71Yu9VsLTUrHT7q8givr/AMz7LA7gPNsXc+0d8A5NY17498J2NnFd3niLS4LWWWSBJXuFCtImA6g56jIyKAL+meGdB0q4SfS9E0uynQMqyW1pHGyhiCwBUAgEgE+uKuabplhpccsemWVrZxzStPItvEsYeRvvOwAGWOOSeTVK68T6Fa6AuuXGr2CaM4UremdfJbJwMPnB54rUjuIZbZbiOVGt2QSLIGBUqRnOfTHegCG202xtr+8vraztob282fabiOJVkn2DCb2Ay20cDOcDpVPVfDehaxewXmraLpl9dwACKe5tY5XjAOflZgSOeeKreF/GXh3xU9yvhzWbLUXtseasEgYpnoSPQ4PPStDU9Z03SpbSPUr62tZLuZbe3SWQKZZGOFRQepJ7CgC/XnHwaBW7+IYOf+Rruzz/ANcoK9Hrzn4OEG8+IWMY/wCEquuhz/yxgoAq/tMyeT8E/EEpzhHtG4OOl3DXf+HBjw9pY44tYhx/uCvPv2nmKfAzxOV67bcdM8G5iFeg+G/+Rd0vA2j7LFx6fIKANGiiigAooooAKKKKACiiigAooooAKKKKACiiigDzD46ttg8EHcV/4qOEZHbNvcDNen15P+0L/wAevgFQ+zd4tsU3dhlZRz7c16xQAUUUUAFFFFABRRRQAUUUUAFeK/GpPM+L/wAJY+fnm1FOPeKIf1r2qvEPjlKYfi/8HHCls6hcpwcY3G3XP60Adf8AGnxpd+DvDdodGexXWtSvI7S0+3MFhXPzO78j5QoPOepH0rz/AMO/E+TRvA/wiXS7eW90++tmsb2G3tmuLjdbwqhEaKc53Anoflr2fV/DGjazq1hqWq2Ed3d2KSJbGYlkjEmA/wAmdpJ2jkgnivO/gz4O8KReE/B0lvp7jVLLT7bWQ5nmKpNdQ7HcAvt+bymyuMDqAM0Abnwh8Xal438Na1fXapazw6pc2duGt2QxomNnmITncM8jI9OK5Twt8Ttdt9AvdR8QwwavM3iMeHbO20+AWzGQMV3lnkI+YleONuOpzx6F4atvCmnpr2laBPbJtne71OKK7ZmikmBJZiWJTIUngjGOMVy3gbw/8L9SM1r4TmhvjbX0OqPGmp3E224jZik2GkOeSckcNxnOBQBl3vxd1qU6MmleF9t5Jr02h6haT3KMySRxh9sbhguWDZ3HIG0juDWb8Qvi7aarofjHQ7XR71rM2epaeL9WDASxwSZLIB8qEggNn6gV3dn4W8B+LLC//s5IL+3OryX9xLaX0u5L7YFdg6OCp2lflBA56VlfFTwD4ai8F+Ndai05or99Nvbt/LuZViebyH/eNCG8sv33Fc55oATT/jDDJpOh6zqvh++0vQdWk8qG/nniZQ3lu4yqsSAShX5sfSqWv/G2PRtD0nVJtAleO8sE1GS3F2vnwwsxCt5YB4KgNltq84yTnHb3fgDw1feCbfwne6Yk2gwKgS282QbdpyCH3bxz/tdDjpUXiT4beE/Ek4l1fSvMf7MLM+VczQBoVOVRhG6hgD0znHagCr4A8SX2ueKvGtrdSh7PTryCOzXYFKI8CuQSOTyT1ruaytG8PaXot5qN1plr5M+oOkly3mM3mMiBFOCSBhQBxitWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua8KXMs+v8AjOKSR3WDVY44wzEhFNjatgZ6DLMcDuSe5rpa4bRrqSz+K2t6ZHEDFqEJ1GWXDHayR2sKLnOBkeZxjnb7GgDuaKbHIksaSROrxuAyspyGB6EGnUAFeb/s6KU+Dfh9SMFftAx9LmWvSK89+AIA+E2i7Pul7kj/AMCZaAPQqKKKACiiigAooooA8w+KPg3V/FHxC8A3mnT31lp+nf2h9s1CxnijmtvMiQJt3g53FSpwp4J6da82sfhb44i0zwrbWRfTr6w1XVLh7+SSCYwrKmIpGXJDbjwQASMngcV9MUUAfOyfDzxXq3gDwT4OfQLXSdP0wTT6iL25SeGaYbgmBG5YhjJJJjoDgdhn074S2XiHRfhva6V4mst2paWslpGFmRhdRJkRMCGIAK7Vw2DxyBXd0UAeL+BdB8Xal4q8Q6z4j0i78L6tqFslvbX1pPaTx2kEbqVhRMvuZhks7LjjAC8VJ8V/Cuu3svgeTTdGuPEmp6Nq9vqFzqrGzgmaCN2ZoeTHySVOFAX5QTzXslFADIHaSCN5I2idlBaNiCVOOhI449q8p+FcGo3l/wCP2sdSSzjTxZd5X7OJC5EcAwST93jGAAfRhXrNeY/A45m+IuTn/ir77/0CKgDN/aA07VW+CviaPUdVhuo1giI8uz8t2ZZ42GTvIySMcAdelekw3UOjeEUu7pXjgsrESyKVwyqkeSMeuBVL4ggf8I7GzAkJqOnydcfdvIT19OKu+Kgk/h65t22tHebLQ55GJnEf/s9AGdaaHr72Mb33iq9TUGXdKttb232dHPJVA0RfYDwNzFsAZJPNWl03XUmDLr8bpj7klip9e6sO5H5fU1vUUAYyWmuAYfV7M5PJFiQcYxx+8/HnPPoOKQWOueYrf21AQoxt+wjDe7fPnP0IHtW1RQBhNpesOwz4hlRcYPl2kQPTryDzn8PanNperP8Ae1+dOc/urWIfQfMG49e/oRW3RQBirpWqBV3eIbtnH3v9Hh2n8NmR+f8AgW/2Tqp4PiK8wMY228GTjrn5Mc+wFblFAGINJ1NRtTxFesv96S3gLZ+ojAx07Z68jsn9j6mMAeJdQI5JJgts5/794x+GfetyigDEGkalgD/hI9Q6YJ8i3z9R+74/WmDRdULbn8T6lkHhUgtguPfMRP15Htit6igDBfRNTkZyfFOqx7lwBFBagKc9RuhY9OOSaH0LUGTaPFWtIf7wis89feDHt+Nb1FAHk3xU8M6he6h4BhXWL3UGXxPaz+TdiBE2xRzTO2UiU52RuAM4PpmvRvEt5PY6NPLZhTduyQQFhkCSR1jQkcZAZgSPQVhePbmGz1rwLPcsUj/t3ygQCfmksrqNBgc8s6j2zk4AJrY8QxmefRoN7Kj36s2O+xHkA/NBQAHSLzaAviDVVOzaW2W5JbH3+Yjg98DC+1NOjXxzjxJqw+kdr/8AGaTQ71Jta8Q2rXIeWC8TbEZMlENtAeFzwuSTxxknvmtugDDGjagp48S6qwJyd0NrnGOgxCO/rnv04wo0a/GP+Kl1c/8AbO0/+MVt0UAYKaHqKqobxTrLEDBJis+fc/uOtObRL84x4n1gY9IrTn/yBW5RQBiLot+FAPibWCfUxWmf/RFKdHviFA8SasMEkkR2vP8A5BraooAxBo1+Ac+JdXOTnJjtOPb/AFFeSfF3SZh8UvhYLi/u78peyzK1wsa+XtmtOnlovX3zXu1eUfFAr/wt74YrIyKrG+5YEjIa2IHHckDH60AeheIDO8VnaW8phN3crDI6sVYRhWdwpHIJVCuRgjOQQQK89+D2nH+xtG+zX99bs3hfR5HxKsgOVn4AkVto9lwPyr0S9QTa7piscCJJpwPUgKn8pDXiHg/xF4y0rw7px8PeELTWXj8LaQFRdUCOI9k21zG0YySd+VDZ+UYJzwATeGPBPiey8U/EY2uiXGl6fr1ui2ckrWPkySRwupE0cWSFd3z8ig4JLc1i/D74VeOLSDVLcXVzoH2jQ4dMFzezQ3kqyrIC4hMZykBUyYG4MCVP8NeS/EP4x/E+61Y2mrTXfh9kcMLG3ga2PXgEn52HHc4NfTf/AAm3xP8A+iR/+XLa/wDxNAFD4EeAPEvhDTvEthq97/Z9rLq0s1nHZRQ4kQqF84Z37VYKu1DgrtOc5GPOfH/w18Tw6V4j1u8fVW23etTzSHUU2mwMDvCSisBhnAygHflQK5744fFD4j6N490yVrO78IXC2KlbBL+O9jnBkf8AeNtGwk424IyNvvXX23xC+JviT4VeJ117wRH9hfSboPqjymyxGYWy4icMZDjJG3AOO1AEOq/Df4hXfg/wpbPHqdxqllZNDJDPeW0ttC/mnAYb1YEIF/eKXbBwMYr6DstF1GO1t1m8Ral5iRqrqiWxXOOcEw5IrfooAzRp115xf+2dQKkYEeyDaPf/AFef1pkmlXbAbdd1NDnJKpbnPGMcxH68Y5H1zq0UAY50e52Jt1zVFlUYMg8klvXKmPb154A9sDipP7LusD/id6lkd9sH/wAarUooAyxpl2MZ1zUjxjlLf8/9VUZ0i9LKf+Ei1UAHkeXa8/X9z/nNbFFAGOukXo3Z8Q6q2c4zHbfL06fuf5+tO/sm7DsRr2phT0XZbkDr0zFnv69hWtRQBkHSbwuW/wCEg1QAjG0R22B7/wCpzSnS7wyI39vamAowV8u3w31/dZ/LFa1FAGU+l3bKANd1JSO4S35/8hUv9l3IBC63qS5/2YDj84zWpRQBkf2Te5H/ABUGqfdI/wBXbdfX/U9f0pP7IvCfm8QaoRnpstx36ZEWa2KKAMgaTe7Cv/CQ6oST97y7bI/8g4pW0q8JbGv6muegCW/H5xVrUUAZI0q7DPt13UwpGAuy3O36ExZ/MnrSPpF0xH/E91RR/EAsHzf+Qsj8MVr0UAZNxpFzJCyxa3qdvIxB82MQsQPQB42X9P61xEtpeQeN9YtL27S5lv8ASba0WfZ5WWknusEqDjcIlGSCNxjyAMgD02uRu9GTUfH01yZpImtYLCf5QD5mxrwBTkHA/eE5HPagDUt/DttYsf7HnudMiYBfItWXyVA6bInDJH3zsC5JJOTgiwdMlZQH1S/bBznMa5PY8IPy6eoNaVFAGWmkyCTfJqmoyZcSEF0UHHGPlUYBHUD69ea5D9n8bfhLoili217pdxOS2LmUbj7nqfc16HXnn7Pzb/hFoLlt2/z3z65uJD/WgD0OiiigAooooAKKKKAGNIiyIjOod87VJ5bHXA71E99aIAXuoFBJAJkAzjrXlvxa0XX9U+KPw1n8OPLZva/2l5uomyN1Da7oEA8wZUDdhlGWHJ4zjFeTSeGbyLwT4Sttb8K6pqF/beMHvLtl0SWUmxEjebkBDhHyp2dGx3xQB9VSX9nFdR20l1bpcyjKRNIA7/QZyadeXltZQ+de3ENvFnG+Vwi59MmvnTV/D2o2/wATZ7zQNDu9UW/1aKSe11nQfkgRSP30N90RFCgqmQRwMHkV0f7SWh6jrN74Way0++ntrYXhkuLawOoLGzxBVR7cDnceA/8AByRjrQB7cCGAIIIPIIqGG8tp32Q3EMj9dqOCa8/+GWneLbHwd4QtmTTNKs7axiivLC6glmuQykg7ZBKAuV2naVO05HPQc58KvBVsPih4j8VQeHf+Ef0y0X+y9KtvsptjMBzLcFSASGPCk9j7UAe1V5f8CiGk+IpH/Q4X4/8AHYq9Qrxn4M6bPfT/ABEeLVb+wVfGGor5dqItrf6v5jvRjk/WgDu/iodngLVHLBRGI5CSM8LKhx+lV9XkUeAtBaMllN1pABUY4N1bj8uayvilol1B8NPFM0viHWrhIdNuJliZoEGVQuPmWIN1Ud+RkdDRc6Ncy+EfDmNe1cpJPprLGfs4A2yRtz+6yfu55PJoA9Iorz/WvC+k6L/bPizxHq9/cXUNrHs1F0jEthHDuYGHYgwWLZdcFXxhlK5U9GdBu5WDXPiHV5AcZRPJiX3xtjDAf8Cz70AbtFY0nh+I48rUNWhb1W9kb9GJFI2hOVCprGrIo6ATKf1Kkn8aANqgkDrxWL/YcgU7Na1ZXPR/NRiOeuChH5io/wDhFtPuJGl1oNrUxUoraikcgjQ9VVAoRc55IXLcAkgAAA3qKxj4fijhC2eoatbSqMLL9tkmZfwmLq3/AAIGhtK1KVSsuv3iAHCm3ghRiv8AtFkbJ91Cj2FAGzRWVFo2zG7UtTkAHIafr75ABpf7FiJ+e71Jh6fbJFz+RFAGpRWUdCtiAPtGpDjBxqE/P/j/AB+FR/8ACOWX/PfVf/Brdf8AxygDZorHj8OWUeNs+qnH97VLpv5yUreH7MnJm1T8NTuR/wC1KAOR+MkvkyeBGIJB8U2SYHusg/rXYayCdR0LAPF62eM/8u81cR8V/D1kul6DcE3zvB4h0x1eS/uG8vdcpGWXL8HbIy/8C9cGuk1HR7X+29KiW41JWYzScahPggJt6F8fxg/5NAHIeE7q6l/aA8aQFWNpBbxjd2DGG1IH5EmvV68h07R9X0/4heJZbnVrS3u7qPT918xC7Ynku7eMqpXYbhlSAYK7N54UgBD6SdCtCgQz6ltHT/iY3Gfz35P4mgDVorHXw7ZKjKJ9Vw3XOqXRP4HzMj8KkXQrRQQJtSxjHOo3B/8AZ/1oA1Kjmmih2edKkfmMETcwG5j0A9T7VnDQbRTlZ9SB7E6jcHH4F8UxfDemvJLJfQtqMskRgZr5jMPLPVQrfKoOBu2gbtq7s4FAGxRWKnhuzhH+j3OqxOAQjDUZ3CZHZXcqcdgQR7VKulXPyCXW9SkUDDKRAu/6lYwR+BFAGrXjvxhlEPxZ+FbEMc3F0mAM/ektR/WvUG0W1LAmXUMjni/nH/s9eI/He0isvid8JRFJfES6o6t/pcjHme0HVmJA56DHagD3Cdh/wkNkvc2s5/8AH4f8a8l+FKSPq/hKVbm4hSHwnpEbQo2EuPMhuiC477fKO30LN616ImmW48UmJZb/AAlmWO6/nb70g6AuQPudq8z+EEevtpUEttbWaah/wjWiC1M8pWKWJPOIbKhimUkdCMZ3KSAAwoA9k1bR9N1iFIdWsLS9iRt6rcQrIFYdxkcHgc1erEg8N2yQRpNe6vcSLy8z6jOrSN3YhGVRk84UBR0AA4qRPD9mihRNqhAOfm1O5J/MyUAWZ9H0241SHUriwtJdQhTy4rmSJWkjXOcKxGQM+lYfxY/5JZ4y/wCwLe/+iHrT/wCEes9oXztUwDn/AJCdzn8/MrnPinpVvF8MPF7rJelk0a8IDXszA4gfqC2D+NAHdUVlS6DaSsGabUgcY+XUrhR+Qf8AWki8P2cWds2pn/e1O5b+clAF9Ly2e7e0S4ha6RdzQhwXUccleoHI/Op6zf7C0z7HBamyiaKBzJGWGXWQ53SBz8287my+dxLEknJqH+xDHIzWWq6paq+SyCYTgnjkecrlcY6Lgc9KANiisl9BtpSGnutTklwNzjUJo9xA67UZVH4ACmHw5ZHP7/Vef+ordf8AxygDZorFPhuxJz5+rf8Ag1uv/jlOHh2yB4n1X8dUuT/7UoA2KKxV8NWIJIn1fn11a6P/ALUo/wCEasSuPP1fH/YWuv8A45QBtUViHwzYE5M+r+nGrXf/AMcpw8N2KqQJ9WwfXVbo/wDtSgDZorGPhyyJJ8/VeeP+Qrdf/HKQ+G7Etnz9WzjH/IVuv/jlAG1RWJ/wjNjx+/1fj/qLXf8A8cpf+Easf+e+rev/ACFrr/45QBtUVjHw3YtnM+rc8cardD/2pSHw1Yk5M+rdMcatdD/2pQBtUVjf8I3Y4H7/AFbjp/xNbr/45Sr4eslBAm1Tn11S5P8A7UoA2KzZSljqOoajeSRwWa2ke+eVwqIEMrMSSeAAwJJwPfriL/hHrLOfP1T/AMGdz/8AHKb/AMI5Ykxh5L+SNXWQxzX00qsVOVyHY8A4OO+BnNAGnZ3Vve2sVzZTxXFtKNySxOHRx6gjgipqxn0CJrmdkvb+G2ncyyWsE3lRlyBlgygOuSMkKwBJJIJJyv8AwjtluU+fquV4H/E0uf8A45zQBsV5v+zmc/BbwufWGQ/+RXrsV8PWSsGE2qZBzzqdyR+XmVxv7OOf+FKeFsjH7iT/ANGvQB6TRRRQAUUUUAFFFFABRXL+JvGmneHfFHhzRNRDRvrf2nyrhmVYovJQOd5JGM7gBjvXJS/GWzOkaXqVj4f1S8t9R1VtGgMUkC5udxVF+aQcNgkN0GOSOKAPVaK85g+KUF74uvNC0vRrq8exuVtbxxcwJJG5xuKxM4d1XPLAdjjOK1fiN4/03wNDpy3yGe81GRo7aDzo4VO0Zd3kkZVRFBGST3FAHY0VR0O/OqaPZXxjWI3ESy7FmWULkZ4dCVYe4ODXFfDj4oWnjzUJ4NN0i9t4IQ5a4mmgIBVtuCiuXGTnBKgcUAeh15f8CwBJ8Rcf9Dhf/wDoMVeoV5D8K9e0fRLv4ipq+rWFi/8AwlV3LtubhIztZIQDhjnBPAPc0Adn8WRn4WeMs/8AQGvP/RD0lvtk8N+ER0DNakZwekRb+lYnxt8T6ZY/CTxI6XlnO97pMn2eNbhcyxyhYhKnXcoMqcjg5AzyK2tEubOfQfBbWFzb3Fq/lrDIj5VwLWX7ueT908dRg+hoAsfEaJLnwheWksKTJdvDamNxkN5kyJgjv97pXgfjr4gaxe+NV8X6D/bL+G/DclpFOLXJtZldd90JPmHzqJI1HB6H616t/at5qdvctPewzw3Ov2c2n+VgobMSW+0p3cHhy3IzICOMVveGNcsrDwNaS3ziE6cF064iXMjLcRsIfLAAyzM+AoAy25cZyMgHU280dzbxTwOskMqh0dTkMpGQR+FSVi6V4ks9S1AWSQ39tcNE00a3drJB5iqwV9u4DO0soPruBGQQakl8R6RHqttprX8JvLj/AFaKSwyQSoLDhSwDFQSC2x9udrYANasHxZ4hOgWyypai52xyXU4Mmzy7aIBpZOhyQCoC92YDKjLB9t4s8P3U0UVtrNhLLJIsaIkyklm+7x2Dfwno2VxnIzHe28OreIbuxuQrQRaaYpE7stw5B/SD9aAOJ1z4ryaLN40sr3SR/auiS26WNssv/IQW4IEJU44OThsZxXqNuZWt4jcKqzFQXVTkBscgH0zXl1v4b8LeM/Gfh3xDqty48W6RbqJ7GOVQvmxk5EilckxyMSMEdVPKkZ9VoAKKqDUrEpZuL22KXuPsreauJ8qWGw5+b5QTxngZqqfEeiDTor/+19PNjLKIUuFuEMbOTgKGBwT7UAatFZT+ItGSO+dtUs9ti4jucTKTE5baFYDoS2VA6lhgc8VDbeK9BuZZ0t9VtJEhha4kmV8wqi/fPm/cyvBYZyoZSQAwJANuisWz8U6Je6jFYWmpQS3kmf3Kk7kYDOx/7jkBiEbDEI5AIRsRr4x8OvdwW0OsWc000giVYZPM2sTtXeVyEBYhQWwGZlUElgCAY/xdZY/DFhI4JCa1pbcf9fsNb92c+K9LTnAtLp/bIeAf+zGvNfjv4ut4dF0e1064gnH/AAkNol+oUsUhhk82RxjqqvEqswyAQynDAgdjN4i0SbxhYzQ6xpkkNvpV5NM63SERRl7Vt7EHAXBByexBoAj8eRW1glzqt4FlidbZ/L2nKmzaa7DZzzyvTA6dTnjtK8jupJNXlt/CmpTXDalqT6pqiRSqQ0VjIs8MQfPKk+emF6jBBAxivRxr9iNI0/UXeTyL5UaBY4nleTcm8BVUFidoJ4HABPQUAatFc8fF2mRtsulvredwHht5LSQzzoTjfHEoLsB/EMbk4LBcipYPFugz/aTFqtqYbeJp3nLbYTGpAdkkPyOEJAYqTsJAbBIoA3KzdX1ZNMltUeCWYSsxkaPH7iJR80rZIyoYoDjJ+bOMAkVtO8U6RqF3Ba29xKs82QiT20sJ3hSxiO9Rtl2gv5Zw+0btu3ms/Xbf+3tV1nSIZzBPHozQiUDO03Rdc/Vfs4OP9r6UAdXRWDpfiiwuktIr5203Up8J9jvVMDmTHzJHvwJMHI3IWB6gkEGt12VEZ3YKijJJOABQAteB/tFtj4p/BodA2sEf+R7Q/wBK9tutZ0u0+z/a9SsoPtCGSHzZ1XzVABLLk/MBuXkeo9a8Y+M+qaS/xN+Ed/c3Ns+lrdXsj3B+ZIjGYDuJ527WT5icbcEnGCQAet2x3eNdSBDfJp9rg54+aS4z/wCgj9K8z8KNqcHgLS5tDuFtdRbwxoEEE0kYdFLySK3B4PB6fT2rtdK8Q6Lc+Jda1a21fT5dLWxsYGvEuUaASebcgJvB27sunGc/MvqM8r8K/Ey6l4N8BaEdNvLZn02ImW6XYM2qWrAqOQyyLJuU5HCnjOcAHA23jrVx8Wbbxi76sPB15qsmiqW/48TBgRRzL833jMrsSR0r6arK8JMX8LaQWl81xaRBnzncwQA/jnNVD4v0YzW4iuhNbTKH+1xDdbxhsBC8g4AfI2no3Y9KAOgrlfix/wAks8Zf9gW9/wDRD1bbxfogzm7cYbH/AB7y8px++Hy8wcj9/wD6sf3q5/4t+INJX4e+MbA30JvjpN5GsCnLs3kNkKBydoILY+6OWwOaAO/orDufFmh27Rh9QjZZUSSN4laRH8z/AFahlBUs/GxQdz5G0GtHS9RtdUtFubGXzIixU5UqysDhlZSAVYEEFSAQeCKAKFxq1nf3uoaFaXk8GppEymRYHxExRSCrldjMBIjbQSeRkV5D8NfHHiTxT4h8PeGbq7ePVNDa7bxK4jA80xP5cKA4x8xYMcY+6ccV6dFby3nh+y1TTZDe3Aujqdsx2gzRSMx2DPGfJkKKSRyFyRg1Z8KHTrqbUtQttB/sjVJZVjvxNBEk7uEV18x4ywf5ZAQdxxkjg5FAHQ0VWn1Czga5We7t42toRcTh5VBiiO7Dtk/Kp2PyePlb0NUbDxJpGoXS21nfRyTljGUwQVkAJMTZHyyAAkxnDYBOMA0Aa9FYaeLdDkntIotQSRrpgsZRGZeThSzAYRXJARmID7l2ltwyl/4t0SwE/n3jM0BYSJDDJMyheHfaik7FPys/3VYFSQQRQBu0ViS+KNKSeaFJLq4khOG+y2c04yOoBRCGIOAcZ2kgHGRUbeL9DDQgXrP50QmRo4JHUg/dUkKQHbnbGfnbBwDigDforETxXojQwSHUI0WZ3QCRWRoyg+fzFIBj25AJcDBZQeWAMa+L9GMEsj3E0UkUixNbyW0q3G5lLriEr5hygZuF6K5ONrYAN+isOPxXoksN7Kl+nlWirJIxRgGRvuNHkfvFY/KrJuDMCoyRin2/inQrmWZINVs5Fiha4eVZAYgi/ePmfd+XgsM5UMpOAy5ANmisWLxRpE01vHHdkvMwQfunAjY/dWQ4xEWJAUPtLE4GTULeMdCWEzC9ZoQw3SJBIyKh/wCWxYLgQ9f33+r4PzcHAB0FFY9z4l0m3aZDd+bLExQxW8bzSMynDKiICzsv8QUEr3xTJvFWixOFN+jho1kR4kaRH3AFEVlBVnYEFYwSzAggEUAbdFY7eJ9FS1guZdRghhmDMGmJj2BSQ3mBsGPDDad+MN8pw3FJB4n0maEyrdMoE5tykkMkb7wN33GUNjb827GNvzZxzQBs1V1W/ttK0y71C+lSG0tYmmlkfO1EUEknHsKzX8VaOkN1K1zIFt2jVh9nk3P5jbYzGu3MgZuFKBgxBwTVXV9StdYspLTTpvNliurIzxsjL+6a4Td94cghZFPXlWU8ggAGzol3cX2j2N1e2n2K7mgSSe1MgkMEhUboyw4Yqcrn2q7WVpU8NrpNzPcTxx28M908ksjBVRRNISSTwAAOvtUVt4o0meSKJro21xLIsSQXUbQSksCVyjgMA2OCRyeOvFAG1Xmf7NZJ+CPhfcMERSj8p5BXY3HirQ4LlrdtSge4RykkUJMrR4OGZwuSqKeGc4VT94iuQ/ZwDL8FvDavjIWcZBBB/fycgjg/UUAelUUUUAFFFFABRRRQBxXjb4f2Pi/xZ4W1bVTbXFlov2rzNPubVZ47rzo1UZ3HA2lQ33Tk+nWuOPwYvrfQNE0nS/EtrawaVrh12LdpW8GUMTGmBMMIoYgjvx0xXs1FAHlXiL4Sv4j8U22ravq9k6296l4jwaSkN5hDlYvtIfJQcDlScDr3rd+JPgM+L7rRr+01FNP1PSjOIJZbUXMTJNH5citGWXORjBzwR3ruKKAOK8L/AAz8NaFpugwvp9vf32jQrDbX9zErTLhmfIP8PzMxAHTNZXg74ZT6L40TxJq2tQX93DaNZwJaaZFYqEZgSZNhO9uPYD0r0qigArzT4NRI158QGdFZk8W3jIWXlT5MIyPTgkfQ16XXmvwVObn4if8AY23n/ouGgDpZvAvhibTb+wl0a0a1vv8AXKVJOBu2hT1QLvfaFIClmK4yae3gnwy97qF1LodjNLf5+0iaISI+4gt8jZVdxClsAbioLZIGOiooA8z8RBk+LOkWYjBiuYTckhtpDJLbhR9MRsT+Vd6+j6c+rR6o9jbHUUXatx5Y3gYI6+wLAHsGYDhjnyv4iXtzafF3SbiBikdpp7s7Afd321+wIPTObda9I8F3Mlx4ZsVuLs3l1bBrO4uSMGWaFjFIxA9XjY0AW9a0bT9ctkt9VtUuoEfzAj5xnBUg46gqzKynhlZlIIJBSfQtIuNNm06fS7CXT5yDLavbo0UhGMFkIwfur1HYelaNFAFPU9Ot9R0yexnUrDNH5eYztZPRlP8ACwOCCOhAIqhpluugaXNcavdxT3c0gku7tImjWVztRcJubaMBFwCeme5rbriPjHq8Gj+CXuJ7qO2/02yG5pAh2/a4d5GfRcmgDovEmg2XiHT1tr6Mb4pVuLacKpktZ05SaMkEB1PI4x1BBBIOJY22o+KYXi8S20lrp8Uf2ae0U+Wl9MGIlfGSxtztARSRvVm3qVK56CfVreDX7LSHEn2q7tp7qNgBt2xNErAnOc5mXHHQHpjnQoAx4fDOjQ3V1OunQNJcgq4kG9QpILKqtlUVmUMwUAM3zHJ5qydH046k+oNZQG8dCjSlASQQAfxICgnqQqg8AY8JtvivqD/G5EbUSfCM+oSaGlsYCFWRUULOJduCGm3LjdwBmsv/AIWT40+ybNl19l/4TX+zv7V8yDZ5Hm7fs3l/f6fxY/GgD6MOlacZ7KY2Fp51ipW1k8ld1uCu0iM4+UFeOMccU+/06y1FIV1CztrpYZVniE8SuI5F+665HDDsRyK574ieJbrwxpdtc2cdg7yzeWReNOq42k8eTFIc8dwB70/4eeIrnxNos15eJYpJHcNCBZtOyYCqefOijbPzHopHTnqAAb2p6fZarYy2WqWlveWcuBJBcRiRHwQRlTwcEA/UVJJa28tq9rLBE9s8flNEyAoyYxtK9MY4xXmnhXxBrD/G3xVoeq6zBdabb2UVxaQRwrEIdzn5TySzBRgnPOM4HSvPLrxnr+k23j298MeLLnxBpOnaWFjub7yWf7d5gEjwKqjMSIxJOCucckCgD6Lt7CztrO3tLe1t4rW3CrDDHGFSIL90KoGBjtjpVSx8PaPY2i21ppdnFbrcfa1jWFdqzZzvAxwwPQ9sADAArzr4Pa5qVz4v8VaHc6zPrem2EFhcW93OUZ1eaHc6FlABGRkDsOKoax8UPE0Pie4sdN0nRpLJNfXw9G09xKsjTPCXRzhSAgxz1J6ADrQBD8Uby5034hS6npUjRajb6S0YkQ8lBe6e3lkHjkPIOeoY16ppHh2303UZLtbm6nIDx20czKUtInZWaOMAA7SyqcMTgKFGFAFfK+qfFDUtT1S81O406ySdVuLS/ZEkljh8p7Y5AX5whMancc43Eds19Z+H9QGraDpuojZi8torj5M7fnQNxnnHPegC/Ve8sbS9a3a8tYLg20onhMsYfypACA65+6wBIyOeTViigCvf2Vvf2xgu4hJGSGAyQVZTlWBHIIIBBHIIyKi0rS7TSoHiskcCRzJI8sryySNgDc7uSzHAVQSTgKAOABV2s3Wtd0vQxA2r3sNmkzbVeU7VHTlm6KuSq7mwNzoudzKCAP13Tl1bR7uxZxE0yERy7AxhkHKSKD/ErBWB7FQax7Oy1LXwk3iSBrG1QJjS0lVxJIpyzyuv3lJ+6gONoy+S2yPp6KAM+00bTrSS5eC0iDXDBpCw3ZwSwAznChmZgowAWYgZJJ47WfDmlz/Gfw3qLWiLdjTNSuHdRjzXBtIRv9cJIw/L0r0GuV1L/kqfh7/sC6n/AOj7CgDbGj6cL62u1s4RcW0YjhYLgRqAwGB0BAdwDjIDsBgMc+VeBr3Ro9I8Ez63eLbHQ/DemXsGWx81xFJbEkdSOQMepWvZK+edJ0nzbPwjczws9teeCNOgJ25BMNzbsQPfE3+cUAewweDNME90955t4skzyQpM5xbI7b3iTGPkZyxYHO5SEbKKqjo5EWRGSRQyMCGVhkEHsaI3WSNXQhkYAgjoRTqAGqiqgRVUIBtCgYAHpXIfEqzttP8AhB4stLC3htbWHQ7xI4YUCIiiB8BVHAH0rsa5X4sf8ks8Zf8AYFvf/RD0AdJa2tvaLItrBFCskjSuI0ChnY5ZjjqSeSe9ZOs+GbHUXkuYC+m6oxyNSskjW4Hy7D8zKwYbflwwOOCMFVI3KKAI7aCK2t4re3jWKCJAkaIMBVAwAB2AFc5rb3ena482l2Mk11qdulskwjaSKKSNmKtKAQAoWV2J3DIj2g7ioN2z10XGvy6abOdYtsjQXgw0UvllFkUnqrBnxg9drEHg42qAMOz8MadEIpLyJL69Sc3TXdwimR5Tt+Y4AHGyMAdB5cfdQRp6lYWeqWUlnqdpb3lpJjfBcRiRGwQRlSCDggH6irNFAEdzBDdW8tvcxRzQSoY5I5FDK6kYKkHggjjFFtBDa28VvbRRwwRII4441CqigYCgDgADjFSUUAR21vDa28cFrFHDBGoVI41Cqo9ABwBTbW1t7QSi1t4ofNkaWTy0C73PVjjqT3NTUUAQx20Ed1LcxwRLcTKqySqgDuFztBPUgbmx6ZPrSm2gN2LowxfaVQxiXaN4QkErnrjIBx7VLRQBWnsLS4vLW7uLW3lurUsbeZ4wzwlhtbYxGVyODjqKW8sbS+EIvbWC4EMqzxebGH8uRfuuuejDsRyKsUUARXdtBeWsttdwxT28qlJIpUDI6nggg8EH0qXAxjAx0xRRQBBY2ltYWkNpY28NtawqEihhQIiKOgVRwB7CnwQQ26MlvFHErO0hCKFBZiWZuO5JJJ7kmpKKAK8Fla29zc3FvbQRXF0ytPKkYVpSqhQXI5YhQAM9gBS/ZLb7aLw28P2wR+SJ9g8zZnO3d125AOOmanooArzWNpPe215NawSXdsHWCd4wXiD43BW6rnAzjrgVS1Gwuptb0q9tZY1igMkd1G+f3kTLkbcfxCRIyCexfua1aKAOYs9BjuNbu5NRsQ1lZ3HnaekzK6GV/wB5JcBQeG3uUBYbl2MVwHJPQX9nb6hZy2t5Es1vKNro3Qj+h9+1Jp19banp9tfWEyT2lzGs0MqHKujDII+oNWKAI7a3htbeO3tYo4YI1CJHGoVUUdAAOAK85/ZvZm+CnhgvjJil6dMedJjH4V6VXnP7O8flfBjwuhOcQP8ArK5oA9GooooAKKKKACiiigDgviH8RrLwP4p8K6frHkQaZrH2rz76WQqLbyUVl4AOdzOF7Yrj1+MmrXvhvQdY0jRNNmg1bXToUXnXzpiRmIjk4jPyEKSe44wD29N1nwpY6v4s8OeIbmW5W90L7T9mSNlEb+fGEfeCCTgDjBHPXNcjc/BrSJdM06wg1zX7WCw1R9Yh8mWDIuixYOd0R+6ScD3Oc0AZ03xaux8RLnw01to+nyW11HbeTqV3JBPeK2MyQny9hHPygtlsds11PxY8eR+A/DrXkVmdR1J1d4LNX2lkRd0jscHaiqMk46lR1IqLVfhnp+sanBc6zrGuX9pDdi+TT7idGgWUHII+TeFz/CH2+2K0/HfgTw/44057XX7GKZ/KeKK5CKZrcN1MbMDtPA7dqAH6T4y0a5tNDXUNT02x1XVbSC6hsJbtFlbzFyAikhmGcgEDnBrm/CPjvWtQ+JV/4T1rTdMie3svthlsbt5TD84URyB0XLENn5cgfjx2Xh3w5pnh/RtO0zTrWNbewiWGFmRd2B3JAHJJJOMck1z/AIb+HNjo3iZNeuNY13WNRht2tbd9UuhKII2OSFwq5J9WyaAO3ryT4SaxbWF78REnivmYeKr2TNvZTTjGyEdUQjPH3evtXrdeX/AsgyfEXH/Q4X//AKDFQB1GqeNbGys3nt7DXNQZGQNFaaVcO4BcK38GMqCWK53YB4zxVr/hLtGSIvc3TWhQ7ZVuYniMLdg+4fKT2z97IIyCK3qKAPKJ5n1jxd4qu7m0ktY10nT/ALGsyMJGRpL+LdJGQCpbzHwp5ClS2DlR0djqkOiLqGj6VbNe6n/alwIbbd5YZ5sXTu7YOyJftA3Pg4yAAzMqnk/iBf3Np8SWjtGIEx8PLcDdtzCdQukYe/zSJx3Ga9ZWztlvpLxbeEXkkaxPOEHmMiklVLdSAWYgdsn1oAxE8ZaMtvm7uGtL1WEUmnSruu0kP/LPyk3M54JBTcGA3KWXDVHfeL4bRfPbSdaOnRgNc3f2FwIAQ3WMjzX5CglEYANkkAMR02Oc96KAMFfEqJD9pvNM1SysS2BczwqF29Q7KrF41xyTIq7f4ttcj8TLeDxNpWt21nLH5q2ENpbXq4kjR7mVWYHGckLFBJjrtZTzkV6ZXMeNFt7fS7eIxIsMk0sjBQVG4QzS7jj/AGlyfUmgDF1LWN/i/wAMTatpOoWElvM9tJcSLGbeOWZCqIJN2WDsFClQRkqrbWO0dneatY2lyLae5QXJUOIVy0mCSAdoyeSrAcc4OOhrE11oZ9alsLvLW1zHbROqu0bDcbjBV1wVYFVIKkEFQQQea1vDujRaHpwtIri5u3LF5bq7cPNM3QNI4A3EKFUE/wAKqO1AGIo8LyaTFpy+HXOmQv56Wp0KVYo33FtyxmIDduJPAzkk+ppWHhZbTyz4fb7P9rF55Y0GYj7QTnztvlffz/H19662igDGHiSyK5EGrdQMf2VdA89P+Wf69u9J/wAJHacH7Lq21jtB/sy45P02ZH1IA962qKAOIfTfCsN7capB4XFnqsjOH1GDQt1wssgIdtwjYsTuOWwynJyTk1yWn+H73wozXGjeFvD+oxyRNHKx0RdPuDE2MhnhVw4b+4Ih7gDkeyUUAeT2PjO38KWVnHZ/DXWtIs7i4/0o2VhGsMSlW/e4j5PzBAd4Q4YnsAdvRfEHgbxFK0uhWdrqk32sXe6304lhdAFRIxKjZIBxvcr1xnrXe1ia54U0HXZVm1bSbO5uF+5cNGBMnGPlkGGX8CKAPEbXSvDWl/Eq0g8UadpNtHqGpXksVveQQbYZ3g0+RYhj5dwBI3DqxPJLc+raBr12+l2VnpWmpqEthaImobbpF8mZQA1upwVaYYbKkqB8u4qGBr5J/aE8I64/xZv9K0PTtd1K0WOKe2T99euQ0SBiGO5jzHjk9E9BXqPwL8VfE/w+0GieMPCmvahoqgLHdvA3n2o6Dlv9Yg9PvAdM4AoA97XxXpD4SKeWW7yA1nHbyNcx56F4Qu9ByPmYBeQc4IoGvXDzhodC1R7DkG5ZERs+oiZhJjO4ElQc4IDKdw3RyKKAMNtcuYZHa80LVILRRzMqxznOcf6uJ3cg5HIB75wBms0tZ+Kr/VTFdwT6QLH+z47iBgw8yYnzlDdG4EGMZGSR1yB11cX8XbpbPwXcTMdpgdb1G9Htgbpf1gHXI9jQBq6frU9r5Vn4kjW2vi6xC4hif7LOWwFZXOQhZiFCO27dwNwKs2hqOsWGnSpFd3KrcSAtHboDJNIB1KxqCzfgDWb4iu0l1jS9AurB57LVIpy9ykxjaB4gjJjb8wY5JDqwKlARzgjQ0XSYtKimxNNdXM7757qfb5sxAAG7aoHCgAYA4HrkkAhbxDZKMmDVOmeNMuT/AO0647XvE1pbfFLwext9QZLrTtUth/oM4dSGtJM7Nm4j90RwO4r0iuV1L/kqfh7/ALAup/8Ao+woA1F160YhUg1IuXCAHT51yScdSgAHuTgdzXj/AMItPOm2fgi3ml8+51DR0v5JGGBz9jEajnqsVsi/8BzXu1eC+Br5YvFPwngJYmTwxbQ4UAjJtZHy3ccRe+c0AesaPrlvBoumRXhlOofYopZraGJ5pY8jGWVASPmDDJxkq3oasLqmpsVceH7tYs4dXuIRLznlVDlSPXLg88A1PoJ01oLqTSLeK3R7qYzhIfKLzByHdhgZLEZ3H7wIYEgg1p0AY/8Aa96FBfw/qY55w9udoz1/1vPHOBk1z3xS1Fpfhf4tU2N6gk0a82s6ADHkPyecrx/ewfx4rua5X4sf8ks8Zf8AYFvf/RD0AbL6hcrIyrpF+6hchw0OGPoMyZB+oAqnc+IJ7RRLdaBrKW+cPJHHFOUz0OyJ2cgnA+VTjOTgBiN2igDhlvbiztbGaZIYhpeoM+qmR1ZlWS0eaQoeANrzKSP7iNjJwD2dpcwXlulxaTxTwPyskThlbtwRwa4TSpHbxtrCkjYviUAZ6/8AIHhOB+ZNdBqnh+a4vrl7K8Npa6hsGoIAS0gUBf3ZBGxmT5Gfk7VXbtKg0AXpde01BJ5dwbgoxRltY3nYMpwy4QE5B6jt3pv9u23lmQW2pGNW2M32CYEHt8pXcR7gEDuRxWjbwxW1vFBbxJFBEoSOONQqooGAABwAB2qSgDLOtQ7GdbTUWVBuk/0OQFR7AgFj7IGPtR/alyeU0XUmQtgNugXI/vYMgIHsQD7VqUUAY7avebn2eH9VdVGVYPbjf9AZQR+IFSDVZnb9zpGoyJ/fIiTnuMO4PHrjB7E1qUUAZSavM+B/Y+pBgMyArGPLPXGd+G/4BuHOOtB1eTcY/wCytS84DcY/LTAX137th+gYt7Vq0UAZjapKFBXStQZmPyKFQFxxzktheD0YqeMYzxTDql8JGH9g6gUA4YS2+Sfp5v5fritaigDJi1S8dkD6DqUe4gEtJbkL7nEv8qedUnSMyTaRqEaAtuP7pyqj+LajljnqAoLe2eK06KAM6PVDLEskFhfujDKbohGWHc7XKlcejAE9gajTW4JCfLtdSYZ2gmylTLenzKP++vu+9atFAGYdXX59tlqDeXw/+jMNp9BnG76rke+Oaa2ryeY0SaVqTzqRuQRoAFP8QcsEP0DFvatWigDK/taYSPG+kaksnPljbGwlwMnDByq/8DK57Z5rlfihqmpN4J1WPTtN1CHUwkUtqm1HNyyyoWiXYzfMQMYOMgnGcHHf1la1o41S90W4Nw8P9m3hu9qjPm/uZY9h9BmQN/wEfUAFOw1q0sLWW3vp4luorqaFbWBS8pXeWjVY1yxPlFGOB056VdGqzCMSS6RqMSjlwRG5jGM9Fclvou41T0KzFp4m8SSKoAvZYLotjkt5QiPPpiEcfX1roKAMyHVLiV0A0fUVVmxvcwgBf7xHmZA9sbvauS+AEfl/BvwqvP8Ax6bufdmP9a9ArhvgYgj+EHhEDPOnxNyPUZ/rQB3NFFFABRRRQAUUUUAFFeVftBX2q2On+CDoM/lX03imxhVWmeKOXIkwkhXJ8skDIweOxrx7xtruqw+CPifNr+rvZ+ILXW7aOxSy1GZURzs3pFypZfLLnaRjqcZANAH1tRXy98TtStbHxCl1pOswa/pCWVvHZaM2qXkF2uQCslq6EidmyCXJZuMdq9j+KmreH9K+HP23xkdRi0791m3guHinlkIysRZGU5z15A45OKAO+orx74N6lryfDTRhoraf4nbzZluZJtVdPsY3BkhD+U5lKq2CTjGMDIxitY+I7a1/aeu9MfxPNc2k+iFFs5rlTHDeG4X9yiKAN2xc85bBPOKAPaq8s+Ah3H4jH/qctRH6R16nXjHwYi1h5viA2kXenwxL4z1Iyx3Vq8pk/wBVwrLIuzvyVbr04wQD2eiuet5vE9oGS9tdM1PBBE9o7WpK55HlPvAYDp+8w2OdlNiPiyTfdP8A2LErDcmnskhdMA/K1wGwSTgkiLC8j5/vEA5bWrB1+P2g3TRhre90SaJ95+UtbzK64GeoMwPI7Ag8GvTK4rUNZjsfEOi33ifSoNNSYyWVhdveh5ElkCsYXQDGZPLO3aX+4BwWAqvoGu3+nTXt/wCKpnt9PvrKXWIklGTYxRtho2AX5SImt2K5b9552CRigDvaK5BtJ1HxVJEfFVhDZaSiF006O7MryyMBteYqqhWj5wqM67zvDZRGrNvtJ1648XaVpMt5qU2gR2k73F8szQPMp2ARM8LKRMsiq6uAuULr13FgD0GuI+KszxaMhj+9HDe3H4LZzj+bitW6Gt6NAtzHM+twRIfPt2jSOdgOjxFAFZ8A5QgBiwKmMDa3n3x18SW9jpfh7UEumbRr2C9SaSA7hLFLaMkfQ8gyPF+hoA6jxK3/ABVk5DHMP9juQTx893cJx7813dcF4pcJe+NZJVR/I8PW04BAOHV71gw9CCoIPYiuy1PUbXS7Q3N9L5cW4IMKWZ2JwqqoBLMTwAASe1AFuiuek8TAutvb6Tqr302WtoZLZo1lTIBkaQ/LGozkhyHwOEJKhlisvEbILh9Xs4rqQ/PbG0862iXnCoQySMwyoLlsNgkRpnAAOgorBW28SsMtqelRuoVQFsXZH67nI80EE/LhQxxhsltw2IuneIYbcCHX7aWdvmdrvTw6hic4RY3QhBnADFm4GWY5JAN+iuf+xeJzkNrmlgbQcppbg7wD6zkbCcZGM4yAwJDCVbvX03Ry6TZSOSBHJFfHy8fxGTMYZOOgUSZPBKj5qANuisN9R12JF36FFK7HYBBfKwVucMxdVxH0yQGfnhDQNT1iJG+1eH3klXn/AEK7jkRhzgKZPLO7pkEAc/ePSgDzHxpay3fx50OC01O802do4wZ7URlwGt74gASK6EfuGySpxkY55HaaZpF5qcMstj8QfEkqRTy20n+jaepWSNyjqQbQHgqfYjBGQQa851OfU0/ab8Ixai0Ye6sluZoUZdsJEGoqka8ZfaGfLnqT0UEKO98PeJobWwtpZU8y+1ewtdRtrZBiS7mkjCOqZ67dsZY9ED7mIHNAGr/wi+r/APQ9+JP+/Gnf/Ita2h6Zd6akwvNc1HVi5BVr1LdTHjPC+TFH1989O1VfJ8SOWuftWnQSb8Cy8tpYvLx3k+VvMJ53Y2gHbsY/PWNN/wAJZqOsro73cVlb20f2i51OztzGZ9zZhWJZPMUYKSLKhJOPLYEb9oAO3rg/jXEJvh7rg4Ji02/mx7CzmTP5uK2YdU12BBbXmhtdXiHBubSVEtpVAJLje29CcfcIbDMBuZQ0g88+K/iBtRl8P2kcosNH1vSdWttRkuIv3tuDHHEq7ezCeRFIHcdcZNAHompX8UetsDuLwrZFT/dE00kf64/lXRV57fmSaPWb+5OyWDRNOvxk5AlhkuJhn1G5Vz3Iz0rqtd1l7C60+wsrcXWp3zsIYmZkRUQZkkkdVbYoBABwcu6LxuyADYrldS/5Kn4e/wCwLqf/AKPsKv8A2/XBmI6JAZycpIt8Dbhc9HYoHDYzwI2HT5uTjktUvNdtPih4fFxY217PcaVqa2y2rFI4Pns2xO7ZOwMgHmKuT5gHl8ZYA9Irxj4T6cl7q/hW6klCvp3g7R5I48Z3eYlyhPsRgc89a9I/4qi2kDs2kajEwx5SRyWjRnsdxaQMOmRhTjJGThT5Z8J4ZdKg0y6uJ5Z/tfg/S8M7EJhUumCAcgbVEa8Yz8zEZYkgHoPw1a4TTBBfK/2uSzsryRmYHJe3SM/+PQt+ddjXP3bxaN4is55N0djewpYmQ48uOVXPkqT/AA7/ADJFBPBYIv3mUG5rWpyWclraWMUdxqV2xEULvtCovLyvgEhFGBnHLMi5BYGgDUrlfix/ySzxl/2Bb3/0Q9aDL4iRyVl0mdHAUAxSRGI93zubzPXZhPTd3rmfincatB8MPFUd5Z21xG2jXkclxayEEHyG+fymHyrnOQHYjjryQAegUVydhqniNoxql3ZWraS8jbbWCKUXYtyzGOch8Hds2boNgYfMQxbER1LbX4JLuGC7truw+0nFq92iotwf7q8kq2OdjhWIzgHa20A8lnj1HU/i34y0+2N9p/2yGNbK8UMqvKtpPE8sLdCUMsasRyCgzXq3hU+Supab9ourk6fciEzXUhkkkLRRyliT6tI3AAUY2qAAAPMtMug/xS8L3WxV81tftcZwCY9RC5x68k/jXqMfmW3iTVLido4rA2VuwdiF+dWm3sT7L5fPtQBYn1nT4NZt9JkuANQnQyJEFJwuGI3EDC52PtDEbvLfGdjY0K47QdATUND1K6vJpXudZu/7RSd7dI5YArKbUbcEZiVIsbwcspLDkirwm8SzwLZG1tLW7BAk1JT5luU7tHFu37zx8jfKu7O+TbhwDo6Kwjot/E8Qs9evI4m/4+TMiTSSHB+dGYbYyTjI2lMZCohO4Ma38TWxljt73TL2JwEiluoWilgPd32HbN1ztUQ9MbucgA6CisSSy17bIYtZtBIHHk77DcmzAyJAJAWbrgqUA4yD3hF7rulo7araQanbqwJn0yNkdU7kwMzE7evyOzMM4XOAQDoaKxl19LlY/wCzrDUrpnYD5rV7dVUjO8tKFBHT7uTzwDg4r+T4oupHk+26Xp0D8LALV7iWNc9fM8xV3EdthCn++B8wB0NFYMf2zSdTsYrrU7i/trwtBm4jiDpKFLqQY1QbSqOCCCc7MY5zvUAFFY11rZkuJrPRbY6hewuI5csYoITjJ3y7SM4x8qhmyy5AByEz4iljc7dJtXYbVG6ScRn++ThN+emzC4xncc4ABtUViJD4kV8Pe6Q6AEZFpIpcno3+sO3b/d53Y6pnh7aZqMyJ5+u3Mbhfm+ywRIpc4ycOrnAPQZPB5LdaANiisJtL1e3VjYa87uykH+0LVJ1Dc4YCMxkdsjOMDgKcmpEHiGO58x30m4t2AXyAkkLJ6v5mXDZ4+XYuM/eOOQDZrK1W+u7fVtFtbSKN4rqeQXLOD8kSwu2VwfveZ5Q5zwW9qiQ+I5LlZJE0i2t0JBgVpJ2mHGD5mEEeOcjY+fUVna1b6hp9jrOtXN9HJeR2zLarFCVjgUAsPlZm3OXxufgEKo2jBJAL2js51EuWGJftKMCOf3dwwXH4Of0rdrj4wtslhqzbwLXUry3mYFmPky3DoeBxgSCFiT91UJzwa1dUv765upNO8Pm3W8jAM93cxNLBa5AIUorKXkYEHYGG1TuYjKLIAbdcV8FCx+EfhDeMH+zIPy2DH6VJ4e8NX3hO0s4dKvJ9VjWEQXC39wVLFQBG64UhdqjYQBkrtJLMvzQ/BH/kkXhDG7/kGw9f90UAdvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlXwC/5qP/ANjnqX/tOvVa8q+AX/NR/wDsc9S/9p0Aeq0UUUAZ3iHSLfXtEvdLvDIsF3E0TPEQHTIxuQkHDDqD2IBqe/06y1H7N/aFnbXX2aZbiDz4lfypVztkXI+Vhk4YcjNWqKACiiigArw7x4kUela5o/8ArlsNB8RSLG6DELh7WaAIO2xJkC46YGOle41wnibQ4dQ8T6qYjPLPcaBc20iFv3cPmMiqVGMbpPLIJJPEK4A5yAM+znX9T8S27D/kIeG7KLcvfzDejgH/AHqXwZrcvjQeG9TubdYXt9OF9cQhmHk3Uq7FAHfCCfgnIDr6g034XzPdsLpyDv0TShndnJ8uRj/6HXYaXpFlpUl/JYwmN765a7uCZGbfKVVS3JOOEUYGBx0oAv0UUUAFFFFABRRRQAV4t+0Nqeq38ukeEPDT6qNQuo5tQuW0o/v44Y1Kx55HytKyA89FNe00UAfNfhzxRDrXifwb4w1UrFLY2UcGpSSfejlitdX83Pcf6st9CPSvobQ7FdM0XTrFQALW3jgGB0CqB/SvOviJaSSeMbS7twyz297oTh1fHym7uo3BHpslcfVh6V6nQAV8zap8SfGkFp4lSFLprW28ayadHqokgCQQCVFFt5Z+c8H72D97rxX0zWU3hzQ3gngfRtNaGe6+2yxm1QrJcZB85hjBkyB8x5460AateXeO/CttcXchvZYGsrVbnV7S1jtQpQrseVHbJ3h5mSXIUEEEc5GPUa47x5EboX0MXzSHQtQQqDyN/lBc+mdrY+h9KANTQ7aK7t2mnRZFnsoLaVHXIYBWYg+oPm1zfg650rStKTULrxFbahpFlt0rTb+e4EkrKSgcSuAAZGkATGOkSnqzCtD4Uvcz+ELK6umYi6t7SaNWUjYps4Mjnr8wY/j7V59ZfDbXYfivJbm3iHw/XVT4kjPmLk3hj2iLZnIAkO/ptwo5zQB7lXK6l/yVPw9/2BdT/wDR9hXVVyupf8lT8Pf9gXU//R9hQB1VeET3g0r4cfDi62jZc6FFDMzEAKFsjtPPHG9/8RXu9fOfi2OO4+GvwStZNpW6NjbMjJuEivahSp+oOMd84oAd8NPiPeeLfH95pXiK7e58O+Jre5/s+0kgaL7OEdgse/aN2+Eb8g9cdDXvemaTa6dJcSwh3ubggzTyuXkkwMKCx7DnAHAyeOTlp0PSSmnIdLsCunY+xKbdMWuBgeVx8mAAPlxxWjQAV89/Fj4l6hA3xY8Lz2FzPa2lhb29pNa2TyJELi3zKZ5Bwn3vlJx0PXFfQledfFHwto1v4F+JGrQ2e3UNV0mSS8l81z5rW8DeUcZwNuOwGe+aAO30K6kvtE067m2+bPbxyvtGBllBOPzqe/s4L+0ktruMSQyDBUkjocggjkEEAgjkEAjmnWlvFaWsNtbrsghRY41yThQMAZPPSodWvDp+lXt6IJLg28LzCGMgNJtUnaM4GTjHPFAHiv2b+zPGfw+t53mnnF9rqrLMFDyu2oRMzkKFXJXe2FAHoABx6j4p0qTVL21S2mjBeCW0uYWnMbfZpSm90AVsuPLAGQPvN8wrmtY0ZofEnwtN8GudUs5riKe4QnY2bORpXIxzulSM7jzn3NZvxustZ0jVvDvjjwppdzqmq6W0tpcWdtGzvPbyoQMqoJIVwDwO+e1AHrMcqSgmN1cA7TtOcH0p1cn8K/DknhXwHpWm3RLX/lme9cnJe4kO+Qk9/mYjPoBXWUAFFFFABRRRQAUUUUAZ+v2Ut9pkkdsUF1GyTwGQ4XzUYOoY4JCkqAcDOCcc1kz+JvtmmwR6NHjWbt2gS1uFBa1kXHmNMqt92PIJw2GJQK37xCemqCO0to7ua6jt4UuplVJJlQB3Vc7QzdSBk4z0yaAItH0630nTYLK0DeVEDlmOXkYklnc/xOzEszHksxJ5NXKKKACiiigAooooAK5r4kTfZ/BGquACTGqgEZzuYDH45rpa4/4tyLH8P9Td/uhoO2f+W8dAGvotrFdaLeW17BHNbzXN5HJFKodJEaeQFWB4IIPIPrVzSNLtNIsxa2MbrHuLs0kjSu7HqzO5LMT6sSaZoShbKUL0+1XJ6+sz1oUAFcV8EyT8I/CG45P9mQD/AMcFdrXEfBAY+EPhHj/mGwn/AMdoA7eiiigAooooAKKKKAPI/wBpC4vodC8Iw6YbhpbvxLZ2zQQXj2huVZZQYjKnKhuBnt17V53o2uapp/w10fxcNW1Se58Na9KurabLPI8ltaSP5b277jmQoCpVm6bj0xx9QUUAfNOrapr174C0ezS41v8AtvxvqcurSR2Llriz09SGCRfMNo2+V3AO5+tenfBnxTfa18LIpr2Ca41/SFl0+9tmbEr3MAxtJJ+8w2kk92NekUUAfPPwk1zxkfiL43h1Wx1C71hrW1ufsV9dLDbW0jZJjUqZNi4OFIViQnzbSam/aD1KL/hFbZtWuV0bxmIvMtrO31O6KhfMYAwGNUWSU4UYdeMn2J+gKKAKWhyvPothLKtwkklvGzLcgCUEqCQ4H8Xr715N8F5tXjf4jf2TZWFyv/CY6iSbm8eA7sx5HyxPxjv+nevZq8q+AX/NR/8Asc9S/wDadAHZPP4t2fJp2g72x1v5sR88/wDLH5+P93+tPNx4qBLDTdEcEHEf9oSrsOf7/kHdkc/dGOnPWugooAwftHiffu/s3RQoAHl/2hLknud3kcY6Y2nPXI6Uom8TNybHRk2LnH22VvNOemfKGwY5z8/pjvW7RQBhrL4keQq1po8KAbhILqWUsf7uzy1x/vbj/u9qUTeJHeJDYaPAjD95KL2WUxn2Tyl3/wDfS/47dFAGGbjxKFJGl6MzZwF/tKUDHrnyD+WPxPafRNKksWvLi+uReX95Julm2bFCDISJFycIoJ4ycszt1Y1q0UAeYfDW8i0PwSNRvVZxFpumwhIwPMmf7LEEjQEgFmdwqjPLNjvXV2Fp4ohie5udSsJ7iZN7WTwERQP/AHI5Vw2wDgs6sScsNoOwYPga1W6g0Ham+zggjvVkVyNsi2kEKK3ZwQ8x56MinqK9CoAxxL4gCI5tNKd2b5oftUiiIcciTyzvJ5ONq46c9acJdeMe82mmB848kXUhGP72/wAv/wAd2/jWtRQBhtL4kIkK2ejqU+4pu5W876nyx5f5P19uV+0eJAP+QbpBO7r/AGhIPl/78de36+1bdFAGHJB4lliDR6ho9rIeShsZJwnHTd5ybue+1c+gpwl8RNhDZ6SmTtM/2uRsD+/5flDJ/wBneP8Ae71tUUAY7f8ACQBTtGlMwYgEmQBhzhsc7T0G3n13dqAviCIYMmlXJAzkJJBuOT8uMvt4x82T/u+uxRQBymsaZqM1xa3TRWLzyXVr5+3zfkiikZwoIyGILN8xCDB5HQVrQnXHCvMmmxEnaYVd5Noz97zMLnj+HYP96tWigDMYay0uVfT4o0JG0q8hlGODnK+XznjD/Wo54dfDxvb3ullFGXiezkBkPoHEvyfXa2PQ9K16KAMd5NfUgpa6XIGXJU3MibG/u58s7gf72Fx/dNGj6Q0C31xqLpPqF+2Z5FzhEGQkKE87EBOOmWZ2wC5FbFFAHA/DbXrWP4RaPqUIeeGKD7PHGmN0kiyGJY1yQNxcBRkgZI6Vv2dt4kt7bzLi/wBPvbhhveB4GiQOeqJIpJVBxgsrt1yeQFxPCWnxw2PhHSY4II7ew05b2eONNoWdlVUYgcfMWuGPfcuetd1QBlJ/bjxneNNhkbkAF5An+z/Duzz83y49DXK3kmtt8TdAaa102OY6PqQVEuXdQPOsuS3ljPO3jA4zz69/XK6l/wAlT8Pf9gXU/wD0fYUAX1m8SbdzWOkbgwXyxeSYcd23eV8pH93ac5+8Mc+TaZpF7rvhH4NQz29jGLaG2vIXNzI3MNsskeVCAZbYAckhc8b690rh/hlp4ufh98PrsvtNpo9sQu37262RetAGvey63FJaxtqWlW013N5cUZ0+WcAhWdk3CVc/KjfOQo46ZIFWP+KgKqP+JUhfIZv3jeRwcEDjzcnHGY8ZPJxzn6rqIfxrpenS+WghkinhPO6R3hvFZfTgR5/E+1dTQBmmLVw4Iu7Bl2gEfZXBDd2z5h46fL+tcx8UU1NPhZ4w+0XFlP8A8Si8yEgaLK+S/Ql25A59+nHUdzXK/Fj/AJJZ4y/7At7/AOiHoA2tmrbyPtFjsxkN5D5z6Y3/AK5/CqV3pmq6i4ivr+1SwM0cxitoHSXCMH8syGQhlJADfIMruXHzZG7RQBkaiXXxFo5UHYVnRjzgfKp/9lqLUWn1HWTptrfvZpbQLcTtbsvnbnLLEPmVht+SRj6lVHK7gbeooP7S0qTAyJnQHHrG5/8AZai0GPdNql4cZubt8DbgqIwIsE9+Y2b/AIFQBCtn4iCxqdY007OrHTmy/Pf99gcdcAc8jA4qw/8AbUqAINOtXIyXJe4APpt+TP1yOnQ541KKAMmdtdjU+RHpk7Hgb5JIgv8AtcK2f93j61CJ/EnU6do/YbRfy8+rZ8nj6Y5z1GOdyigDJMOu5BF7pmADlTZyfOe3Pm/L+R9faom/4SOEsqnSLsHcwkIkt9vou395nPdsjH901t0UAZCDXpEVnfS7d3X5owkkwibHUNlPMGccbU6+3I0OvNJlb/TEj2kbTZSOSezZ80ce2PxrXooAxntvEBWPZqmlqw+/nTpCG+n7/ig2/iHy8DVNJ8zPX+zZMY+nn/1rZooAyY4tdVWWS70yRmJ2yrayJ5Y9CnmHf/30uPehjrsYjRE0y43cPKXkh2e4TD7vXG5fTPetaigDJaLXVVSt5pkrDOVNpJGG9MN5rY/I59uoRYNeCtu1HS2OflxYSL+B/fH8616KAMiOHXyWaW/0tAw+WNbKRth9C3mjcOvO1fw6U4wa5uB/tDTNvp9hkz+fnf5/WtWigDK8nWyVH27TRjO4/Y3O/jjA835efrn2ri/jFLq9v8O9Xe6bTzBE9u3mIkm6UecnGzcNmDjnc2RngV6TXB/HOJJ/hdq8MkoiWV7aMue264iH9aANjQBrLaXbjfpqLIHmMwEknLOx27CQehBLbuuRt71oCLWt5zeacVIwMWjgqfX/AFnOfTjHqaoaLfGPwToV3lUM8VmDxkZlaMH891dHQBkuNdjmt9j6ZcwkYmykkLDkcry+eNxwccgDIzkc58Df+SQeEc/9A6L+VdzXF/BZSvwk8IA9f7Ltz/44KAO0ooooAKKKKACiiigCK6uYLOFprueKCFeryuFUfiaiuNRsbeGKa4vLaKKXAjd5VVX+hJ5ryv4xaXLN438Japq2gXniLwpaJcJc2NrbG6Mc7ABJWgH3xjI6HHPrzwvjzQN93Y6t4U8NavayR6Y0FtouoeG/ttnIrSu2zGT9mcnk5wArL05FAH0xkYzkY65qCe9tYLX7TPcwx2//AD1eQBPzPFcZ4ktN3wdks9V0u7jl/syKKSw0rzpHjl2qBHH5R3sqvgHBIKg5yM15Jp2mX83gH4WnU/Dms3OmaFdyRavpsumStIWMR2P5DLmRAW+8ARyfegD6TR1kRXjYMjDKspyCPUVHFd20tzLbxXELzxYMkauCyZ6ZHUV5V8G9E8aaP8O/DdmZLDT4o2leez1G1kluEiaZmRFZZVCHYRwwbHHpiuN+G3gvWdP+LunT21vc/wBm6ZLqUl5qlxp0lpLeifhI5Hc/vyG+YMo2gDOTngA+ja8s+Ai4HxFPr4y1I/rHXqdeMfCbSb/UV8dmy8Q3+mIPGGoh0tobdgV3qTy8bHJ9c8enGaAPZ6K5SLwtqsdv5I8a+IAqbFjcR2bOFUYwzPA24k5Jbgnj3JnXw7qSTyMni7XFhYfLF5do2xiSSdzQE9xgZwO3GAADpK5u915/+Ey03SrC60+WH96moRcvNDJ5YkhXhsJuUO2GBJAyO5pt34Ta/tZLTUtf1q7sp1KXVu7wotypXaQxSNWUYxxGUB5znJzwGk+Fo9Mg1DxXZQ319dRXdlttbNd80v2ONrRwCzAMSry8EjpyT2APZaK5C38Kag8aXlz4k1a31uXDXMltPvt1JxujigkVo1QYAU7N/GSWLOWvP4evXdJG8T62ZYx+7J+zqqnABJVYgH6HhgQNxIwcEAHQ0VzZ8MTXcCxax4g1q8Gd5WGcWQD+oa3CPjqNrOw9ckA1Imj6xbIptfEt1cSjIxqNrDLGQSOoiWJsgZAO7vyDQBxP7PF0134KkubiQCW2llsplYj920c8zjPJH3JUz9DXqNpcwXlpDdWc0U9tMiyRSxOGSRCMhlI4IIIIIryj4PeHYtb+GumDU76/uNOaa7WXTpBEkM5W8lOZFRAxyR8ybtrAkMGHFdwPDdzBd3Q0vWrjTNOnmFyLa0t4cpKf9YFLqyiNz85AUNvLtv8AmIoA6SiuXTw1Np9swi8V6/DawxEJ5ssM3lfLy5eWJnc9T87MAe2AAJbfw1c2wZIPE2vCIpjZJJDLhydxkDPEXzn+HdsA4CgYFAHR0Vz58P3wTEfijW0Y/efbasW6dmhIHTHAA5PfmiTw/eOWZfE+tpISxDqLbgEYA2mHbx24z65oA6CiudufDl7NOko8Va9E6IEXy/swUfMCWKmHDE4A5BwPu7SSS8eHJmQC58Qa3PIhDJJ5scRUg5BxGiqw9mBBHBGKAN+iuZuvCkl7Gkd94j8QTKrFv3dylsTlSpBMKIcYP4EAjB5qQ+G7x7fypfFOvOSCrSZtkZlJPHywgD6gA8deuQDoqxbrXPJ8VWWjR2xlE0LSTTrIB9nJyYgVPJDiOfkdDHgj5garXHhiS6t7m2ufEOvNZyqESKO4SFocDgpNGiyk9CSztnHOQSDg+HL6/wDEXhaHxJpYNxfNeeYtrPiMfugbaWEN2BZZnB7F6APQaK5mDwqZI3l1LWNWmvrlAt49vezQRPxyIow2IV6YMeHwoy7EsWdF4b1CGyitovF2vgRAKJHW0kcgHoWaAk8cZPJ6kk5NAHSUVzmq+FItVtfJvdY14MM7JbXUJLV0J6n9zsDfRgQMcAUv9harbpGbHxRqLNETsjvYIJomHGA+1EkbA6ESA55JagBngy4j1A313G6loH/st0X+Frd3Uk+5LE49MVvWN3bX9pDd2NxDc2syh4poXDo6noVYcEe4rnbjwgL+CRNU1rWJxdKVvoobpoYrgc4VVB3QqucARMrMABI0nJL5fCz29xP/AMI9qcmh2t1l54rS3ib97kfvI96siEjcGGw7jtPBDbgDpq5XUv8Akqfh7/sC6n/6PsK0ZtFupfM3a/qwJJaMr5C+UcEZGIsNjPR9w9QcCuQvfDSQ/E/w5FBq2tJEml6lOiteNIVYS2S43PuZl+YNtYlcqOMZBAPSK5X4T/8AJLPBv/YFsv8A0QlXo9CuYrrzYfEOsKjEtJExhkR2K4z88ZK9AdqlVz25OeO+GvhOG/8Ah14OurrV9eLHSrRjHDqMlvHs+zACLbEVAUFt24fOSoyxHBAM3xjfNF8f/CsBQNGkcMpwMthotQiz9AzoD/vCvX68Oi1TToNQ1HxOkE66b4SaXQpUB86eQWgklypYnOUZRuZgdwOeOa9NtvD013DBd6pqOrR6kf3xWC+ZY7d2wSiouEkVSAB5itwOcksSAdJXK/Fj/klnjL/sC3v/AKIerX/CNNJIWutd1ycbV+X7SIhvViwf92qnPJBX7hGAVOBjmPil4flj+HXi66Ou6zIw0e9aSN5U8uX9ycAqEwo+QD5NvVs5LMSAej0VgXHhtrmVTPretNErlhElyIhsP/LMlFViBxySW4+9ycxDwhaLKjrqevgRYMSnVrghGDFtxy535JHyyblwoG3GQQC/rMvl6loK/wDPS9Zf/JeY/wBKf4c2tolpMn/Lwv2k8fxSEyH9WNc54mtb6yvdLubnWLiaxhuZpxmONJY3FrP1cDaYwOilM7sEuR8psaT4IsILezmu59Sl1SOBIZLtb2WB3CqAFKxFE2DGQm0KCWbG52JAOtorFbQ59h2a7qyTcAShoiQobdjaYyh4JUkqWIPJyARG3hzdJHK2s6150O4wsLrAj3DHKAbJMDp5gfHUc80Ab1FczbeEIoQivrXiCZIzvQSalJxJk5ckEFs5A2MTGNowoyczHwyJYpI7zWtbuUlO5/8ASzAScgjDQhCmNo4UgHkHIJyAdBRXNjwjBKFbUNX1+8uP4pjqctvv4A+5AY4x0H3VHPPc5mm8OPKx3a5rQj8tohGtwqgK33vmC7snjDE7l/hK5OQDeorD/wCEbiWBYItT1lIV+YD7dI7b+PmLsS56Y252c/dzzRF4dEcyMurawYyWaaJrssJ3ODuJI3JjBwsZROSNuMAAG5RWJF4bggnklt7/AFhGlOZQ2oSyqwIwQFkZgmeOUCkY4IycwjwuscjzQa1rsVyzD979taQBAeIxG4aMDb8u7ZvPUsWy1AHQ0VgT+GUe0Nvb6vrVsgC+WyXrO8ZAxndJuLZHBDlhnkANzTT4Wikt5be51bXJoZSHcfb3iYyZyXDx7XTPHyKwQY4Uc5AOhorn18NOXJm17XJUeIQyIbhUDgZ5yigo3P3kKnjrmox4UAvFuk13X1kjTyoV+2lkiTbjGwgrIep3yB3yfvcDAB0lFc3F4Rto5VLapr8kEa7IYW1WfEY7ksGDyEnJzIz4zgYAADYvB1vGrR/2x4haFnMjRtqkxJffuBD7t6gDK7QwUqfmUkAgA6auH+NVvJd/Dq+t4MedJc2Spn+8buHH61p3PhGK4Mxk1nxAGuNvnmPUZI/MAYHChSBF0APlBCRn1NYXjbwnbQaNatY3+tRv/aWnI3manPcAr9shB+WZnXI67gM5A5xkEAXW7xtM+Eui3T7Q8H9lMQ/AyJ4OvHArsfD11cX2gaZd3yRx3dxaxSzJHnarsgLAZ5xkmvO/iN4R1ifw1P4f0aTzvDtzZzLdNfXbTSwlLaUR4LhmIMvkMSG+Uxnghjjp7PSJdWaZNQS/0+LTibOxENwyZA5FwpRtr7lMYAdflKSDkMcgHW1yfwjXb8K/Bw6/8SezP5woaut4YhkluHn1PW5PtKBZ1GoSxhyBgMoQr5RAz/qtgOcsGIBFT4T/APJLPBv/AGBbL/0QlAHVUUUUAFFFFABRRRQAUVFdXMFnC013PFBCvV5XCqPxNRXGo2NvDFNcXltFFLgRu8qqr/Qk80AWqKZLLHDC0s0iRxKNzOzAKB6k022uIbqBJraWOaF+VkjYMrfQigCWioDeWwm8o3MIlzt2Fxuz6YqegAry/wCBBzH8QB6eMNSH/jyV6hXlnwEJI+ImT08Zal/OOgD1OiiigCvqN5Bp2n3N7eyCK1tommlkPREUEsfwANedfDvxXZyfCbWPEWigahFBd6texQ7jEZM3U8yISR8pZWTqON1b3xW8Oan4t8G3Gg6RdQWYv5Y4rueUkFLbcDJsABy5AwAcDk8iuG8PeENS8Gp4i3arZ6noGs6pYsjRARyJcPcxwz5RF2AHIHB4K8jrQB7OrBlDKQVIyCOQRS1ieBxMPBXh/wC1ndcf2fb+YfVvLXP61t0AFMlljiCmWREDHaNxxk+g96fXE/GXwzL4r+HmqWNjuGpwqLyxZOGW4iO9Nvucbf8AgVAFr4Zwx2fhhbMModLy9bZvycG7mOeecc11leMfCKPU7HR/FHjzxVptzZatqcuIbG7zE8cSZ2R/MAU3yu/Ud1NehaP4x0u7iEOp3VnperxzNbXFhPdIJI5QSMAHDMrBd6MVBZGVsDOKAOhlhjmMZlRX8tt657N6/rUlV7+1F7bNA8s0aNwxico3Tsw5HODx6elWKACiiigAooooAKKKKACsLxnqlzoXhm/v9MggmurdPNWGQkKy7xvJxzwCT9a2p5oreCSa4kSKGNS7yOwVVUDJJJ6ACuW8XSxP4i0HTp8+XqMd1bNgdQUUkZ7cA0AdZRWb4Z1Rdc8N6TqyIUW/tIroIf4Q6BsfrWlQAUUUUAFFZviHUpNK0ma4trV728I2W1ohIM8x+4mQDtBPVyMKuWPAJqW11SyubTTrhLmIR6gFNrucAzZQyALz8x2KzYGeFJ6CgC7XK6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hQB1Vcr8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QlAHn1joER8Ma1YqJWPiPxBrzT7z9wlLqEbeBxtjX15JOewh0j4zyaj8XrfR4n04+F7qZtOhfd/pAuliR8sN33CzGMcckGukkuVt9Xs7AgqLHxRJFv3kCVrmGS5xjHYTgdSDg/Srfhv4c+DpPCOlWK6TA6WU4m81JHWVbqOQ7280EOSJA/GccYxgAUAehVyvxY/5JZ4y/wCwLe/+iHrqq5X4sf8AJLPGX/YFvf8A0Q9AHVUUVHNPFBs8+WOMO4Rd7AbmPQDPUn0oA868TeONC1fwNJqFhctIs18dHjRomDi6k3Q7Ch5yN5bHoK9JryK1+Fd9D8XpdeN9bHwmbs6wmnfN5n9oGLyzIRtxjlnzuznHHevTLnWrC11m10ue4RLy5jeSNWOAQvOM/wB4gOQOpEchHCNgA0aKq6ZqNlqtjFe6XeW17Zy5Mc9tKskb4JBwykg8gj8KtUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWH4yXdpFuM4/wCJjYHpnpdwmtyq2o2v2y3SLzDHtmilyBn7kivj8duPxoAg8RMyeH9TZMbhaykZ9dhrE+Gt0934fupHAAOp3zpgEZR7mSRP/HXHNbHinA8M6vuzt+xzZx1+4a534Rywt4K0VYo/LefS7K9cevmQKM/XKNQB2tcr8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QlAHVUUUUAFFFFABRRRQB5D8YtLlm8b+EtU1bQLzxF4UtEuEubG1tjdGOdgAkrQD74xkdDjn154Xx5oG+7sdW8KeGtXtZI9MaC20XUPDf22zkVpXbZjJ+zOTyc4AVl6civpiigDyL4u6Nqmo/BLTtNi0aYXg+wi5tNPHnm0ClS+yPnzgmMbOc9e1Z/wa0XxhpvhHUodMi0/SWl1m6uBJqumSobqN9u2RbdZE8gcEbOmAOB1PttFAHiut+CbbxH8etMuYPDv2HT9EA1O81Q2pj+33ZwYkWTHzhMBjgkZBB7V7VRRQAV4p8KPD8msr8Qgdc1qygbxZqSiGymSII4YYkVgm/IyDtLFDtGVILA+115j8ClxF49Oc7vF+pH6fOooA3dR8FXd68cK+LvEdtpwjUSW8FwiySSAjD+ftMi5xyqsFPoBkGE+CNSuJ5Z77xz4meRycJbNBBGoDZjwoiPzABdxztchsrtYpXb0UAcc/geWWGC3m8XeK3tI3DNELxI2lAOdrSpGJcZJ+64POOgUDDi0wxa0vh7SYYrLSoPEEV1JBEgUG3js0m+XPc3QjLEcncSc5avTa5R7u3HxPg0+PaJzpUt5IM8nMscanH0Uj8KAK+m6FrM/m6Zql3Lb6JaTyeQ1tdOtzeISWjDSJtMSIG27V+ZjGpLBcq9hvAmlzGRry8125mkjMLSPrFyh8vPyrhHVflGBuxuOMsWYsx6uigDlH8A6G0UMA/tIWMblmsjqNw9tIh/5ZNCzlPLyB8gAGBtxtLKas+k2/gq8g1LREt9P8O/6vU7CNNkMYOAtygHyx7D/rOilCzMcxjPa1Fc28N3bS291FHNbzIY5IpFDK6kYKkHggg4waAOCa51jxVe2dvd6cy+HZtSW7tr2ylRlktoPnjE27n95LGrgoCpjZQT1z2V7omlX8F1BfaZY3MN1IJriOa3R1mcKqhnBGGICKATzhQOwrQooA5hfCJi3La+IvEMMJAAi+2CXbjAyGkVn5QBeW9XGJCXNSTwVeyRPnxn4mWdmO2VZoRsQjaFCeXtJC5+YgncdxJIXHZUUAcfb+CXUwPdeJvEc0ts5+zst80YRPmCK6j5ZiuVJaUOWKDdkFg0lv4U1O1gEMPjPX2jbzjK8620kjNI27crGL5NuSFUDaBgYwK6yigDjP+ECjkuZbm68ReI5rq4VUuZ1u1gedU3eUpMKJsCF3ICbQxc79/GJ38Fhpjcr4i8QpfSQmC4uFulzOvO3KbPLjKkkgxohyTnOTnrKKAOQ/4QaOBbgaZ4h8SWBlJ2mO+84RqxyyqJlcEs+X3sC4JIDBflpureCZ9TMCy+LvE8MCM0rpbXSQtLIVKqxZEBAUHPljCEgEqec9jRQBzMPgnSxFHHfS6jqafK0yaheyTx3DquA8kTHyye+AoXdtIGVTbyV7p8dj4+8I29mqQ6dZ6xdWsNtEoCRB9OMwUAdAGViAOmR2r1OuC8Qxwr8R/DcUZAla++2uPX/QryIn8tn/AHzQBZk8J6tdOljP4guLLQLWYPbW2mD7PPJGGV1ilm6iNeY9sYVioBLkkgMvvhtpkunPZaZqniDR4CwkX+z9SkRo5OhdSxYglcqR935icbsMO3ooA5eXwfFLNAk2pajcabsUXdndTG4S7ZDlCxfO0ZJLKm0NhQflBUsbQn8MxJdeGIr+5WICOTS3vXlSWLPAh86TZEy5yMYUqChH3WTq6KAOZ0/RNWm1Sy1PXdW81oS8w06CNRbwSsmxdj7RI4VGkBL53M24LHgKMTRfD8+pXeqWGtWM1jbaY8ttp89rMVSWOWZLhJEGBh4/LgGcEB0cDINeg0UActd+E7u9nf7X4q1/7IZVcW1vJFbjaCGKGRIxJgsOSHBx8owC27lrvwvfP8R9Lg1TxVrd4brRdSUtGYbYwqJrPiMxRqyk7gS2d3yLyBkH1KuV1L/kqfh7/sC6n/6PsKALK+G7h76O4vPEmu3MSbf9GMkUMbYYMMmKNG6hc/NyBtPyswbjfhd4Ra6+HfguW78R+IJrJdNtrj7ALlIoiWhBCl40WUou7AQuVwACDivU65X4T/8AJLPBv/YFsv8A0QlAHL+LNIsfDVz4I0/SYjb2Z8RQFEDFtpaG64yTnAUKgHZQqjgAV2H/AAi5jluJLLW9Ws/MlkljSBotkJkJaTajRlWy5L5cOQehAJB83+LLXtt8XfA++5VrG9u7UQWrMzBZIZJfNkC/dU7biIbs5PIPAr2qgDnJPDE8rs8viXXmkJbDLLFGFRlAZAqxhTnaCGILqc7WXJB5/wCJWiTW3w38aSS63q11bDRrwxWszxbIsQvj5lQSPxx87tnvk816HXK/Fj/klnjL/sC3v/oh6AGxeELlZGlfxX4iM0lx9pk2zRhC3y7UVDGQka7ThB13HfvOCJ4vBunTlJNfkn8Q3Ko0Yk1TZIgDAg4hVVhU7SV3KgYqSCSCa6WigDj7K+v/AA9dy6ELLUdXihhjlsJgMvJFhg0Ukr4QumwAMzAsJI93O5zpaZo0d1YSS6/pth9uvZku7mFR5saSpt8vDMBuKBE+bA5UkAZwN6igDmL/AMF6fdapJe213qem+ed1zBp101tFcvnPmOEwd/C5cEMQoUkqMU2HwXbQRvFBq+vRwSAtLGuoP+8lJz5u77yNnJKoVQljuU11NFAHNW/hKOB1lTWtca6MK28s73e5polYlVYEbQQCRvRVfkksWJNLF4UFuWa11zX4pACsLNemfyVPJULKGV+cndIHYZwGC4UdJRQBy9t4W1CFI1PjLxHKsaBY/MFoSpC7dxPkZc9T85YZ5xkDE0/hVJUkVdZ16LzkCzFL9syEFcsM58slQy/u9g+ckYZUZeiooA5IeDJHidLjxN4ib5XhTy7wx7ITnYmQMll+U+axMjFcMxVmQ2oPCvlxkSa7r00wiMKTPeYKAHKHaoCMy5PzMpLZ+ffgY6OigDAtvD11Gym68S63eKpBCyGCPnjJPlRITkBhjp85wAQpV0fhi1S58032sugYukTanPtRj94/fywPHysSq4+ULk53aKAOUvPBUc8J8nXfEFreywiC5vYb397cJg5BDKUQkksGjVGUk7CoJBvL4d2WsSJrGsi8iXaLw3W5z7mMgwscccxn164NbtFAHNyeEYGkjnj1jX4rxB/rl1KVgW2Mu4xMTCTlt2Nm3KrxgYqB/BUNy5Oo674ku1zvCjU5LYKxVQx/ceWTkruwcqpLbQoOK6uigDlB4OZruN5/EfiGe281riS3N6YxJKV2g74wrKgBP7tSEyAdoIObY8MgWr239s635GAkY+2HfHHkblEmN7bgNpd2Z1BJRlbmugooA5uLwjbwzQvFquuqkUhdIjqMrLtIPyNkksN58zLEvn5d3l/u6itvBlvAiw/2xrz2iv5ggN+y5Y8sTIuJDub5iC5APAAUlT1NFAHnvjW2i8F+EPEd/pRjjt30qfdHcO8rS3SofLcknc7uMq7sxYhI/Q0/wb4buX8F+FVi1GeziOiWllfRR5DyxpENojkBBibLMC687WONrBXWz8Z9LGq/DTXB5rRPaQNfIVHLGH95s+jBSp9mNdN4dt1tfD+mW8YISG1ijUHsAgFAGb/wjDsjiTX9deTBMUn2hVMMhJJcBUCvyR8kgdAFACgZBr/Cf/klng3/ALAtl/6ISuqrlfhP/wAks8G/9gWy/wDRCUAdVRRRQAUUUUAFFFFAHN+MPGekeE2sYtSa6mvb5mS1s7O3e4nnKjLbUQEkAdT0rKm+J+gBrWG2h1e8vZ7c3RsrXTppLiGIOULSR7cp8wK4PJPQGoPHvhPXLzxfoPirwnPp39qabFNbPbakXWGaKTGcMgLKwI9Dn8OeV8ffDfxN4we2vLy28Mpra2phXVLa7u7Wa0csx+TaCJUAK4Dbed3rQB6jq3ibSdI8MN4h1K7FtpKwpMZpEYHa2No243bjkALjOTjFS+HdZTXdPN3FZahZrvKeXf2zW8h4BztbnHPX6+lcp8QPAt74n+Gdt4eGpJPqlqLaQXd4DsuZYSpJkAycPg5xnGe9ZfgX4WyaXoV3aaxqF3ZmfUZ76K00PUri2gtEk2gRKylC6jbnkAZJwOpIB0Y+Imgt4un8NxHUJtTgmSCYQ2MrxxM4BXdIF2qMHqTXYV5Dq3w31nUPifZ6/broml2sGopezX1nLcfbbuNVx5EiH93tYcE56DgDkH16gArzX4HLtt/HBz97xbqZ/wDIgH9K9Kryr4SaDpWoW/jCXUdLsLqQ+KdTIee2Rz/rsdSPb9KAPVCwDBSRk9BnrTWljRdzuqryMk4HHX+RrIHhPw4FcDQNIAcAOBZx/MB0B+XnrTofDGgQSb4dD0uN+fmS0jB568gUAXZNSsYlZpL22RVALFpVGASAM8+4/OsTWPEPhTSY7rxDfXmm+ZZWn726iCyzJbsy8fIC+wttOBxnFa6aNpcZQx6bZKUOV2wKNp9uK4j4w+EptW8HXUegWlksywzxzx+RlpbeSM+YsYUEmTesTr6tGtAHX+G9Xk1Swla+t4rPULaUwXdqk4mEL7VdRvwM5R43HA4cZAORVy81Kxssfbb22t9zbB5sqplsZxyeuKgvtB0i/vheX2lWNzdhPKE01ujuE5O3JGccnj3NEOg6PAxMGlafGSNpKWyDI644HSgCRNY013dE1GzZ0QysonUlUHViM8AetWoriGW3E8UsbwEbhIrAqR656YqqdH004/4l1nwcj9wvB/Kqs/hjQLidZp9D0uWZWDrI9pGzBh0IJHWgCvD4z8N3FysFrrVjdOXSNmtpRMkTOQqCR1ysZdiAoYjceFyanfxTocd3JbS6nbRSRiQlpW2IfLOJArnCsUPDAElT97Fak9vDcW0ttcQxy28qGOSJ1DK6kYKkHggg9Kij06yjs4bOOztktIABFAsShIwOm1cYGO2KAMVvHnhBNu7xVoA3dM6jCM/+PU7/AITnwngn/hKNCwOCf7Qi4/8AHq6IADpxTSiltxVS2Nucc49KAOdk8eeEI4w8nivQFQjIZtRhAIzjOd3sfypP+E+8HYz/AMJZ4fx1z/aUPqR/e9QfyrowihmYKoY9SByaUADOAATyfegDm/8AhPvB2cf8JZ4fz/2EYf8A4qg+PvBy5LeLPD4A4OdSh/8Aiq6QADOAATyfeloA5lviB4NRtr+LfDyt0wdShB/9CqUeN/ChUsPE+hFQCxI1CLgAZJ+96c10NIQDwQCOvNAHPjxv4TOMeJ9C5XcP+JhFyPX73SuR1bXdMt/Ftx4s0nXdM1KJLSx0t7O2u1lKiW+CNKVUnGA+F9SCD0r04KFzgAfQVwvxU0r+2j4e0xZXtm1G8msnuYh88aG0nmBB7Ylghb6oKANnQdfK+HnuPFFzp9lqFiRFqRV/LhglwDwXPClWUgk9GFWV8VeHnOF13SWPteRn+vsa0JbCzmvI7uW0t3uoxhJmjBdRzwGxkdT+ZqWWCGVdssUbr6MoNAGMnjDw1IcJ4i0Zjt3/AC30R+X1+904PNbEdzBLAZop4nhAJMiuCoA6nP4U4xRkYMaYzu+6Ovr9apvoulyTiZ9NsmmH8ZgQt+eKAKD+MNAE4iTU4ZvnVHkgDSxRMxAUSSICsZJYYDEZzxVrTdf0vU765s7K8jlurdmV48FSdrbWK5A3KGypZcgMCucggaMkUckLxSRo8TgqyMMqwPUEelUb/Q9M1CK3ivLKGWKAFEjK4UIQAUIHBQ4X5TlcqpxkDABaF3bFSwuISqruJ3jAGM5+mCD+Ncpqd5ar8T9Aka5hEa6Lqe5jIMD/AEixHJ+oI/A10jaPprBQ2nWZ2tuGYF4Pr061zGoafZD4qaABaWwLaLqIbEa8gT2OM8dstj6mgDrnvLWOLzXuYVjxneXAGPr+B/KuR+FmpWMXwu8HLLe2yMNGtQQ0qggrboW79hyfSumXRtLVty6bZBvUQLn+Vc18K9Ps5fhh4QkltLd3fRbHezRqS2IUIycc4oA88+Nep6fe/Ev4YCxv4p7mG/3BbaQSFAbqzDFtudq7BJycdCPWvVdM8VWT6DHqOuz2Wjvv8qaKe7XbE5G5VLNt5KFWAwOGB968/wDixpkOo/F74Wac7PBBOurAtAQrIRbo6svuGUHoRkc5r1mKws4byS7itLeO7kQRvOsYDso6AtjJA9KAKtlr+j37Itlq2n3LSfcENyj7u/GDzWB8Vry1f4Y+MYkuYWlOj3wCCQE5ELgjHsetddPbw3AxPFHIB2dQ38/pXHfFjTrEfC3xgfsdsCuj3ZU+UvBED7SOO3GKAOrj1GylIEd5bOSpcBZVOVztz16Z4+tVpvEGjQSIk2r6fG7naivcoCxzjABPPNWpNPs5CxktLdyzbyWiU5b16dakFvCq7VhjC4xgKOnpQAtxNFbwvLcSpFEgyzuwVR9SazYfEuhz209xb6zp00EBRZZIrlHCF8bASDwWyMDvkYzmn23h/RrW4We20nT4Z1yRJHbIrDPXBAqzcabY3N7b3lxZW0t3bZ8meSJWeLPXaxGRn2oApN4m0SO4+zz6rZW90EDm3uJRDKqnnJRsMB9RQnifQZM7Nb0tsLvOLuM4XGc9emCDn3rWZQwwwBHoaR0V8b1DYORkZwfWgDJTxT4fdnVNd0pmQbmAu4zgccnnpyPzFNHivw6WYDXtJJUgEC8j4J49a2HRH2l1Vtp3LkZwfUU6gDIj8TaDJF5ket6W0e/y9y3cZG7+7nPX2pH8UaAn39c0pcDPN3GOM4z19Qa1mjRmyyKTgjJGTg9RSqoUYUAD2FAGNF4r8OyyGOLXtJdxnKreRkjAyeM9hQfFfh0JAx17Sds4LQn7ZHiQA4JXnkA8cd62HjSQYkRWGQfmGenIoEaBnYIoZyCxA5JHTNAGMfFvhsRmQ+INI8sEjd9tjxwMnnd6EGnL4q8PNCZl17STCCAXF5HtBIBAzn0IP41s45z3puxd+/aN+Mbsc/55oAzU8Q6K6Rumr6cyybthFyhDbfvY55x39Kemu6Q4UpqtgwYlVIuEOSOoHNW5bW3m3ebBFJvxu3IDux0z9KBaW4ZmEEW5sFjsGTg5GaAKI8RaIbVLkaxpptnxsl+1JsbJ2jBzg5PH1qO48U+H7dpluNd0qJoSFlD3camMnoGyePxrT+zQby/kxbycltoyT606OKOKNUiRUReFVRgD6CgDHbxb4bV1VvEGkBm+6Dex5P0+akHi/wANFJHHiHR9kf32+2xYXnHPzcc8VuUhAOMgEjke1AGS/ibQUxv1vS1yCRm7jGQOp60knijQI3KSa5pSuMZVruMEZGR39Oa1wADwAKFVV4VQo9hQBwPxE8U+H77wH4jtLPxBpEt1NYTQxxpexFmd0KqoG7qSQAO5re0XxHFqOr31rEtslhCpFtOJxunaJzHcDy8AoIn2KTzktTfiNGJfAXiGMttLWMwVu6tsOCPcHBHvUujeH7RdB0631WxtLm7iVZpnlt48vckAySkAbd7NkkjqTQAXnjDw1ZsyXXiLRYJAm/bNfRLhf73LdPeqfwn/AOSWeDf+wLZf+iErob8+Rpty0W1CkTFeOBgGue+E/wDySzwb/wBgWy/9EJQB1VFFFABRRRQAUUUUAFFcN458YalpniXRfDPhrTrW+1zU45Zw15OYYIIo8ZZiqsxJJwABXK+Lvitq/hnWNM0bWNO0bR764tDcSXWoXcv2N3DlRFHIkZ5IAYlsYBwR6gHsdFc9q/ieHR/B8euX8YZ3hjMdtbSCUzTSABIomH3yzEAEcHr0rnPAnxQ0vWfBFhr3ie50zw7JdzTQrDdXyKpMblTtZ9u7oCcetAHolFebeIfHetaH8S9F8Pz6bpkun6rOIYTHdv8AalTaSZmUoECghhtDEnFek0AFcD8HFC6b4oIOS3ibVCfb/SWFd9Xl/wAMvEGl6bY+I4r268kjxLqivI8TiOMm5cgNJt2AkEEZPOfrQB6hRXL33jXSkhiezneYyXcNsrC1mZH3yBSUZUwwweGHy8rzyM2h4s0plVof7QniYZSW3025ljcequsZDfgTQBvUVz6+LtJfzPKGpShG2sYtMuXAPpkRnnt9cjqMVU1rxfBBp1x9it9SF2yOsL3GmzxRLJtbZuaRVXBYKo55LD1zQB1dFcH4N8e2eo6NDf61f2VrFc20V1DJJiBMEeXIgZmIdllR8kYwskY75PQx+J7CRwq2+sAnH3tIu1H5mOgDborCPinT9u77PrOP+wPd5/Lyqi/4TXQAVDX5RmA2q8EisSei4K53cH5fvcHjigDoqK5651y+vFWPw7pU00rD5p9Rjks4YfqHTe59Aq44wWXiorDxlp8yxwXiXFtq4D+fpyQvPNAU+8WWNSdnTa+AGDLjqBQB01FZH9v2xXctrqjDOP8AkHzg9cdCgP8A+qkHiK0J+W21UqDgn+zLgY/Apk/hmgDYorGPiOyAz9n1XHf/AIldz/Ly6jHiixO0G01kMwyFOk3X8/LwPzoA3aKw28SQCQINP1hiTwRp8uMY+9kr9eOvtyMxjxKxVnOha4If+Wbm2X95zgYTdvXP+2q474oA6CiuOufFVyuv6RCdM1i2tJ4rl5FezDlmQIQPlYsv3iRxg9M5wDpDxDOf+Ze1rPUjy4uFxnP+sx+A59qAN+oLi0t7ma1lniWSS1kM0LEcxuUZCw99rsPoTWS/iCXe4i0HWZRx5bCKNRJ9Nzgr/wAC21k+KfE97FoGoHT9M1WymkiMFrqE0EXlxTyApEzRs+/HmFByncZ4yQAdnRXnfgrV7TSbR9qahdx6ug1q2e2tZJ0kMqgyqrKCATIC+CQB5ygcdOoh8QSYIvND1izcjKI8KTb/AGzC7qv/AAIigDcorB/4SGcTMjeHtaCA/wCs2REFf72BJn8Mbvapf+EiswYw1vqoZ8DH9l3JwT6kR4H16UAbNFc/c6rqt4/kaJpUsZZSft2oKI4Yz6eXuErtnHGFUjPzjgGPT/F1nMiwXkU0GroHFzp8UbXEkBUgEkICdpyGViBuVlIHOKAOkrktRx/wtjQOuf7E1L6f6+xrWOvQbdyWeqOOOlhKp59mUHjr/wDX4rmNR1i2/wCFmaFdCLUCi6LqK7fsEwcn7RZdF2bj+WBx60Ad9XK/Cf8A5JZ4N/7Atl/6IStN9etdjlYNT+UEkjTrj9Bs5/CuZ+F2tW0Hwx8IxvDqBZNGswSlhO4OIU6EIQfw69qANPV7CK5+Jfhm6kaQSWmnagyBSMEs9qpzx6E11VeeeMfEcljrem6jptldSG3tJzO1xayxqsBntd4XcF3SsF2oufvHLcA5l8IeJLh7VdS1SG+eHVY1nxbQTXSW9zGPKmiUIG2R/u0ZfVmkOSTQB31cl8XW2/Crxief+QPdjg4/5YtWuNbjLYSx1NlxkN9kdRnOMYIB6c9MfjxXLfFnUxN8L/GEZsb9B/Y9yQ7QHbkxsMcc8dSegHegDv6KyZNaIP7nTNTnUdWWDZgeuHKk/QAn2xzQNZYu27StTWIHiUwqQwzgkKG3cdcFQT2BoA1qKxf+ElsC+0Q6oWBAI/su645x/wA8/wDP4VDdavqsYa9XR5V02DPmxNh7qVf78caEggDB2k725AUEAOAdBRWPb+IrG5Aa2S/mjPIkSxm2EeobZhh9M1J/bcGMG11EOQSE+xSn9Qu3n60AalFZJ123UAyWupqp6H7BM2evZVJHTuB1+uEfxBZopJg1PHtplyf0EdAGvRWT/b1t8pFtqew8bv7Pn4PpjZu9ecY45IyMja0Q+F0zU2XPLiDAC/3sE5P0ALc9KANaismTWxuxb6dqc4xnK25jH0/eFeaeNXUxlhY6hvHRPs5BJ9Mnj8c496ANOisz+11CBmstQA/j/wBGYlD6YHJ/4Dn2pG1qJUz9k1Etk/ILSTOB3zjHv1z7Z4oA1KKy21mJf+XPUSD93Fo/zep6cY/2sZ7ZpRrEe9Q1nqKq5wrfZXIP1wCR36gdPcZANOiso60gCsbDUvL53v8AZWOz0+X7xz/sg474pW1qNHIay1IIOri1dh+QBY/gKANSisx9Yi2DybXUJnI+VBaSISewy4UD05I684HNINZiaNnS01EqOObSRST3GCAePXp6E80AalFZ51WIY/0e+9/9Fk+X9OfwzTDrMIYK1rqAOCT/AKHIcAe4GD64GT+PFAEHjSNpfCeqxr1a3cdcdqv/ANo2wvxZyzRR3LsRFG0ihpcKrNtXOTgMM8cZFYuv6mL7Rr62tdL1W6ndCqQrbGMydOQ0pRB/wJgeOmcZ5y01WXV/Fms3GlQtctpv2O7gjePY7xTxDzAA+3DFBxuwQy4OBmgDtvEsnk+HNVl5+S0lbj2Q1j/Cf/klng3/ALAtl/6ISovGOsznwrr+zRdVa3WwuCJ8RKGAiY8I0gk9uVH5c1N8Kht+F3g8emjWY/8AICUAdTRRRQAUUUUAFFFFAHKeNPA+n+KrzTb+S81HTNV04v8AZr/TZhFMiuMMmSrAqcdCD+prL1X4Y22qab/Z934m8TvZSQG3uYnvEkFypZiS++M4Y7iMptOMDsK7+igDDu/Ceg3vh6z0K+0q1utIs0jSC1uE8xECLtTrnoOM1neA/h/oPgnQTpOk25lgMzztJcqjOzMe5CgcDAHHQCutooA4jVPhzY6t4ntNY1TWNdu47O9XULfTpboG0inX7rqu3dxyQN2OTxjiu3oooAK4n4Tf8gbXOSf+Kh1Xr2/0yWu2rjPhUpGiauSB82v6qf8AydmH9KANTxvMYdHtWGfm1PT04PreQj+tb9cp8SX2aHp/IBbWtLAz3/06D+ma6ugArlfiupPww8Wsm7zE0q6kjK8FXWJmVhjoQwBB9RXVVU1jT7fV9JvdNvlZrS8ge3mVWKko6lWAI5HBPIoAj0fR9P0bTbTT9MtY7eztF2QRqMiMexPPc1foooAKKKKACiiigAooooAKKKKACiiigDmNbdh488MIM7WhvCR24WP/ABrp65LxCzr8QvCAU8NHehuOo2If5gV1tABXKfE4uPCilG2H+0tOycZ4+2wZ/TNdXWfrulx6xYLazSNGguILjKgE5ilSUDn1KAfjQBR8AaZPovgTw5pd5GI7qy063t5kBBAdIlVhkcHkHkVvUUUAFFFFABSYG7OBk8ZpaKACuV1L/kqfh7/sC6n/AOj7CuqrldS/5Kn4e/7Aup/+j7CgDp5jthc5xhSc+lcx8J/+SWeDf+wLZf8AohK6S9OLOc4JxG3A+lc38J/+SWeDf+wLZf8AohKAMT4yDGi3UpGRHplwxG3dwJrYk+nGK6fwNokvh7wzbaZcSpLJFJM5ZCSPnldwBkDoGA6dqqfEuxW88G6ttSL7T9maNHZQSFZlLKD6Hav5D0rqaACuO+MgLfCfxgAD/wAgm5PBx/yzauxrkPjAcfCjxief+QRddP8Ark1AHX0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnPw1srlfG/jzUJ1byZruO2jdjy5jaZj+QlRR7KPevRqxPDFqLaXW8ADzdRklOOvKp1/wA9MUAN8eceB/EX/YOuP/RTVU+FalPhh4PVgAV0ezBA/wCuCVZ+IIz4B8Sj10y5/wDRTVW+Fhz8MfCBzuzo9nz6/uUoA6iiiigAooooAKKKKAPO/H/iXXE8beHfCHhm4stPu9UhnuZb+7gM4jjjA+VI9yhmJ9TwB+XL+PPGXjbwreWNvqkiwaVHZtLc69p+jveRGcOw2yR+YPKUIFJ5POcHHT03xd4O0HxdFax+ILAXRtXMkEiyvFJEx67XQqwzgZwecCse4+Fng6eCGF9KkWGOH7P5cd7cIske5m2yBXAkGWY/PnqaANS4vrzUPAcOoaZrGm2lzPaRXA1OSEvbIhCs8oRmU7du4jcwxxnvXH/D74iXL+D11HxkJ5PNvp4LC8sNLuJFvbdCNk/lxq5jDZOM9QMjNdz4g8LaN4g8NtoGq2SyaOyon2aJ2hUKhBVQUIIAwOAccUnhPwtpPhOxks9Cgmgt3feVlupZ+cAcGRmIGAOBxQBzN74q1y2+NOmeGJYdPXQ7ywluo5EZ2nYoFzuyAF+YkYG7I5yOg9Brlr/wD4ev/FsPia6tbptahZWjnW/uFCbcYAjDhNp2jK7cNzkHJrqaACvO/AOqXlnpGpx2/h/VL1P7b1UiaCS2CN/p8/TfMre3IHIP1r0SuV+Gn/IuXn/Ya1b/ANONxQBzfxK1q9m0vSI5vDer2q/27pZWSWS0KsRdxHaNs5OTjHTqfTJHVDxFqZ6+DdfH/bax/wDkmsz4sLv0vw+M4/4qHTD9cXSH+ldvQBzjeIdTBGPB2vH6TWPr/wBfNL/wkGpbWP8AwiGu5A4HnWWT/wCTFamnaxpupzXMOm39pdy2rBJ1glVzEx6BsHg+xq9QByWl+LbzVJr5rHw5qMlnaz/Z/MZkieUjAYoshUEJIJUb5h9wFd4bi6uv6kTg+EtcX3Mtl/8AJFc/8eb7WNN+FWt3Ph6SeG9VYw01uCZIojIokdccghC3I5Aye1eLW2syP4f023uWMHg2LxT5F/qtjc3IgvYREArs8kjOE3KAxDbSffqAfRS67qJPPhTWl+stn/8AH6T+3tRxn/hE9b+nm2f/AMkV83wapfv4a8Ef8JfqOqQ+EJJNW23Mk8sZkCqfsnmOCGPfZk84HWvV9B17xBpH7Nseuag8n9v2ujvcB7pSzEqGMZcHkkrtJzye9AHoJ1XUDF5i+H7/AIODG01uHI9RiQr+bCmJrN+y5PhnV1P90y2uf0mxXh0/j/x1YXGqPPrdhcQ6XPpErxjTQhnS9xuizvO1V5weWOeorf8ABfxB13VPjDc6Df30VxZefdLHDYQxyRxRxg7fOJIliboMsNrNwODkAHqI1nUcgHw1qnTOfOtcA+n+toOraruYL4dvMADBNxAM9P8Ab/zityigDC/tbWCwA8OXIHcm6h/+KpE1PXGJB8PbPQtex4P5Ct6igDIW71phkaTap7SXuD+kZpwuNbLEf2dp4Xjk3z//ABqtG4mitreWe4kWOGJS7uxwFUDJJPoBUOmajZarZpd6ZeW95av92a3kEiN9CDigDzvxhdainxR+Hyy21kkznUhEgvGw5Fupwf3eex7HGPeu5E+t4JOnadn0F+//AMZrj/HiH/ha/wAMJB0FzqCHn1s3PT/gNehu6xozyMFRQSzMcAD1NAGYLjWiuf7OsAfQ3z//ABqke410A7NN0wnHGdQcA/8AkGrOlarp+r27z6Ve217AkhiaS3lEihx1XIOMjNXaAOE8G+K/Eev6Na6hcaDYWKXLv5SXGoFJHXcSm1QjZwpAbJB3K2Bt2k7UerarJePax2uiNcoMvCNVYuo45K+TnvXkHxB8O+MZvjN4X1pdIS+0221FY7L7PO/l20AQ7zKojIQsxJLknOFXjGTJJaQ6j8d7a6sPCWr6GmmyXSDVI9JkUalcygqZJZgu3yV5IJJznsDQB69b6pqlxNNDDbaLJPDgSRx6m7FD6MPJyKs+frmzP9naZvz0+3yYx9fJrwP4K+GNY0/xd4RMmgahpl1pdjfw67d3Fu0a3cjykxgSnibnDZBOB34rf+MH/CcHXvEU/hq58RRQWGl2tzYRWEJaKe588h1PyHednJQHpyRQB62bjX93GmaXt9f7Rkz/AOiKVbnW25GmWCr2D37bvxxER+teI+Il8d6dZ+ItOs9S8TzW9vrURtbmS0lmkuLdoNzr5kKb1Tf/ABRqQCMcAmvWPhzd36fDvTLvxNDd2F4sDyXKahOJJYwGY5d8D+HB5GQODyDQBtGbWMHFhYE/9fr+v/XKuX1KfUx8T/D+bK083+x9SCqLptpHnWOcny8joOx6+1dhpmo2Wq2aXemXlveWr/dmt5BIjfQg4rm9WJHxX8MAHrpGpg8/9NbGgDWu7jVhaTk2NmuI2ORet6H/AKZ1z3wtm1Nfhj4PENlaSR/2NZ7Wa6ZSR5CdR5Zx+ZrsdSwdOus5x5TZwcdjXO/Cf/klng3/ALAtl/6ISgC3rltqup6Vd2TWNhtmTaD9tcc/9+u361X0W+8W3HnvqWi6XbJ50giQ37bxGDhc4jYEkhmzkfKy8A5A6eigDMM2s7eLDTi3ob5//jNcr8V5dUb4V+L/ADrKzQf2Td7tl2xIHlNkjMYzxk449K72uQ+MIz8KPGP/AGCLr/0U1AG952rc/wCg2PX/AJ/H/wDjVIJtXx81jYZ9rxz/AO0q0qKAMvz9axxp+n/jfP8A/GaYlxru797pmnbP+md+7H8jCB+ta9FAGZ52s8/6Bp/Xj/TX6f8AfqgTaznmw08fS+f/AONVp0UAZwm1fHNjYZ/6/H/+NUGbVuMWVh7/AOmP/wDGq0aKAM5ptX522NgfTN44/wDaX0pPO1jbzY2G70+2vj8/KrSooAzBNrOebDT8Z/5/X/8AjVP83VdozZWO7uPtb4/9FVoUUAZqzawW+ex08D1F65/9pUpm1bPFlYY/6/H/APjVaNFAGcZtW2nFjYlv+vxsf+iqUTarz/oVkD2/0tv/AI3WhRQBnCbVs82Nj+F4/wD8apwl1T/nzsun/P23X/v3V+igCj5up78fZLPbnr9qbP5eXSLLqmfms7IDnpdsfp/yzq/RQBS8zUcHFraZ7f6S3/xujzdRyf8ARLTHtctn/wBF1dooApCW/wAZNpbZ7D7Qf/iKzrS61eC6lim0KFVlbes1tfCRMkcmTeqMvT+FXreooA5L4hTX48AeJTJZ2pUaXdFgLlv+eLcD5Kl+FmP+FY+EMMGH9j2fI7/uUqb4jkD4eeKCwyo0q6yPUeS1RfCwY+GPhAA5A0ez5/7YpQB09FFFABRRRQAUUUUAFFeKftC6vq/hLU/D3iHR5btknju9Ie2jkIR55YWNs23OMiQE564rkPBWv6xofivUbfxPqN9PZfD7S7w3MjzN/psskrGEsCfmzFjbnvigD6aor5s+D93rNx4gvvC/jubXo18TWI1KBrmZ4XWdG3SxwMrblTDKeCOFP4u8DeG4tV+EnijWb3VvED6hZzagIZBq9yNohD+XwHwcfr3oA+kaK+Yr6ze0+E3ge+XxSbWbUUS9vYdb1C6Ftft5YyjTISY8FshchWP0r2H4IX7al8OrC5OnXenK7y7ILm5kuPl3nBR5PmMZ6rnoPbBoA7yuV+Gn/IuXn/Ya1b/043FdVXn/AMPI9al0K7eyvNPit21jVSEmtHkdf+JhP1IlUHnPYdqANf4hOUstGwzKDrFkpIGesyj+eK8d+NPww+KHiMzvpXi/+09ObppnFlx/d+X5H+rkV6X49tdca10QS32lyH+2LMjFhKNpEmc/6+ulNt4k3HGq6Rt7D+zJP/kigD54/Ze8F+O/DcviqKVYNBZ2tlK6ppslwJiBJzGVmjGBu5ILA5HTHPvH2Hxx/wBDD4b/APBDP/8AJlXvs3iTJ/4m2j47f8SuX/5I+tP+z+Ic/wDIU0n/AMFsn/x+gDO+w+OP+hh8N/8Aghn/APkyj7D44/6GHw3/AOCGf/5MrRNv4h7appP/AILZP/j9ILbxFk51XSSO3/Etk/8AkigDP+w+OP8AoYfDf/ghn/8Akyj7D44/6GHw3/4IZ/8A5MrRFv4g76ppX/guk/8Aj9H2fxDz/wATTSunH/Etk6/9/wCgDO+w+OP+hh8N/wDghn/+TKPsPjj/AKGHw3/4IZ//AJMq+9t4jx8mq6QD76ZIf/bil+zeIsf8hXSc/wDYMk/+SKAM/wCw+OP+hh8N/wDghn/+TKPsPjj/AKGHw3/4IZ//AJMrTW318ff1LSz9NPkH/telaDXeNupaYPXOnyH/ANrUAZf2Hxx/0MPhv/wQz/8AyZR9h8cf9DD4b/8ABDP/APJlaf2fXvm/4mWl+3/Evk4/8j0n2fxBj/kJ6Vn/ALBsn/x+gDj/AB9pHjm88C+IrYa3oVwZtOuI/Jt9EmSSTMTDYjG6YKx6A7TjPQ181fCj4OfFP7ZFqGlz3HhSJiC09xO0TsPQxLlj9GAFfYot/EA+9qelH6adIP8A2vTvI13/AKCOmf8Agvk/+PUAcBf6RrVp4p+Httq2vHUtTia/3X32VIck2pUHYODgnPvXlnxn+EvxW1x5p4/EzeJbDJZbNXFoVHXiLIjOB3zk17lrdpqr+L/C7PfWBlj+0kEWL4x5YB/5a+4ro/J1nH/H/p+f+vJ//jtAHhn7M3hfxzoXgS/tmnstEzqUjfZdU0mWaX/VxjeCJ48KcYAwehOeePXPsPjj/oYfDf8A4IZ//kytfydZ5/0/Tv8AwBf/AOPUCHWdvN/p5b1Fi/8A8eoAyPsPjj/oYfDf/ghn/wDkyj7D44/6GHw3/wCCGf8A+TK2DDrHOL7T/b/Qn/8AjtKYdX7X1h/4Bv8A/HaAMb7D44/6GHw3/wCCGf8A+TKPsPjj/oYfDf8A4IZ//kytdoNXJ41CxAwOlm3v/wBNfpSfZtW/6CVtn2szj/0OgDJ+w+OP+hh8N/8Aghn/APkysHx9pHjm88C+IrYa3oVwZtOuI/Jt9EmSSTMTDYjG6YKx6A7TjPQ12b2erNjGrRLx2tB6/wC9TGsNXLZGtBRxwLRf8aAPjr4UfBz4p/bItQ0ue48KRMQWnuJ2idh6GJcsfowAr6LtrPU9M+JPgW01/WP7Y1BdN1Pddm3WDfza9EXjsa7kafq+TnXD/wCAiVw2u2l8PjF4Phk1V3m/svUmWX7PGCuTAP8AD8vc0Aek6l/yDrrv+6f+RrnvhP8A8ks8G/8AYFsv/RCVY1LTNSNhcl9duCnkuCotocN8p65WsP4WWF+/wz8IvHrFxHG2j2ZWMQxEKPITgErn86AO+orHbTNR35TXbsD+60EJH/oApRp2pgD/AInk5PfNvF/8TQBr1yXxdx/wqrxjn/oD3f8A6JatoWWojH/E2Ykdc26c1ynxagv4vhX4waXUVdf7Kusg268jyzx19MjPvntQB31FZrWupH7upRr/ANuwJ/8AQqclvqQYFtQhYdx9mx/7NQBoUVm/ZtU2Af2lBuyTu+y9fb71KbbUs8ajFj3tuf8A0KgDRorNFtqYP/IShI97Xn/0Kk+y6rzjUoMds2nT/wAfoA06Kzlt9UAb/T7ZiembU4H/AI/QYNV3ZF/aYx0No3/xygDRorOSDVQRuv7Q+uLRh/7UoNvqh2/6fbjHXFqef/H6ANGis/yNSyP9Pt+3/Lsf/i6Uwakcf6dbjrnFsef/AB+gC/RVIQ3+4E3lvjuPs55/8fpGi1Lcdl3aAZ4BtWOP/IlAF6iqAi1THN5ZE+1q3/xygxap2vLIfW0b/wCOUAX6KzxFqvGbyx9/9Ef/AOO0eVqv/P7Y/wDgG/8A8doA0KKoeVqe3/j8st3r9kbH/oyjytUwP9Mss9/9Ef8A+OUAX6Kz2i1X+G9sR9bRz/7VpTFqmRi8svf/AER//jlAF+is5YdW43XtifXFm/8A8dpwi1Tcc3llt7D7I+f/AEZQBk/E0A/DbxYGOB/ZN3n/AL8vS/DUEfDnwqCCCNKtOD1H7lapfEpL8fDnxYZLq12f2RefdtyCP3L45LkfpWj8PQF8A+GgOg0y2/8ARS0AdBRRRQAUUUUAFFFFABRUF5eW1lD517cQ28Wcb5XCLn0yaa1/Zrjdd24yAwzIvIPIPWgCzRUC3lq0mxbmEvjO0SDPTPT6U4XMBSNxNHtkO1DuGGPoPWgCWimSyJDGXldUQdWY4A/GiSRI0LyOqpx8zHA/OgB9cf8ACht3hGVs5zq2qHP/AHELiuwrjPhF/wAiY3/YU1T/ANL7igC546ODoGT8o1RJG57JHJIf/QK3NX1Ox0fTpr/VbuCzsoRuknncIijpyT78Vx/xhunsvD0F1EN0kJu5VXJGWXT7th09wKsfFvQD4k8GTaeNLudTLTRyCK0vEtZ0KnIkjd/l3DsG4NAGlp/jbwzqGk3mp2mt2D2FmcXExlCiE4z82cEcc89a3LW4hu7WG5tZElt5kEkciHKupGQQfQivCLnwj40vvhf4q0vX9Km167vZPL0iG/ltJLy2HlsBLLLuCEgnghiwyfWvWvh5HfW/gnRbXVtPl069tbWO2kglkjkIKKFzlGZcHGRz35xQB0VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc14kJj8S+HJg2NskqkeoYKuP1FS+JPGnhzw1cxW+vazZWM8ieYscsmG2ZxuI6hc8ZPFR+JXRNa0pnJHGAB6m5th/X9a84+KvhHxJeeL7jWPBlhq9prElolumo2eo26W0wB+7cwS8kL/shsjtQB6ydd0kalZ6f/AGlaG+vIzLbwCVS8qAZLKM8jBzmtKvGdU8Oa/D8X/CGvW/hVbiPT7NrbUtStHtoRcPJEqBgrOHKp83BGQOFBr2agAooooAKKKKACiiigCK7eWO1mkt4xLMqMyRltoZgOBntk968X+Hvj3xPrPiD+yPEN0uk6/cW87ppN9oskCK6g7Whm8w+ag4znBIyRivabiGO5t5YJ0DxSqUdT0ZSMEV55H4J8K6TrLWNrokkn2q1+xyTS39xI8MEwkDLHuYmMHy8fIV6+3IBV+HPiDxBrt14y0/VL2z1nTdPKwWmr2dubdJ5DGTLGAGYHYcDIPX9On+E//JLPBv8A2BbL/wBEJTvBngLw54LMn/CN2U1osiCMo15PMgXOeFkdgvPoBTfhP/ySzwb/ANgWy/8ARCUAdVRRRQAVxHxvbZ8IfFxzj/iWzD81xXb1wnx1OPg/4t/7B8lAHd0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBy3xVOPhf4wOQMaPecnoP3D1d8CLt8D+Hl54063HIx/yyWqXxVx/wAKv8YZJA/sa8yR2/cPWj4N48IaH/14wf8AotaANiiiigAooooAKKKKAPF/j1ok1/reiahZxapJeWME3kouif2rZylsAo8YyY3OOHxjHcVzuqfD9dTX4W3WqeCLK2vZbrbrEFpabooohGdqyYztTpwTgHjtX0VRQB4BcaDaQfGvX5NO8J3kNp/wj0llaXUejyLCLoK2Ssmzbkx/IGB+bO3JziuL0f4c+L9P034Yz3cd5PpthrenzwWKwSGazWU+ZdNOu35FSSMYJ6B2zivrOigDyH4/aVrPi0aL4V0nSbm9sbh3vL+QOYYgka4jjMpBUEuwbHX5K4Txhb61rPwG0LT9X8P+IpPFOmXSWYit7S5dWEMiAyMEG11aMKQzAgndtOc19M0UAV9Ou0v7GC7jjniSZA4SeJopFB7MjAFT7EZrgPhpBrT+F5W0zUNOgtTquqbY7ixeZwPt8/VhMue/bv7c+j1yHwqGPCcw541fVev/AGELigCHxN4e1bV/7Kt76/t54hNOJDFZFVUPaXEQZgZD8uZMY78dOTV3SvFP2rTLLyrG/v8AUmgRrqC3hCeTJj51dnZUV1YEGMvvGRxjmuopskiRqGkdUUkLljjknAH4kgUAYxvPEDkNBo1gkZJ4udRZJAPcJE6+vRj2/CYT64U50/TFYg/8vzkA9v8AliM1q0UAZJbXWbAi0yNfXzJH/TaP/r+1V2tvE7MSuq6Ki+h0yVj+f2gfyrcEiGVow6mRQGZM8gHOCR6HB/I06gDDS28TAnfq2jEZ4xpco4/8CKatr4n/AI9Y0Y/Lj5dKlHzev/HwePb9a3qbFIk0SSROrxuAyupyGB6EHuKAMkWuvFfm1XT9/P3dPYD24MxP60v2HVxgjWIyQf4rQEEfgwP6/lWvSFgCASAWOBk9TQBlJZ6vuBl1WAjPISz28e2XPv8Ap6HLxZ6mH/5CilduMG2XO71znp7frWnRQBmiyv8AcQ2qylMdoYw2frjGPw/Gmiw1AjDaxKOeqwRjjt1B/H9MVoRTJI8qITuibY2RjnaG/HgipKAMxLC+H+s1i5I/2YYgf1U0Np12Ux/bV+DknISD+sdaMjrGjPIwVFBLMxwAB3NKrBlDKQVIyCOQRQBxPi/w7ez2xuUv9UvJbSHz4gFg3F4riCdUVQi5ZzDt5OB+NbUeuzX650XS7u4UqGWa6VrSLJ7HePM6c5VCPfNbtNaREZFd1VnO1QTjccE4HrwCfwoAylm19jhrDS4xn7wvpHwPp5I/nUQg8SOWP9oaPED91fsMsmPqfOXP5CtyigDn3tPFRHyazoYPvpEp/wDbmj7J4rx/yGtDzxz/AGRL+P8Ay8/Wt5JEdpFRlZo22sAfunAOD+BB/GnUAYUdp4kP+v1nS8f9MdMdT/49O1Sx2GrkL52tDdkZ8q0RQR7AlsH8fwrYJwMnpTY3WRFeNgyMAVZTkEHuKAKCWF3geZq92T32xxAH/wAcNMXTLsKoOuaiSOp8u35/8hVqVQ1G+a0vNKhVFYXly0DEk/KBDJJkfjGBz60ARHTLsqANc1EHGMhLfP8A6KrmNesbyzvHni1HUrueBbO4lYxxEtBHc7pAFjiDMfLL8LyegGTz3dZ6xD+35ZuM/ZUQ+o+djQBnSa3eX0EraNpcssGDturuX7LE4weU+VpPxKAHqCRzWD8Lhrcnwy8Hi3fTbeEaPaYZ1eZiPITHAKYPTuf6121zNG9teKjhmiUq4HJU7QcH8CD+Nc98J/8Aklng3/sC2X/ohKALrW3iYn5dW0YDng6XKfp/y8fWn/ZvEXl86rpXmeo02TGPp5/X8a2icDJ6UgIYAqQQeQR3oAyls9YIG/VoM4JOyzxz7Zc8e3X3rjfjZb3sfwk8Wtcagskf9nyfKIFUnp3z9R6816RXCfHXP/CoPFoABJ0+Xg/Tn9Mn8KAOo+w3+4k6vNyeghjwPp8v8809bG62ndq14Se4SEY+nyVoUUAZh026Lsf7a1AAnhQkGB/5Cpv9l3eW/wCJ7qXPT5Lfj/yFWmrq7OqsCUO1gOxwDg/gR+dOoAypdLu3A267qUeB/Clvz+cRpTpl2Rga5qI9wlv/APGq0LqZba2lncMUjQuQoycAZ4qSgDK/su83E/27qWD22W/HT/pl/nNNbSb09PEGqL9I7b/4zWvTS6iQIWXewLBc8kDGT+o/OgDJbSL0ooHiLVVIGCwjtcn3P7mg6Re5z/wkOq/Ty7b/AOM1sUUAYv8AY19uz/wkur49PLtf/jNPGk3gbJ1/UyPTy7b/AOM1rKwYZUgjJHB7jrS0AZQ0u8BGde1M8947f/41S/2Zd7SP7c1HPrst8/8AoqtNmVBl2CjIGScck4H60tAGX/Zl3n/kOal9Nlv/APGqQaXdhif7d1Ig9ilvx/5C/wA4rVppkQSLGXUSMCwXPJAxk49sj8xQBmnTLv8A6Dmo/wDfFv8A/GqUabd/9BvUf++Lf/41WnRQBkHSbw7ceINUGDk4jtuR6f6npSjSrwMD/b2pnHby7bn/AMhVpQSiZCwBGHZef9liP6VJQBlLpd4Dzr2ptxjmO3/P/VU1NJvVQKfEGqMf7xjts/pDitWSRIlDSuqKWCgscDJOAPqSQPxp1AGSdLvCTjXtTGRjiO345/65U0aTegD/AIqHVDwR/q7b/wCM9q2KQMpcoGG4AEjPIB6fyP5UAcH8S9Nu7f4aeLZJdc1K4VNHvCY5EtwH/cP1KxA/lXS+Dv8AkUdD+Xb/AKDBx6fu1rN+LH/JLPGX/YFvf/RD1qeEV2eFNFX0soR/5DWgDWooooAKKKKACiiigAooooAKKKKACiiigArzrS/B/jDTNOms7TxXo6xyzXE5YaLMGVppZZWxi7AGGmbHH8K9cZr0WigDi/7G8c7Nv/CWaHjzDJ/yA5s/f3bc/a+nbHpxVOXwx44mS2WXxlpLrAFADaE5DlWjYM2brlsx9f8Aab2x6BRQB59H4a+IMedvj7Tjn+9oG7+FR3uP9nP1ZvbELeFPiC0LRn4hWeCXORoPPzbu/n9Bu4Hbavpz6PRQB5wfCXj/AO1PcJ8QNOjldVVivh1eVUuQOZv9s/kPfLh4W+Im7J+I9t06Dw9F7f8ATX2/U/h6LRQB5nD4H8cRoqf8LHJUMjf8gODPy7Mc7v8AYH5n2xNB4M8bQ28UMXxImijiQIoj0O0UAAAcDBAGB0/pxXo1FAHm3/CC+L2eR5PiPeM0g2t/xJ7TGPm4AKnH32+tPHgfxcIniHxHvvLZmb/kE2eQWJLHOzuWb9PfPo1FAHnkng/xsWGz4lXYUNna2jWZB7/3RTY/CHjtJFf/AIWQzFRjB0K3wRx1wf8AZH5n2x6LRQB5tb+DfHlvGywfEaJSxBJOgQknCqoz8/Jwo/zgBZPB3jx5kl/4WNGrLzxoMPXDD+//ALZ/Ie+fSKKAPOB4L8blpS3xImxICrBdEtsYyT/Fn+8fwx+L/wDhCvF5BD/EnUCpYNgaRZDkYwf9X7D8q9EooA4G38FeJYXVh8QtWG1do2abYrgYAx/qf9lfyp0/gfXLhGSfx7rLqwKsPsFgMggg/wDLD0ZvzrvKKAOGXwh4mVmK/EPWQT6afYfX/nh7moW8Da9J/rvH+sNmRZDt0+xU7lKlTnyOxRf++RXf0UAcLbeBdVtIoI7Px1rsSwRiKIfZLA7UwBj/AI9+eFUZ9qr3PgfxLKsgj+IeqqJAVfdplicg5z0hH95vzr0KigDztvBnjRsf8XLvsg5GdGsjg/8Afv601PA3ixJPMT4jXyyYwCNIsuPug8eX6Iv5V6NRQBwUHgzxNFEIh8Q9VEYAXaumWIGBxj/U+mBUM3w+1eeYTXHjzWnlHRhZWI7SA8eR6Syf99fSvQ6KAOIg8G69ArLD4/1xUZmcj7FYcsxyT/x7+pJqF/AerSTwTyeO9cM0KGONhZ2ACruVsY+z+qIfw9zXe0UAcSngjUVaUnxvr+JAQwW208ZBAUj/AI9vRVH4VBZfDqWy0i00u28Y+I0sbW3W1hi8qwO2NUKBcm1yflJGSc813tFAHIL4P1JZjKPHHiQOcc+Rp/bP/Tr/ALTfnSf8IfqW93/4TjxJudgzHyNP5Py/9Ov+yv5V2FFAHEx+BbuOKKNPGniMJEFCAw6ecbduP+XXtsX8qTWfAl5rOk3umah418RzWd5C0E8Zh08b0YbWGRagjg9QQRXb0UAcO/gO9kDCTxr4hYNu3Zg0/nO7P/Lr/wBNH/76q43hTVWXDeOfEZGQceRp3UHP/Pr611lFAHH/APCH6l9pFx/wnHiTzgGUN5Gn5AO3I/49f9hfyptr4Kv7WLy4PG3iREyp2+Tp5+6qqP8Al17BV/KuyooA46XwbqMoQP448SEIzOv7nT+CQQT/AMevox/OiDwbqMBcxeOPEgLklsw6ec5ZmPW19Wb867GigDkpPCmrSLg+OvEZ5BGYNP6g5H/Lr7VXXwTqSwxxDxx4h8uPbsAt9P42kFf+XbnG1fyrtaKAOOHhDVxL5g8d+IA4GAfsun8Zxn/l2/2R+VRyeCL+VGSTxr4gKMCGH2bT8HOc/wDLr33N+ddrRQByB8J6yDlPHfiBT6/ZdP8Af/p19Sahk8FalJN5reOPEBbduybbT85ypH/Lt6on/fNdrRQBxcXg3VYI0ig8c6+kcahUH2XTzgAADn7N7L+VNn8G65KST4910lhtJaysDxz/ANO/oT+ddtRQBwSeC/EkahY/iHrAAdpMHTrE/MSST/qfUn86UeDfE2/cfiFqpYdD/Zlh7f8ATH2X8q7yigDg4vBfiGMEL8QNXAJBONPsOowB/wAsPRV/KpG8I+JmGG+Ieske+n2H4/8ALCu4ooA4ePwb4gSRpB8QNaDtgEiwsBnkn/nh/tN+dPj8JeIU4HxB1wDk4FjYDk85/wCPf1zXa0UAcLJ4I1lvK2+PNb/dKFTfZWDYwVI/5d/VVP4VMvhHxApbZ8QNdXccn/QrDnsP+Xf0A/Ku0ooA4qTwdrcqus3j3XmWRdj4tLAEjnjP2f3P50qeDdXUg/8ACda/uVy6n7Jp/BOcn/j2/wBpvzrtKKAOJ1jwLe6vpV7p1/428SS2l5BJbTIYbAbo3UqwyLUEZB7EH3rr7G2Wzsre2RndIY1jDORuIAxk478VPRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 420 ms; this results in a prolongation of the PR interval and increase in the AH interval to 184 ms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5672=[""].join("\n");
var outline_f5_34_5672=null;
var title_f5_34_5673="Enteral stents for the management of malignant colorectal obstruction";
var content_f5_34_5673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enteral stents for the management of malignant colorectal obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5673/contributors\">",
"     Todd H Baron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5673/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5673/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/34/5673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral stents are used increasingly as a non-surgical alternative for the palliation of luminal gastrointestinal neoplasms, particularly in the esophagus and biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/1\">",
"     1",
"    </a>",
"    ]. They also have an emerging role in the treatment of obstruction in other segments of the gastrointestinal tract such as the stomach, proximal small bowel, and colon.",
"   </p>",
"   <p>",
"    This topic will review the role of expandable metal stents in the management of colonic obstruction. Stenting of other portions of the gastrointestinal tract is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\", section on 'Stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25514362\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major indications for colonic stenting in patients with colorectal cancer: palliation of advanced disease and preoperative decompression. In the latter case, placement of a stent can convert a surgical procedure from an emergent two-step procedure (including a colostomy) into an elective one-step resection with a primary anastomosis, which can be performed laparoscopically. In addition, by avoiding an emergent operation, a patient&rsquo;s medical status can be optimized prior to surgery. However, randomized trials comparing stenting with emergency surgery have had variable results. (See",
"    <a class=\"local\" href=\"#H107268607\">",
"     'Stenting for acute obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Colonic stenting can be performed in many patients with a partial obstruction or with complete obstruction if there are no signs of systemic toxicity. However emergency surgery is recommended in patients with complete colonic obstruction with evidence of systemic toxicity, as these patients may have ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morbidity and mortality are substantially higher for emergent surgery than for elective surgery. In one review, morbidity and mortality for patients requiring emergency operation were approximately 39 and 12 percent, respectively, compared with 23 and 3.5 percent for patients who were treated on an elective basis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/2\">",
"     2",
"    </a>",
"    ]. In other reports, more than one-half of patients undergoing emergency surgery for colon cancer required a stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Even with contemporary surgical procedures, mortality rates are approximately 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/5\">",
"     5",
"    </a>",
"    ], and are even higher in patients with advanced tumor stage and those with comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, patients who undergo surgery with a primary anastomosis appear to have a higher survival rate than those treated by initial tumor resection and subsequent reversal of the diverting colostomy, such as may be required after emergency surgery in the unprepared bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/7\">",
"     7",
"    </a>",
"    ]. A cost-effectiveness analysis concluded that colonic stent insertion followed by elective surgery was more effective and less costly than emergency surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stenting can achieve long-term palliation in patients who are not operative candidates. More than 75 percent of such patients can achieve adequate palliation with a stent, although tumor ingrowth, stent migration, and stent-related complications may necessitate reintervention either with an additional stent or with other palliative measures such as laser or argon plasma coagulation therapy or surgery.",
"   </p>",
"   <p>",
"    The role of palliative stenting for patients who are operative candidates is less clear. Surgical palliation, radiation therapy, or attempted resection may be a better option for patients who are relatively healthy with advanced local disease, except for those who refuse an ostomy. The estimated life-expectancy of such patients should be considered when weighing options. Prognosis depends to a large extent upon the presence, extent, and site(s) of metastatic disease, as well as comorbidities. Some metastatic sites (eg, isolated liver metastases) may be amenable to potentially curative surgery, and should not necessarily influence the decision to pursue surgical treatment for a locally advanced or recurrent, potentially resectable primary lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stenting may also permit a patient to take a bowel preparation and undergo colonoscopy prior to surgery with examination of the proximal colon (to exclude synchronous lesions) and can be used in some patients with obstruction from extracolonic pelvic tumors (eg, ovarian cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The role of colonic stenting for benign disease is less clear. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Stenting for benign causes of obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Of note, high perforation rates have been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . We suggest that colonic stenting be avoided if possible in patients who are or who will be receiving bevacizumab, especially if the obstruction is subtotal, since these patients may respond to therapy with improved luminal diameter and not require stent placement. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Perforation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral stents may be uncovered or covered (referring to whether the meshwork of the stent is bare-wire or has a covering to decrease tissue ingrowth into the stent). Stents available in the United States used for colonic obstruction are uncovered. Boston Scientific Corporation (Natick, MA) manufactures the Wallstent&reg; Duodenal and Colonic that can be used within either the small or large bowel. It is available in 60 and 90 mm lengths, with internal diameters of 20 and 22 mm. Because the predeployed stents pass \"through the scope\" (TTS), they can be deployed under direct vision, without having to reinsert the endoscope alongside the delivery system to visualize deployment. More recently, Boston Scientific introduced a new nitinol stent, the WallFlex&trade; Colonic Stent. These are also TTS stents and expand to mid-body diameters of either 22 or 25 mm and proximal flanges of 27 or 30 mm, respectively. They are available in lengths of 60, 90, and 120 mm. Other TTS stents are expected to be introduced into the United States market pending Food and Drug Administration approval, including an uncovered stent from Cook (Evolution), which has been available in Europe for several years, and a variety of covered and uncovered stents from several different South Korean stent companies.",
"   </p>",
"   <p>",
"    The Ultraflex Precision Colonic Stent (Boston Scientific) is a nitinol stent that has a proximal flange of 30 mm and body of 25 mm, and it is available in lengths of 57, 87, and 117 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It differs from the previously mentioned stents in that it is too large to be passed through the channel of the endoscope (non-TTS deliverable), it cannot be reconstrained during deployment, it has a string release mechanism, and it opens from the distal end (closest to the endoscopist, below the tumor), as opposed to the other stents that open at the proximal end (above the tumor). It also has less foreshortening than the previously mentioned stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal self-expanding metal stents (SEMS) are usually placed under endoscopic guidance, preferably with the aid of fluoroscopy. The endoscopic placement of SEMS is especially advantageous compared with radiologic placement when the obstruction is proximal to the rectosigmoid region or in the presence of a tortuous colon. Most experience has been with placement of stents in the left colon for lesions that are at least 5 cm proximal to the anal verge. However, successful stent placement in the right colon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/13\">",
"     13",
"    </a>",
"    ] and within 5 cm of the anal verge [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/14\">",
"     14",
"    </a>",
"    ] has been reported. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It may be helpful, though not absolutely necessary, to obtain a water-soluble or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema examination or a rectal contrast CT scan prior to colonic stent placement to assess the anatomy, stricture length, and degree of obstruction. Radiographic evaluation can also identify additional sites of obstruction that might mitigate the effect of a successful stent placement. Much of this information can also be determined by CT scan.",
"   </p>",
"   <p>",
"    In patients with subtotal obstruction in the distal colon, a few cleansing enemas are sufficient preparation for stent placement, whereas in those with more proximal lesions, a cautious standard colonoscopy bowel prep should be given. Prophylactic antibiotics should be considered in completely obstructed patients who have a markedly dilated colon because the introduction of air during the procedure may lead to microperforation and clinically important bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initially, a gentle attempt should be made to traverse the lesion with the colonoscope. If the colonoscope cannot be passed easily through the obstruction, a guidewire (flexible tip, stiff shaft, 0.035 inch, long-length biliary guidewire often passed with the aid of a biliary catheter) can be passed through the stricture under fluoroscopic guidance. Balloon dilation of the stricture should be avoided since it is usually unnecessary and increases the risk of perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After confirming the length of the lesion either by passage of the endoscope or with contrast injection under fluoroscopic guidance with contrast, the stent is passed over the guidewire until the tip is proximal to (above) the tumor. When TTS delivery is performed, it is necessary to use a therapeutic channel endoscope with a diameter large enough to pass the stent through the working channel. If a non-TTS approach is used, after placing a guidewire, the endoscope is withdrawn, the stent is passed over the guidewire to the level of the obstruction, and the stent is deployed under fluoroscopic guidance or endoscopic visualization after the endoscope is reinserted. The stent should be deployed with at least 2 cm exposed distal and proximal to the obstructing lesion (",
"    <a class=\"graphic graphic_movie graphicRef69586 \" href=\"UTD.htm?17/32/17935\">",
"     movie 1",
"    </a>",
"    ). With ideal stent deployment, there should be a \"waist\" in the stent region where it traverses the tumor with a flare of the proximal and distal ends of the stent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78044 \" href=\"UTD.htm?11/61/12255\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55070 \" href=\"UTD.htm?13/38/13922\">",
"     picture 1",
"    </a>",
"    ). After deployment, if either end of the stent is not flared or expanded to produce a waist, the stent may be too short to traverse the stricture. In such cases, a second or third stent can be used end-to-end with the first to completely traverse the stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dietary recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following stent placement in the left colon, stools should ideally be maintained at a soft consistency to avoid fecal impaction at the stent. This can usually be accomplished by advising patients to consume a low residue diet and to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    supplements or laxatives regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients should be instructed to avoid foods that are high in fiber, such as fruits, vegetables, and whole grains (",
"    <a class=\"graphic graphic_table graphicRef51448 \" href=\"UTD.htm?17/2/17453\">",
"     table 1",
"    </a>",
"    ). Mineral oil can be taken orally in doses of 15 to 45 cc per day. However, it should not be given to patients at risk for aspiration. As alternatives, other stool softeners or laxatives (eg, polyethylene glycol based products) can be taken to prevent stool impaction and stent occlusion.",
"   </p>",
"   <p>",
"    Patients with stents in the right or transverse colon can consume normal diets as the stool in these portions of the colon is typically still liquid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published experience on colorectal stent placement for colonic obstruction is derived mostly from case series, small comparative trials, and retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/4,9,13,17-44\">",
"     4,9,13,17-44",
"    </a>",
"    ]. The greatest experience with stenting has been for left-sided lesions. A systematic review focusing on 88 studies that employed self expanding metal stents found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical success was achieved in a median of 96 percent of patients (range 66 to 100 percent) and clinical success was achieved in 92 percent (range 46 to 100 percent)",
"     </li>",
"     <li>",
"      There was little difference in technical or clinical success rate based upon indication (palliation or bridge to surgery) or based upon the etiology of the primary obstruction (eg,",
"      <span class=\"nowrap\">",
"       primary/recurrent",
"      </span>",
"      colorectal, urogenital, or pancreatic cancer)",
"     </li>",
"     <li>",
"      The median duration of patency was 106 days (range 68 to 288 days), though it was only reported in 14 of the studies",
"     </li>",
"     <li>",
"      The median rate of reintervention (ie, need for unplanned surgery, placement of a second or subsequent stent, or other interventions to maintain stent patency) was 20 percent (range 0 to 10 percent)",
"     </li>",
"     <li>",
"      The median stent migration rate was 11 percent (range 0 to 50 percent)",
"     </li>",
"     <li>",
"      The median perforation rate was 4.5 percent (range 0 to 83 percent)",
"     </li>",
"     <li>",
"      The median rate of reobstruction was 12 percent (range 1 to 92 percent)",
"     </li>",
"     <li>",
"      Other complications (such as rectal bleeding,",
"      <span class=\"nowrap\">",
"       anal/abdominal",
"      </span>",
"      pain, and tenesmus) were rare and generally mild",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107268578\">",
"    <span class=\"h2\">",
"     Stenting for palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the systematic review as well as subsequent studies suggest that colonic stents are an acceptable option for palliation of large bowel obstruction, though concern remains regarding perforation rates, especially in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/46\">",
"     46",
"    </a>",
"    ]. A randomized trial done after the systematic review compared stents with surgery for the palliation of malignant obstruction in the left colon using the Wallflex stent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/39\">",
"     39",
"    </a>",
"    ]. The study was closed prematurely due to a high rate of delayed perforation in the stenting group (6 out of 11 patients). However, other studies have demonstrated lower rates of delayed perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/38,46,47\">",
"     38,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Perforation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A retrospective study also published subsequent to the systematic review compared stenting with palliative surgery in 114 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/42\">",
"     42",
"    </a>",
"    ]. There was no difference between the groups with regard to early success rates (96 percent for both). The median patency duration of the first stent was less than surgery (137 versus 286 days). However, in patients who were able to receive a second stent, the overall stent patency duration (229 days) did not differ significantly from the patients who underwent surgery. There were fewer early complications in the stenting group (16 versus 33 percent) and more late complications (34 versus 18 percent; primarily stent obstruction). However, there were no differences between the groups in either early or late complication rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107268607\">",
"    <span class=\"h2\">",
"     Stenting for acute obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data are less clear with regard to the use of stents for acute colorectal obstruction due to malignancy. A cost-effectiveness analysis concluded that colonic stent insertion followed by elective surgery was more effective and less costly than emergency surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/8\">",
"     8",
"    </a>",
"    ], but randomized trials and meta-analyses have had contradictory outcomes.",
"   </p>",
"   <p>",
"    A meta-analysis that included five randomized trials with 207 patients compared stent placement with surgery. Stents were placed for preoperative intent in four studies and in one for palliation. Stent placement was technically successful in 86 percent of patients, with a perforation rate of 6 percent, a migration rate of 2 percent, and an obstruction rate of 2 percent. Despite the high success rate for stent placement, the average time of clinical relief of obstruction was significantly lower with stent placement compared with emergency surgery (0.7 days versus 3.6 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/48\">",
"     48",
"    </a>",
"    ]. There were no significant differences with regard to 30-day mortality or complication rates.",
"   </p>",
"   <p>",
"    In a second meta-analysis with eight studies and 601 patients, those who received stents were less likely than those treated with emergency surgery to require care in an intensive care unit (risk ratio [RR] 0.42) or to undergo stoma formation (RR 0.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, patients treated with stents were more likely to have a primary anastomosis (RR 1.6) and had lower complication rates (RR 0.42). There was no difference between the groups in mortality or long-term survival. However, this analysis did not look at issues such as the duration of stent patency.",
"   </p>",
"   <p>",
"    An additional trial was published after the meta-analyses. It included 98 patients with acutely obstructing left-sided colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/47\">",
"     47",
"    </a>",
"    ]. The patients were assigned either to stent placement as a bridge to elective surgery or emergency surgery. Interim analyses showed increased 30-day morbidity in the stenting group, and the study was suspended prior to enrollment of the goal number of patients (120). In the final analyses, there were no differences between the groups in mean global health status score, 30-day or overall mortality, or stoma rates at latest follow-up. Patients in the surgery group were more likely to have stomas directly after initial intervention and had a reduced frequency of stoma-related problems. Perforations occurred in 6 of 47 patients in the stenting group.",
"   </p>",
"   <p>",
"    At least one study suggests that colonic stents may be inferior to emergency surgery for patients with extrinsic colonic obstruction due to advanced gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/50\">",
"     50",
"    </a>",
"    ]. The study included 69 patients undergoing stent placement for imminent obstruction. Patients treated with emergency surgery did better than those treated with stent placement with regard to technical success (94 versus 74 percent), clinical success (74 verus 54 percent), and stent patency (median 183 versus 117 days). However, the rate of acute complications was higher for the surgery group (19 versus 4 percent), though there were no significant differences in the rate of early or late complications or procedure-related mortality.",
"   </p>",
"   <p>",
"    Some of the differences in the individual trials may be related to the experience of the endoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/51\">",
"     51",
"    </a>",
"    ]. As an example, in the trial published after the meta-analyses, 21 of 25 centers were non-university settings, and the technical success rate of 70 percent for stent placement in that trial was much lower than that seen in other series (at least 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/47\">",
"     47",
"    </a>",
"    ]. However, given the high perforation rate related to stent placement, until more data become available, we suggest that stenting for acute malignant colorectal obstruction be reserved for patients who are at increased risk for complications of emergency surgery (eg, patients with multiple significant comorbidities) or who would benefit from having their medical status optimized prior to surgery. In addition, colonic stenting should be performed by endoscopists with significant experience with stent placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Covered versus uncovered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Covered and uncovered SEMS designed for use within the colon have been studied. Covered stents have been used mainly in the setting of malignant colovesical, coloenteric, and colovaginal fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/18,52,53\">",
"     18,52,53",
"    </a>",
"    ]. A theoretical advantage of covered stents is reduction in the risk of tissue",
"    <span class=\"nowrap\">",
"     (malignant/benign)",
"    </span>",
"    ingrowth. However, they also have a greater tendency to migrate.",
"   </p>",
"   <p>",
"    Studies have not shown a significant advantage for covered stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nonrandomized study of 80 patients, there were no differences in technical or clinical success rates comparing uncovered with covered stents (100 versus 95 percent and 100 versus 97 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/34\">",
"       34",
"      </a>",
"      ]. There was a lower rate of loss of stent function in the patients who received uncovered stents (60 versus 19 percent).",
"     </li>",
"     <li>",
"      In a randomized trial of 151 patients with malignant colonic obstruction, there was no difference in clinical success rate for the placement of covered compared with uncovered stents (96 versus 92 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/54\">",
"       54",
"      </a>",
"      ]. There was a higher rate of stent migration among patients with covered stents (21 versus 2 percent) and there was a trend toward a lower rate of cancer infiltration into the covered stents (4 versus 15 percent, p = 0.057). There was no difference between the stents with regard to complications or stent obstruction from debris.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of stent placement for colorectal obstruction are perforation and stent migration; less commonly, abdominal pain and bleeding occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the systematic review discussed above, perforation rates ranged from 0 to 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the rate of perforation in experienced hands is probably less than 5 percent, particularly since balloon dilation prior to stent insertion is no longer performed routinely. The median rate of perforation was 4.5 percent in the systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perforation can be immediate or delayed, and is more likely in the distal colon where sharp angulation and redundancy make stent deployment challenging. Furthermore, the anatomy of the left colon predisposes the colonic folds to drape over the two ends of the stent, which can cause excessive tension at the points of contact, and subsequent pressure necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data concerning the safety of self-expanding metal stents (SEMS) in the colon or rectum of patients who have undergone radiotherapy or are receiving the anti-angiogenic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as a component of chemotherapy; both treatments may increase the risk of perforation, though the majority of perforations are seen in patients without these potential risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=see_link&amp;anchor=H12#H12\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\", section on 'Intraluminal stent placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, accumulating data suggest a significantly increased risk of perforation in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/46,57,58\">",
"     46,57,58",
"    </a>",
"    ]. In a study of 233 patients, 26 received bevacizumab after SEMS insertion (23 for palliation, three as a bridge to surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/46\">",
"     46",
"    </a>",
"    ]. Colonic perforation occurred more often in patients who received bevacizumab after stent placement compared with patients who did not, though the result did not reach statistical significance (15 versus 7 percent, p = 0.06). None of the six patients who received bevacizumab prior to stent insertion had a perforation.",
"   </p>",
"   <p>",
"    Similar results were noted in a retrospective series of 201 patients who received self-expanding metal stents for palliation. Stents were successfully placed in 184 patients (92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/57\">",
"     57",
"    </a>",
"    ]. There were 12 perforations (6 percent). However, four of the eight patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    experienced a perforation, a rate significantly higher than seen in those who did not receive bevacizumab (odds ratio 20; 95% confidence interval 5.9-65). The study did not report when the bevacizumab was given relative to stent placement.",
"   </p>",
"   <p>",
"    Based upon these data, we suggest that colonic stent placement be avoided if possible in patients who are or who will be receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stent migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent migration has been described in up to 50 percent of patients (median 11 percent in a systematic review) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/45\">",
"     45",
"    </a>",
"    ]. It is usually detected within one week of insertion. Migrations tend to occur with stents that are too narrow or too short in relation to the obstructing lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/15\">",
"     15",
"    </a>",
"    ] or in the presence of a non-obstructive stricture, or tumor shrinkage following oncologic therapy. In a review of the published data on colorectal stenting, stent migration was reported in 54 (10 percent) of 551 technically successful cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/59\">",
"     59",
"    </a>",
"    ]. The migration occurred within three days in 14 of 54 patients (26 percent); the remaining 40 occurred after three days. Factors that predispose to stent migration include benign stricture, extrinsic lesion, laser debulking, stricture dilation, small stent caliber, covered stents, and the administration of post-stent radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postprocedure bleeding is usually minor and probably due to tumor friability, superficial tissue tear, or mucosal irritation from to the sharp end of the stent. Minor rectal bleeding generally requires no treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient and mild abdominal pain is common and may be felt up to five days after stenting. For low-lying rectal lesions, care must be taken to avoid stent-induced irritation of the nerve endings near the squamocolumnar junction, which can lead to severe tenesmus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/23\">",
"     23",
"    </a>",
"    ]. Mild abdominal pain generally requires no specific treatment other than the judicious use of analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FAILURE TO ACHIEVE DECOMPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 6 percent of patients, stenting does not result in immediate colonic decompression despite successful stent deployment. There are several potential reasons for treatment failure, including the presence of additional sites of intestinal obstruction (eg, from synchronous lesions or extrinsic compression such as from peritoneal carcinomatosis), incomplete stenting of the entire length of the stricture, early stent migration, an underlying motility disorder, fecal impaction within a newly inserted stent, poor stent positioning, or incomplete expansion of the device due to bulky extrinsic compression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/9\">",
"     9",
"    </a>",
"    ]. A retrograde radiographic contrast study (eg, a water soluble or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema examination) is useful to assess the anatomy, length of stricture, degree and various sites of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LATE RECURRENCE OF OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late recurrence of obstruction may be due to tumor ingrowth through the stent mesh or overgrowth at either end of the stent. This may require additional stent placement through the original stent. Alternatives include laser ablation or argon plasma coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STENTING FOR BENIGN CAUSES OF OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nonmalignant conditions can lead to colonic obstruction, the most common of which is diverticular disease. The role of stenting for benign causes of colonic obstruction is unclear. It may be considered for emergency temporary decompression in patients in whom elective surgery is planned (such as those with obstruction due to diverticular disease), as such patients may otherwise require a temporary diverting colostomy.",
"   </p>",
"   <p>",
"    Case reports have described the use of self-expanding metal stents (SEMS) in such patients, usually to achieve temporary decompression prior to subsequent elective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/24,60\">",
"     24,60",
"    </a>",
"    ]. Long-term stenting of benign colonic strictures is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/61\">",
"     61",
"    </a>",
"    ]. Late colonic perforation, chronic abdominal discomfort, and late stent occlusion can occur. Patients undergoing stenting for benign lesions should probably have a stent placed that can be removed subsequently.",
"   </p>",
"   <p>",
"    Experience with stents for the management of benign colorectal disease is limited. In a series of 10 patients, metallic stents were placed for diverticulitis complicated by pelvic abscess (two patients), colonic fistula following surgery (four patients), and postsurgical anastomotic stricture (four patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/30\">",
"     30",
"    </a>",
"    ]. The stents helped resolve the abscesses in both the patients with diverticulitis, but they subsequently developed fistulae and perforations. Of the four cases with colonic fistulae, two resolved with stent placement. The stents temporarily relieved the symptoms of obstruction in the group of patients with postsurgical stenoses.",
"   </p>",
"   <p>",
"    Another report included eight patients who underwent stenting for benign strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5673/abstract/35\">",
"     35",
"    </a>",
"    ]. Many of the patients required reintervention and only three were considered to truly gain a benefit from stenting. Complications included death (three patients) and anastomotic leakage (3 patients). The authors concluded that stenting of benign strictures was ineffective and associated with a high rate of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stenting for acute malignant colorectal obstruction is an option for patients with obstructing colorectal cancer who require decompression in order to permit elective surgical intervention. However, studies suggest increased morbidity compared with surgery, so we suggest that it be reserved for patients who are at increased risk for complications of emergency surgery (eg, patients with multiple significant comorbidities) or who would benefit from having their medical status optimized prior to surgery. In addition, colonic stenting should be performed by endoscopists with significant experience with stent placement. (See",
"      <a class=\"local\" href=\"#H25514362\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H107268607\">",
"       'Stenting for acute obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stenting can achieve long-term palliation in patients with colorectal cancer who are not operative candidates. More than 75 percent of such patients can achieve adequate palliation with a stent, although tumor ingrowth and stent migration may necessitate reintervention either with an additional stent or with other palliative measures such as laser or argon plasma coagulation therapy.",
"     </li>",
"     <li>",
"      The role of palliative stenting for patients who are operative candidates is less clear. Surgical palliation, radiation therapy, or attempted resection may be a better option for patients who are relatively healthy with advanced local disease, except for those who refuse an ostomy. (See",
"      <a class=\"local\" href=\"#H25514362\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of stenting for benign causes of colonic obstruction is unclear. It may be considered for emergency temporary decompression in patients in whom elective surgery is planned (such as those with obstruction due to diverticular disease). Such patients may otherwise require a temporary diverting colostomy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Stenting for benign causes of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk is perforation, which occurs in approximately 5 percent of patients when stenting is performed by experienced endoscopists. However, higher rates of perforation have been described, particularly with antecedent balloon dilation of the strictured segment, a technique that is generally no longer performed routinely. Data are accumulating that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      puts patients at significant risk for perforation, and we suggest that colonic stenting be avoided if possible in patients who are or who will be receiving bevacizumab, especially if the obstruction is subtotal, since these patients may respond to therapy with improved luminal diameter and not require stent placement. There is little experience with stenting in the setting of radiation therapy, in which immediate and delayed perforation may be more likely. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/1\">",
"      Simmons DT, Baron TH. Technology insight: Enteral stenting and new technology. Nat Clin Pract Gastroenterol Hepatol 2005; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/2\">",
"      Leitman IM, Sullivan JD, Brams D, DeCosse JJ. Multivariate analysis of morbidity and mortality from the initial surgical management of obstructing carcinoma of the colon. Surg Gynecol Obstet 1992; 174:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/3\">",
"      Scott NA, Jeacock J, Kingston RD. Risk factors in patients presenting as an emergency with colorectal cancer. Br J Surg 1995; 82:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/4\">",
"      Gandrup P, Lund L, Balslev I. Surgical treatment of acute malignant large bowel obstruction. Eur J Surg 1992; 158:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/5\">",
"      Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Br J Surg 1994; 81:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/6\">",
"      Riedl S, Wiebelt H, Bergmann U, Hermanek P Jr. [Postoperative complications and fatalities in surgical therapy of colon carcinoma. Results of the German multicenter study by the Colorectal Carcinoma Study Group]. Chirurg 1995; 66:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/7\">",
"      Fielding LP, Wells BW. Survival after primary and after staged resection for large bowel obstruction caused by cancer. Br J Surg 1974; 61:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/8\">",
"      Targownik LE, Spiegel BM, Sack J, et al. Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc 2004; 60:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/9\">",
"      Baron TH, Dean PA, Yates MR 3rd, et al. Expandable metal stents for the treatment of colonic obstruction: techniques and outcomes. Gastrointest Endosc 1998; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/10\">",
"      Pothuri B, Guirguis A, Gerdes H, et al. The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer. Gynecol Oncol 2004; 95:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/11\">",
"      Adler DG, Baron TH. Endoscopic palliation of colorectal cancer. Hematol Oncol Clin North Am 2002; 16:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/12\">",
"      Small AJ, Baron TH. Comparison of Wallstent and Ultraflex stents for palliation of malignant left-sided colon obstruction: a retrospective, case-matched analysis. Gastrointest Endosc 2008; 67:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/13\">",
"      Repici A, Adler DG, Gibbs CM, et al. Stenting of the proximal colon in patients with malignant large bowel obstruction: techniques and outcomes. Gastrointest Endosc 2007; 66:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/14\">",
"      Song HY, Kim JH, Kim KR, et al. Malignant rectal obstruction within 5 cm of the anal verge: is there a role for expandable metallic stent placement? Gastrointest Endosc 2008; 68:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/15\">",
"      Mauro MA, Koehler RE, Baron TH. Advances in gastrointestinal intervention: the treatment of gastroduodenal and colorectal obstructions with metallic stents. Radiology 2000; 215:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/16\">",
"      Baron TH, Rey JF, Spinelli P. Expandable metal stent placement for malignant colorectal obstruction. Endoscopy 2002; 34:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/17\">",
"      Tack J, Gevers AM, Rutgeerts P. Self-expandable metallic stents in the palliation of rectosigmoidal carcinoma: a follow-up study. Gastrointest Endosc 1998; 48:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/18\">",
"      Repici A, Reggio D, De Angelis C, et al. Covered metal stents for management of inoperable malignant colorectal strictures. Gastrointest Endosc 2000; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/19\">",
"      Rey JF, Romanczyk T, Greff M. Metal stents for palliation of rectal carcinoma: a preliminary report on 12 patients. Endoscopy 1995; 27:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/20\">",
"      Spinelli P, Mancini A. Use of self-expanding metal stents for palliation of rectosigmoid cancer. Gastrointest Endosc 2001; 53:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/21\">",
"      Cam&uacute;&ntilde;ez F, Echenagusia A, Sim&oacute; G, et al. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 2000; 216:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/22\">",
"      Dohmoto M, H&uuml;nerbein M, Schlag PM. Application of rectal stents for palliation of obstructing rectosigmoid cancer. Surg Endosc 1997; 11:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/23\">",
"      Coco C, Cogliandolo S, Riccioni ME, et al. Use of a self-expanding stent in the palliation of rectal cancer recurrences. A report of three cases. Surg Endosc 2000; 14:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/24\">",
"      Tamim WZ, Ghellai A, Counihan TC, et al. Experience with endoluminal colonic wall stents for the management of large bowel obstruction for benign and malignant disease. Arch Surg 2000; 135:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/25\">",
"      Mainar A, De Gregorio Ariza MA, Tejero E, et al. Acute colorectal obstruction: treatment with self-expandable metallic stents before scheduled surgery--results of a multicenter study. Radiology 1999; 210:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/26\">",
"      Binkert CA, Ledermann H, Jost R, et al. Acute colonic obstruction: clinical aspects and cost-effectiveness of preoperative and palliative treatment with self-expanding metallic stents--a preliminary report. Radiology 1998; 206:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/27\">",
"      Law WL, Choi HK, Lee YM, Chu KW. Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents: prospective evaluation of outcomes. Dis Colon Rectum 2004; 47:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/28\">",
"      Clark JS, Buchanan GN, Khawaja AR, et al. Use of the Bard Memotherm self-expanding metal stent in the palliation of colonic obstruction. Abdom Imaging 2003; 28:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/29\">",
"      Seymour K, Johnson R, Marsh R, Corson J. Palliative stenting of malignant large bowel obstruction. Colorectal Dis 2002; 4:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/30\">",
"      Pa&uacute;l L, Pinto I, G&oacute;mez H, et al. Metallic stents in the treatment of benign diseases of the colon: preliminary experience in 10 cases. Radiology 2002; 223:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/31\">",
"      Shim CS, Cho JY, Jung IS, et al. Through-the-scope double colonic stenting in the management of inoperable proximal malignant colonic obstruction: a pilot study. Endoscopy 2004; 36:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/32\">",
"      Garc&iacute;a-Cano J, Gonz&aacute;lez-Huix F, Juzgado D, et al. Use of self-expanding metal stents to treat malignant colorectal obstruction in general endoscopic practice (with videos). Gastrointest Endosc 2006; 64:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/33\">",
"      Repici A, Fregonese D, Costamagna G, et al. Ultraflex precision colonic stent placement for palliation of malignant colonic obstruction: a prospective multicenter study. Gastrointest Endosc 2007; 66:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/34\">",
"      Lee KM, Shin SJ, Hwang JC, et al. Comparison of uncovered stent with covered stent for treatment of malignant colorectal obstruction. Gastrointest Endosc 2007; 66:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/35\">",
"      Meisner S, Hensler M, Knop FK, et al. Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center. Dis Colon Rectum 2004; 47:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/36\">",
"      Law WL, Choi HK, Chu KW. Comparison of stenting with emergency surgery as palliative treatment for obstructing primary left-sided colorectal cancer. Br J Surg 2003; 90:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/37\">",
"      Fregonese D, Naspetti R, Ferrer S, et al. Ultraflex precision colonic stent placement as a bridge to surgery in patients with malignant colon obstruction. Gastrointest Endosc 2008; 67:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/38\">",
"      Repici A, De Caro G, Luigiano C, et al. WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers. Gastrointest Endosc 2008; 67:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/39\">",
"      van Hooft JE, Fockens P, Marinelli AW, et al. Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. Endoscopy 2008; 40:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/40\">",
"      Cheung HY, Chung CC, Tsang WW, et al. Endolaparoscopic approach vs conventional open surgery in the treatment of obstructing left-sided colon cancer: a randomized controlled trial. Arch Surg 2009; 144:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/41\">",
"      Nagula S, Ishill N, Nash C, et al. Quality of life and symptom control after stent placement or surgical palliation of malignant colorectal obstruction. J Am Coll Surg 2010; 210:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/42\">",
"      Lee HJ, Hong SP, Cheon JH, et al. Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. Gastrointest Endosc 2011; 73:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/43\">",
"      Yoon JY, Jung YS, Hong SP, et al. Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc 2011; 74:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/44\">",
"      Meisner S, Gonz&aacute;lez-Huix F, Vandervoort JG, et al. Self-expandable metal stents for relieving malignant colorectal obstruction: short-term safety and efficacy within 30 days of stent procedure in 447 patients. Gastrointest Endosc 2011; 74:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/45\">",
"      Watt AM, Faragher IG, Griffin TT, et al. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. Ann Surg 2007; 246:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/46\">",
"      Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors. Gastrointest Endosc 2010; 71:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/47\">",
"      van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol 2011; 12:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/48\">",
"      Sagar J. Colorectal stents for the management of malignant colonic obstructions. Cochrane Database Syst Rev 2011; :CD007378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/49\">",
"      Zhang Y, Shi J, Shi B, et al. Self-expanding metallic stent as a bridge to surgery versus emergency surgery for obstructive colorectal cancer: a meta-analysis. Surg Endosc 2012; 26:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/50\">",
"      Kim BK, Hong SP, Heo HM, et al. Endoscopic stenting is not as effective for palliation of colorectal obstruction in patients with advanced gastric cancer as emergency surgery. Gastrointest Endosc 2012; 75:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/51\">",
"      Song LM, Baron TH. Stenting for acute malignant colonic obstruction: a bridge to nowhere? Lancet Oncol 2011; 12:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/52\">",
"      Choo IW, Do YS, Suh SW, et al. Malignant colorectal obstruction: treatment with a flexible covered stent. Radiology 1998; 206:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/53\">",
"      Cwikiel W, Andr&eacute;n-Sandberg A. Malignant stricture with colovesical fistula: stent insertion in the colon. Radiology 1993; 186:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/54\">",
"      Park S, Cheon JH, Park JJ, et al. Comparison of efficacies between stents for malignant colorectal obstruction: a randomized, prospective study. Gastrointest Endosc 2010; 72:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/55\">",
"      Lo SK. Metallic stenting for colorectal obstruction. Gastrointest Endosc Clin N Am 1999; 9:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/56\">",
"      Datye A, Hersh J. Colonic perforation after stent placement for malignant colorectal obstruction--causes and contributing factors. Minim Invasive Ther Allied Technol 2011; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/57\">",
"      Manes G, de Bellis M, Fuccio L, et al. Endoscopic palliation in patients with incurable malignant colorectal obstruction by means of self-expanding metal stent: analysis of results and predictors of outcomes in a large multicenter series. Arch Surg 2011; 146:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/58\">",
"      Cennamo V, Fuccio L, Mutri V, et al. Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy? Clin Gastroenterol Hepatol 2009; 7:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/59\">",
"      Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/60\">",
"      Davidson R, Sweeney WB. Endoluminal stenting for benign colonic obstruction. Surg Endosc 1998; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5673/abstract/61\">",
"      Cascales-Sanchez P, Garcia-Olmo D, Julia-Molla E. Long-term expandable stent as a definitive treatment for benign rectal stenosis. Br J Surg 1997; 84:840.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2678 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5673=[""].join("\n");
var outline_f5_34_5673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25514362\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dietary recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107268578\">",
"      Stenting for palliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107268607\">",
"      Stenting for acute obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Covered versus uncovered stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stent migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FAILURE TO ACHIEVE DECOMPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LATE RECURRENCE OF OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STENTING FOR BENIGN CAUSES OF OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2678|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/61/12255\" title=\"diagnostic image 1\">",
"      Colonic stent barium enema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2678|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/38/13922\" title=\"picture 1\">",
"      Colonic stent Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2678|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/32/17935\" title=\"movie 1\">",
"      Colonic stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17453\" title=\"table 1\">",
"      Dietary fiber in foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5674="Immunology of HIV-1 infection";
var content_f5_34_5674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunology of HIV-1 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Jenna A Rychert, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Eric S Rosenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5674/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/34/5674/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/34/5674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate and adaptive immune responses play a role in controlling HIV replication. Yet, immune dysfunction is common in HIV-infected individuals and the virus has developed multiple strategies to evade host defenses. Thus, in most untreated individuals, viral replication is not fully contained, resulting in persistent viremia, progressive disease, and the development of acquired immunodeficiency syndrome (AIDS).",
"   </p>",
"   <p>",
"    This topic is an introduction to the immunology of HIV infection and begins with a glossary of some of the common terminology used in the field. Other factors governing the progression of HIV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link\">",
"     \"Factors affecting HIV progression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOSSARY OF TERMS AND CONCEPTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     CCR5 and CXCR4",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5 and CXCR4 are chemokine receptors that are expressed on T cells, macrophages, and dendritic cells. These molecules normally act as receptors for chemokines, proinflammatory chemicals that are released in the setting of inflammation. CCR5 and CXCR4 are expressed on different cell types; thus, the tropism of a viral variant is partially determined by its coreceptor preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection begins when the envelope glycoprotein (gp120) of HIV binds to its cellular receptor, CD4. After a conformational shift, gp120 then binds to a coreceptor, either CCR5 or CXCR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     R5 viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;R5 viruses utilize CCR5 as a co-receptor. Phenotypically, these viruses are macrophage-tropic and are sometimes referred to as \"M-tropic viruses\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     X4 viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;X4 viruses utilize CXCR4 as their coreceptor. Phenotypically, these viruses are T lymphocyte-tropic and are sometimes referred to as \"T-tropic viruses\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dual tropic viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual tropic viruses are capable of utilizing both CCR5 and CXCR4 as co-receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Syncytia-formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncytia formation refers to the fusion of multiple cells, creating a larger cell with multiple nuclei.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-syncytia inducing virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-syncytia inducing virus (NSI virus) fails to produce syncytia in immortalized T cell lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Syncytium-inducing (SI) viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncytium-inducing virus (SI virus) is capable of producing syncytia in immortalized T cell lines.",
"   </p>",
"   <p>",
"    Phenotypically, X4 viruses are SI viruses, whereas R5 viruses are NSI viruses. A switch from NSI to SI virus appears to be involved in disease pathogenesis, since viral isolates from individuals recently infected tend to be R5 viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, X4 viral isolates have been isolated from subjects during later stages of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Macrophage inflammatory protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophage inflammatory protein (MIP-1) refers to a family of chemokines that bind to the CCR5 receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Regulated on activation, normal T cell expressed and secreted chemokine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulated on activation, normal T cell expressed and secreted (RANTES) is a chemokine that binds to the CCR5 receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stromal cell-derived factor type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal cell-derived factor type 1 (SDF-1) is a chemokine that binds to CXCR4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Programmed death-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programmed death-1 (PD-1) is a transmembrane protein that is a member of the CD28 family of costimulation molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/5\">",
"     5",
"    </a>",
"    ]. PD-1 is expressed on activated T, B, and myeloid cells. Upon ligand binding with PD-L1 and PD-L2, PD-1 inhibits activated T and B cells. The PD-1 pathway may play a role in functional impairment of HIV-specific T cells and their inability to control viral replication. CD8 T cells can further up-regulate PD-1 expression when they express activation markers, such as CD38 and HLA-DR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis refers to programmed cell death, a normal process for deleting aging cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     T-cell anergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A state of T cell unresponsiveness that is usually reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INNATE IMMUNE RESPONSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dendritic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dendritic cells (DCs) are antigen-presenting cells (APCs) that can present HIV antigens via MHC class I and class II molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The class II pathway is designed to target exogenous antigens, which are then degraded in lysosomes, loaded onto MHC class II molecules, and presented to CD4+ T helper cells (TH).",
"   </p>",
"   <p>",
"    In contrast, intracellular antigens are broken down by proteases, sent to the endoplasmic reticulum for presentation on class I molecules, and presented to CD8+ cytotoxic T lymphocytes (CTLs). Dendritic cells are unique among the professional APCs; they are able to circumvent the need for cytoplasmic processing and can present exogenous viral proteins to CD8+ CTL in a class I restricted manner [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/8\">",
"     8",
"    </a>",
"    ]. It has been shown that autologous DCs, primed with peptide, can boost TH and CTL memory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and generate primary immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] both in vitro and in vivo. Studies are currently underway to determine if such strategies could be used in the development of an immune-based therapy or vaccine for HIV.",
"   </p>",
"   <p>",
"    In addition to their role in the immune response against HIV, dendritic cells are believed to be the initial cells infected at mucosal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/14\">",
"     14",
"    </a>",
"    ]. They then migrate to lymph nodes and allow HIV to infect CD4 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. During primary HIV infection, the number and function of DCs begin to decline. Function can be partially restored with potent antiretroviral therapy (ART).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Toll-like receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toll-like receptors (TLRs) are pattern recognition molecules that activate cells of the innate immune system. Single stranded RNA derived from HIV is capable of activating DC and monocytes via TLR 7 and 8 resulting in the secretion of IFN-alpha, IL-6, TNF-alpha, and IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This interaction can also upregulate PD-L1 expression. When PD-L1 binds with PD-1 on T cells, antigen-specific T cell function is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Natural killer cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural killer cells (NK cells) are considered cytotoxic effector cells of the innate immune system. They make up approximately 15 percent of peripheral blood lymphocytes and are also found in liver, peritoneum, and placental tissue. NK cells act as a bridge between the innate and adaptive immune response by inducing DC maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. NK cells express a wide repertoire of activating and inhibitory receptors; under normal conditions, inhibitory receptors predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/23\">",
"     23",
"    </a>",
"    ]. However, when a viral pathogen is present, the pattern of NK cell receptors is altered, enabling NK cells to recognize and lyse infected target cells without need for prior sensitization.",
"   </p>",
"   <p>",
"    During acute HIV infection, NK cell responses precede the development of virus-specific CD8+ T cell responses and antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/24\">",
"     24",
"    </a>",
"    ]. They are able to kill HIV-infected cells by direct lysis and antibody-dependent cell-mediated cytotoxicity (ADCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Progressive untreated infection is associated with NK cell changes in gene expression, increased apoptosis, and loss of NK cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/29-34\">",
"     29-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peptide-specific natural killer cells are associated with markers of less severe disease progression among HIV-infected women and with stronger HIV-specific T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, genetic polymorphisms that affect NK inhibitory receptor expression may also play a synergistic role in slowing disease progression in association with certain \"protective\" HLA backgrounds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Host determinants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADAPTIVE IMMUNE RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the paradoxes of HIV infection is that the virus elicits a broad immune response that is not fully protective and only partially effective in containing ongoing viral replication. Immune dysfunction may be due to the fact that HIV specifically infects cells of the immune system, such as CD4 T cells, macrophages, and dendritic cells. Chronic infection leads to general activation of the immune system, which results in perturbations of cytokine expression, redistribution of lymphocyte subpopulations, increased cellular turnover, cellular dysfunction, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CD4 T-helper cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although other viruses can chronically infect CD4 T cells, HIV is unique in that it selectively targets and infects activated, expanding CD4 T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During acute infection, viral replication occurs at an extremely rapid rate, producing the highest level of circulating virus observed at any time during infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/39\">",
"     39",
"    </a>",
"    ]. This creates a situation in which rapidly proliferating virus-specific CD4 helper T cells become activated and expand in the presence of high viremia, resulting in subsequent infection and impairment of these cells. Within the first weeks of infection there is a massive loss of T cells in the gut-associated mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/40\">",
"     40",
"    </a>",
"    ]. This is followed by the progressive loss of CD4 cells in the peripheral blood, which is a hallmark of this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TH cells have been shown to be an important component of the HIV-specific cellular immune response. During chronic infection, there is a significant negative association between HIV plasma RNA levels and HIV-specific TH responses (directed towards HIV gag protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Furthermore, vigorous TH cell responses have been observed in individuals with apparently non-progressive HIV infection (\"controllers\") [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/41\">",
"     41",
"    </a>",
"    ], and TH responses appear to be associated with transient control of viremia following structured treatment interruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in most infected individuals, HIV-specific TH function is relatively weak or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/41,44-50\">",
"     41,44-50",
"    </a>",
"    ]. This is one of the most notable immunologic defects in HIV infection. This qualitative abnormality in immune function is present in the earliest stages of infection, before the quantitative decline in CD4 cells is observed. CD4 T cell dysfunction manifests as a lack of proliferative responses, decreased IL-2 production, and reduced expression of the IL-2 receptor (CD25) and the co-stimulatory molecule, CD28.",
"   </p>",
"   <p>",
"    The mechanisms by which TH dysfunction arises are not completely defined but may include: induction of T cell anergy (unresponsiveness) due to high levels of antigen, antigen-induced apoptosis, defects in antigen presentation, or viral sequence variation within CD4 epitopes. Restoration of HIV-specific TH responses has been achieved in individuals who received HAART during acute infection; however, little is known about whether these responses are associated with clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/41,51\">",
"     41,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cytotoxic T lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of a virus-specific CTL response to HIV in the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/52\">",
"     52",
"    </a>",
"    ] led to the realization that the cell-mediated immune response could play an important role in containing HIV infection and delaying disease progression. Although the correlates of immunity have not been directly established, many studies have found associations between CTL responses and control of viral replication.",
"   </p>",
"   <p>",
"    HIV-specific CTL have been identified in most persons infected with the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. During primary infection there is a strong temporal association between the decrease in plasma viral load and the appearance of CTL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/55\">",
"     55",
"    </a>",
"    ]. Moreover, CD8 T cell depletion of macaques, just prior to infection with an analogous non-human primate retrovirus, SIV, leads to sustained high viral loads and rapid disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During chronic infection, CTL remain an important defense against the virus. Individuals that control HIV in the absence of therapy have been shown to have strong virus-specific CTL responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], and several groups have shown that high levels of CTL correlate with low viral load and slower disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the presence of HIV-specific CTL, most HIV-infected individuals eventually progress to AIDS in the absence of antiretroviral treatment (ART). As disease progresses, virus-specific CTL responses decline, but persist at low levels even in patients close to death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/50,62\">",
"     50,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies are currently underway to elucidate the mechanisms for the failure of CTL to completely control infection. It has been shown that HIV-specific CTL appear to have shorter life spans than CTL with specificities for other viruses. This may be due to the upregulation of markers for apoptosis that is observed during HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Under the influence of CTL pressure, HIV can mutate to avoid immune detection and destruction. Mutations at key positions within CD8 epitopes result in either the loss of peptide binding to MHC class I or the loss of recognition of the peptide:MHC I complex by the T cell receptor (TCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. This prevents CTL from recognizing and killing HIV-infected cells. The ability of CTL to respond to HIV may also be negatively affected by PD-1 expression, which is upregulated in chronic HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/20,70,71\">",
"     20,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Humoral immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective neutralizing antibody response is able to contain many viral infections, but the role that antibody plays in HIV disease is unclear.",
"   </p>",
"   <p>",
"    In the context of mother to infant transmission, neutralizing antibodies have been associated with prevention of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/72\">",
"     72",
"    </a>",
"    ], and in a monkey model, passive immunization has been shown to be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/73\">",
"     73",
"    </a>",
"    ]. Similarly, in highly exposed but HIV-seronegative individuals, neutralizing IgG and mucosal IgA have been detected, although this appears to occur only in a minority of these subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. For the most part, an effective neutralizing antibody response appears to be difficult to reproduce in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/76\">",
"     76",
"    </a>",
"    ]. It has been shown that neutralizing antibody titers are not predictive of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/77\">",
"     77",
"    </a>",
"    ]. Although some individuals with long-term nonprogressive infection have broadly cross-reactive neutralizing antibodies, these responses are not observed in all controllers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/78\">",
"     78",
"    </a>",
"    ]. In one study of 22 elite controllers and 75 viremic chronically-infected untreated patients with CD4 cell counts above 400",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    controllers had generally the same or lower levels of neutralizing antibodies than viremic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of an effective neutralizing antibody response can be partially explained by the fact that HIV has multiple mechanisms of evading the humoral immune system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For example, the host may mount a neutralizing antibody response that becomes ineffective once the virus mutates [",
"      <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/80\">",
"       80",
"      </a>",
"      ]. Mutations are frequent due to HIV's error prone replication and the structural flexibility of the viral envelope (Env).",
"     </li>",
"     <li>",
"      HIV also evades antibody by coating itself with sugars. By adding asparagine-linked glycosylations during processing of envelope proteins (gp160), the virus is able to produce a 'glycan shield', thus preventing antibody binding [",
"      <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/81\">",
"       81",
"      </a>",
"      ]. Furthermore, point mutations, insertions, and deletions can alter the positioning of the sugars, resulting in an ever-changing disguise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies are currently underway to devise molecules that mimic the native Env structure in order to elicit neutralizing antibodies as part of a multivalent vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immune activation and regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune activation is part of the normal host response to infection. During HIV infection there is hyperactivation that may persist over the course of disease. In fact, one of the best correlates of disease progression is the expression of the activation markers CD38 and HLA-DR on T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Additionally, the level of pro-inflammatory cytokines including TNF-alpha, IL-6 and IL-1beta are elevated.",
"   </p>",
"   <p>",
"    Multiple mechanisms likely contribute to the chronic immune activation that is observed in most HIV infected individuals. In addition to excess antigen exposure (eg, uncontrolled viral replication), the HIV proteins Env and Nef are able to directly stimulate T cells. Furthermore, the massive depletion of T cells that occurs in the gut-associated mucosa during acute infection is associated with loss of mucosal integrity and translocation of gut flora into the peripheral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/40\">",
"     40",
"    </a>",
"    ]. It is also possible that activation is induced by other pathogens (eg, CMV and EBV) that have been reactivated due to a decline in cell-mediated control as CD4+ T cells are lost.",
"   </p>",
"   <p>",
"    Regulatory T cells are thought to be important for controlling immune activation. Two regulatory subsets that likely play a role in the pathogenesis of HIV infection are Tregs and Th17 cells .Studies suggest that the inflammatory milieu during HIV infection may promote the expansion of Tregs at the expense Th17 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/84-88\">",
"     84-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of Tregs in the pathogenesis of HIV remains unclear. On the one hand, Tregs can suppress immune activation. Studies suggest an inverse relationship between the proportion of Tregs and the proportion of activated CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. On the other hand, Tregs can suppress virus-specific cell-mediated immune responses. For example, Tregs from HIV-infected subjects suppress HIV-specific cytolytic activity, cytokine and chemokine expression, and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/92\">",
"     92",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Th17 cells are critical for maintaining the integrity of the gut mucosa. It has been proposed that the loss of these cells in HIV-infected individuals may contribute to translocation of microbial products (eg, lipopolysaccharide; LPS) into the peripheral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/93\">",
"     93",
"    </a>",
"    ] thus perpetuating the hyperactivation of the immune system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     HOST DETERMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progression of HIV infection varies greatly among individuals, including those infected from the same source. This observation has led investigators to explore host genetic factors that might account for these differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Polymorphisms in chemokine receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral entry is dependent on the binding of the viral envelope protein, gp120, to CD4 and a chemokine coreceptor, either CCR5 or CXCR4. After the discovery that CCR5 acted as a coreceptor for viral entry, it was shown that individuals homozygous for a 32 base-pair deletion in the CCR5 gene were more resistant to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/94\">",
"     94",
"    </a>",
"    ] and individuals heterozygous for this deletion tend to have slower rates of disease progression than those that are homozygous for wild-type CCR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/95\">",
"     95",
"    </a>",
"    ]. These observations provide a biologic rationale for a new class of antiviral agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , which blocks viral entry via the CCR5 receptor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     HLA background",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human leukocyte antigens (HLA) bind antigenic peptides and present them to T cells to initiate cell-mediated immune responses. It has been shown that certain HLA haplotypes that present peptide to cytotoxic T lymphocytes (CTL) influence the rate of disease progression.",
"   </p>",
"   <p>",
"    HLA-B57 and B27 have been associated with viral load setpoint and slower disease progression among Europeans and African American patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The mechanisms that underlie this apparent protection are still being determined; however, HLA-B57 restricted CTL responses appear to target multiple peptides, with HIV gag-specific responses being the most prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Some data suggest that differential protein targeting (eg, gag and not env), rather than the quality of the CD8 T-cell response, may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the other end of the spectrum, HLA-B35 has consistently been associated with rapid disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. It has been shown that the structure of the binding groove of HLA-B35 differs from other HLA-B molecules that have been associated with slower disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/105\">",
"     105",
"    </a>",
"    ]. This implies that different peptides are able to bind HLA-B35 and suggests that some epitopes are better than others at eliciting protective responses. Additionally, CTL response in patients expressing B35 and other HLA alleles associated with rapid progression appear to recognize a smaller proportion of HIV epitopes than patients with HLA alleles associated with slower progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA supertypes (eg, HLA molecules that have similar peptide binding motifs), rather than single alleles, may be a better predictor of disease progression than single HLA haplotypes. There is a strong association between specific HLA supertypes and viral load, suggesting that HIV can adapt to common alleles expressed in the population, thus giving those individuals with rarer supertypes a selective advantage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expression of the NK cell receptor, KIR3DS1 and its ligand, HLA Bw4-80I, has been associated with slower disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/108\">",
"     108",
"    </a>",
"    ]; homozygosity at the KIR3DS1 locus was also more common among HIV-exposed seronegative subjects than among acutely infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/109\">",
"     109",
"    </a>",
"    ]. These genetic studies are supported by data that showed that expression of KIR3DS1 is associated with better NK cell effector function and diminished CD8+ T cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/110\">",
"     110",
"    </a>",
"    ]. Furthermore, functional studies have shown that KIR3DS1-expressing cells are better able to inhibit HIV-infected Bw4-80I-expressing target cells than NK cells that don't express this receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genome-wide association study was conducted to define the host determinants of viral load set point and disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/96\">",
"     96",
"    </a>",
"    ]. Variation in viral load set point was explained by two polymorphisms. The first polymorphism is in the gene called HCP5, an endogenous retroviral element. The single nucleotide polymorphism (SNP) in HCP5 is in linkage disequilibrium with HLA-B57, which may explain why it is associated with viral control. The second polymorphism is upstream of HLA-C. The authors suggest that this variant is associated with higher expression of HLA-C. Since HLA-C can present peptides to both NK cells and CD8+ T cells, its increased expression may enhance both innate and cell mediated immunity to the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28456149\">",
"    <span class=\"h1\">",
"     NATURAL IMMUNITY TO HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some persons who have been exposed to HIV remain uninfected. In some high-risk cohorts, a 32-base pair deletion in the chemokine receptor 5 (CCR5) gene, which results in failure to express this coreceptor on the cell surface, is associated with high-level protection from HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/112\">",
"     112",
"    </a>",
"    ]. Other potential protection may be afforded by decreased susceptibility of peripheral blood mononuclear cells, low levels of CD4 T cell activation, and cellular restriction of viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC BENEFITS OF ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of ART on restoration of the immune system can be seen in the setting of acute and chronic infection.",
"   </p>",
"   <p>",
"    The initiation of ART in individuals with acute infection results in the restoration of HIV-specific T helper cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/41,51\">",
"     41,51",
"    </a>",
"    ]. This suggests that rapid reduction of replicating virus during acute HIV infection allows for the survival of the cellular immune response; however, not all patients have obtained benefit from early initiation of treatment. One determinant of the response is the DRB1*13 haplotype of class II alleles. In a small study, all seven patients with this haplotype maintained virus suppression throughout treatment; such a response was seen in only 3 of 14 patients without this haplotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initiation of ART in early infection has also been associated with better recovery of B cell function and changes in B cell subpopulations favoring increases in na&iuml;ve and resting memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During chronic untreated HIV infection, there is an intimate link between HIV RNA increases and CD4 cell count declines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/116\">",
"     116",
"    </a>",
"    ], whereas reduction of viral replication with ART is associated with improved cellular immunity. The frequency of HIV-specific CD4 and CD8 T cells is higher in treated patients with low level viremia (detectable but less than 10,000 RNA",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    compared to subjects on therapy with viral loads greater than 10,000 RNA",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Uncommonly, declining CD4 T cells are seen despite viral suppression on antiretroviral therapy. This failure to reconstitute T cells may depend on several factors including the CD4 count, disease stage, and degree of T cell activation prior to initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. It may also be impacted by the degree to which the lymph nodes had been damaged, as was suggested by a case series that found significant fibrosis of the T cell zone of lymphoid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9401250\">",
"    <span class=\"h1\">",
"     LATENT RESERVOIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the presence of potent antiretroviral therapy, HIV-1 RNA can be detected using ultrasensitive assays. One of the sources of this residual viremia is the latent viral reservoir, which is established during acute HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/122\">",
"     122",
"    </a>",
"    ]. The latent reservoir consists of long-lived infected cells or cells that harbor non-replicating virus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/123\">",
"     123",
"    </a>",
"    ]. Despite the fact that treatment does not eradicate HIV infection, viral evolution is constrained by potent antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/124\">",
"     124",
"    </a>",
"    ]. Understanding how the viral reservoir is maintained and contributes to low-level viremia has been the focus of intense research. In vitro data have demonstrated that while potent antiretroviral medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , are effective against cell-free virus, these same drugs are minimally potent against infections involving cell-to-cell spread [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/125\">",
"     125",
"    </a>",
"    ]. Thus, cell-to-cell spread of HIV may be one mechanism to explain viral persistence despite potent therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     HIV SUPERINFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Implications for host immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduction of infection with another strain of HIV following containment of the first is called \"superinfection\" and has been described in experimental animals and in several well-documented case reports in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/126-131\">",
"     126-131",
"    </a>",
"    ]. The frequency of superinfection is unknown. In a cohort of 20 women from Kenya infected with subtype C or D virus, subtype A superinfection was diagnosed in three, suggesting that the barrier to reinfection may be relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of superinfection may be highest during primary HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/126\">",
"     126",
"    </a>",
"    ]. In the macaque model, four of four animals challenged with HIV two weeks after their initial infection became superinfected. No macaques were susceptible to superinfection after eight weeks of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/133\">",
"     133",
"    </a>",
"    ]. In a human study, no evidence of superinfection was found in chronically infected injection drug users followed for &gt;215 person-years of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/134\">",
"     134",
"    </a>",
"    ]. These data suggest that there may be a narrow window of susceptibility when the immune response to HIV infection is immature and the individual is at risk for superinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical consequences of superinfection are still unclear, but may include a decline in CD4 cells, increased viremia, and accelerated disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. One study found that superinfection could occur despite robust CTL responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/130\">",
"     130",
"    </a>",
"    ]. Furthermore, CTL responses declined coincident with infection by a second strain and appeared to be related to differences in viral sequence between the two infecting strains. These results raise concerns regarding the ability of vaccination to induce fully protective immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HIV VACCINE DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Obstacles to vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vaccine that prevents HIV infection is considered to be the best strategy for containing the epidemic. However, there are many obstacles that must first be overcome. Designing an effective vaccine has been hampered by the fact that the virus is highly variable. This makes it difficult to design a vaccine that will protect against all forms of the virus. In the event that prevention is not achievable, it is hoped that immunization can boost T cell responses when HIV infection does occur. This strategy would hopefully blunt the initial burst of viremia and reduce the \"set point\" HIV RNA level, thereby prolonging the disease-free period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to develop a vaccine to prevent HIV infection have focused on eliciting humoral and cellular immune responses to block HIV acquisition and inhibit replication. A few of these large clinical trials are highlighted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     STEP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase IIb randomized, multicenter, double blind, placebo-controlled clinical study of an adenovirus-based HIV vaccine (containing HIV subtype B gag, pol and nef) was conducted in 3000 HIV-seronegative participants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/136\">",
"     136",
"    </a>",
"    ]. The primary objective was a reduction in HIV acquisition rates (tested every six months) or a decrease in HIV viral load set point (measured three months after diagnosis). The trial was halted since it failed to protect against infection or reduce early viremia in those who became infected, despite the presence of in vitro T-cell responses in those who were immunized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In post-hoc analyses, vaccination was associated with an increased risk of HIV acquisition in men with pre-existing immunity to adenovirus and in uncircumcised men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/137\">",
"     137",
"    </a>",
"    ]. Laboratory investigations demonstrated that the vaccine was highly immunogenic in patients who did or did not acquire HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/138\">",
"     138",
"    </a>",
"    ]. Ongoing studies will analyze other potential mechanisms to explain these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Thailand trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized multicenter, double-blind, placebo-controlled efficacy trial was performed in Thailand among 16,000 persons at low or moderate risk of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/139\">",
"     139",
"    </a>",
"    ]. Four priming injections of a recombinant canarypox vector vaccine (ALVAC) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX) were administered. HIV infection was diagnosed in 56 patients in the vaccine group and 76 patients in the placebo group.",
"   </p>",
"   <p>",
"    In the intention-to-treat analysis, there was a trend toward the prevention of HIV infection among the vaccine recipients. In the modified intention-to-treat analysis, which excluded the seven subjects who were found to be HIV-infected at enrollment, vaccine efficacy was 31 percent. Vaccination did not decrease the level of viremia or improve the CD4 cell count in patients who did acquire infection.",
"   </p>",
"   <p>",
"    The trial suggests a modest protective effect of this prime-boost vaccination strategy among persons whose main risk factor for HIV acquisition was heterosexual sex. Vaccine efficacy was lower among those at high risk for HIV infection (eg, men who have sex with men (MSM) and injection drug users).",
"   </p>",
"   <p>",
"    In a case-control analysis to identify the immune correlates of protection, it was shown that vaccine-induced IgG antibodies specific to the HIV envelope protein inversely correlated with infection, while vaccine-induced envelope-specific IgA responses were associated with an increased risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/34/5674/abstract/140\">",
"     140",
"    </a>",
"    ]. Although these results do not prove causality and must be confirmed, they do suggest that the generation of envelope-specific IgG antibodies may be an important component in the design of future vaccine candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most chronic viral infections, both virus-specific T helper cells (TH) and cytotoxic T lymphocytes (CTL) are required to effectively eliminate an infected cell. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adaptive immune responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark of HIV infection is the progressive loss of activated CD4 cells and the onset of immunodeficiency. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adaptive immune responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During initial infection, the emergence of HIV-specific CTL responses is important for initial viral control. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adaptive immune responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lack of protective immunity in chronic infection is likely a result of multiple mechanisms that the virus uses to evade the host immune response.",
"     </li>",
"     <li>",
"      Certain HLA haplotypes influence the rate of disease progression. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Host determinants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral entry is dependent on the binding of the viral envelope protein, gp120, to CD4 and a chemokine co-receptor, either CCR5 or CXCR4. Individuals who are homozygous for a thirty-two base pair deletion in the CCR5 gene are more resistant to infection and individuals heterozygous for this deletion tend to have slower rates of disease progression. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Host determinants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of superinfection with a second strain of HIV suggests that immunity to the virus is incomplete and raises concerns about the ability to generate an effective vaccine. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'HIV superinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Destruction of the cellular immune system is inevitable in the vast majority of patients. The introduction of antiretroviral therapy leads to immune restoration. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Immunologic benefits of ART'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/1\">",
"      Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997; 276:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/2\">",
"      Rucker J, Doms RW. Chemokine receptors as HIV coreceptors: implications and interactions. AIDS Res Hum Retroviruses 1998; 14 Suppl 3:S241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/3\">",
"      Roos MT, Lange JM, de Goede RE, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/4\">",
"      Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/5\">",
"      Farrell A. Defeating T-cell fatigue in HIV. Nat Med 2006; 12:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/6\">",
"      Sauce D, Almeida JR, Larsen M, et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007; 21:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/7\">",
"      Becker Y. \"HIV-peplotion vaccine\"--a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review). Acta Microbiol Immunol Hung 1996; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/8\">",
"      Bachmann MF, Lutz MB, Layton GT, et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996; 26:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/9\">",
"      Fan Z, Huang XL, Zheng L, et al. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J Immunol 1997; 159:4973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/10\">",
"      Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol 1993; 5:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/11\">",
"      Peshwa MV, Benike C, Dupuis M, et al. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell Transplant 1998; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/12\">",
"      Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 1994; 153:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/13\">",
"      Macatonia SE, Patterson S, Knight SC. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 1991; 74:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/14\">",
"      Blauvelt A. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Am J Med 1997; 102:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/15\">",
"      Rowland-Jones SL. HIV: The deadly passenger in dendritic cells. Curr Biol 1999; 9:R248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/16\">",
"      Grouard G, Clark EA. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis. Curr Opin Immunol 1997; 9:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/17\">",
"      Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/18\">",
"      Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115:3265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/19\">",
"      Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007; 81:8180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/20\">",
"      Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/21\">",
"      Cooper MA, Fehniger TA, Fuchs A, et al. NK cell and DC interactions. Trends Immunol 2004; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/22\">",
"      Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 2:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/23\">",
"      Lanier LL. On guard--activating NK cell receptors. Nat Immunol 2001; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/24\">",
"      Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007; 195:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/25\">",
"      Brenner BG, Dascal A, Margolese RG, Wainberg MA. Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol 1989; 46:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/26\">",
"      Bonaparte MI, Barker E. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 2003; 17:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/27\">",
"      Bonaparte MI, Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 2004; 104:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/28\">",
"      Tasca S, Tambussi G, Nozza S, et al. Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. AIDS 2003; 17:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/29\">",
"      Kottilil S, Jackson JO, Reitano KN, et al. Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 2007; 46:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/30\">",
"      Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985; 134:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/31\">",
"      Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/32\">",
"      Ahmad A, Menezes J. Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals. AIDS 1996; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/33\">",
"      Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/34\">",
"      Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/35\">",
"      Tiemessen CT, Shalekoff S, Meddows-Taylor S, et al. Natural killer cells that respond to human immunodeficiency virus type 1 (HIV���1) peptides are associated with control of HIV���1 infection. J Infect Dis 2010; 202:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/36\">",
"      Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/37\">",
"      Johnston MI, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med 2007; 356:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/38\">",
"      Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/39\">",
"      Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/40\">",
"      Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/41\">",
"      Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/42\">",
"      Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73:6715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/43\">",
"      Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/44\">",
"      Lane HC, Fauci AS. Immunologic reconstitution in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/45\">",
"      Wahren B, Morfeldt-M&aring;nsson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987; 61:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/46\">",
"      Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988; 82:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/47\">",
"      Pontesilli O, Carlesimo M, Varani AR, et al. In vitro lymphocyte proliferative response to HIV-1 p24 is associated with a lack of CD4+ cell decline. AIDS Res Hum Retroviruses 1994; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/48\">",
"      Schwartz D, Sharma U, Busch M, et al. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses 1994; 10:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/49\">",
"      Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69:5838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/50\">",
"      Hay CM, Ruhl DJ, Basgoz NO, et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol 1999; 73:5509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/51\">",
"      Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/52\">",
"      Walker BD, Flexner C, Paradis TJ, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988; 240:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/53\">",
"      Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/54\">",
"      Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/55\">",
"      Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/56\">",
"      Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/57\">",
"      Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/58\">",
"      Wagner R, Shao Y, Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine 1999; 17:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/59\">",
"      Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/60\">",
"      Lubaki NM, Shepherd ME, Brookmeyer RS, et al. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. J Acquir Immune Defic Syndr 1999; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/61\">",
"      Greenough TC, Brettler DB, Kirchhoff F, et al. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J Infect Dis 1999; 180:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/62\">",
"      Gamberg JC, Bowmer MI, Trahey JC, et al. Functional and genetic integrity of the CD8 T-cell repertoire in advanced HIV infection. AIDS 1999; 13:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/63\">",
"      Gehri R, Hahn S, Rothen M, et al. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS 1996; 10:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/64\">",
"      Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999; 93:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/65\">",
"      Haas G, Hosmalin A, Hadida F, et al. Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors. Immunol Lett 1997; 57:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/66\">",
"      Gould KG, Bangham CR. Virus variation, escape from cytotoxic T lymphocytes and human retroviral persistence. Semin Cell Dev Biol 1998; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/67\">",
"      Goulder P, Price D, Nowak M, et al. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev 1997; 159:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/68\">",
"      Goulder PJ, Walker BD. The great escape - AIDS viruses and immune control. Nat Med 1999; 5:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/69\">",
"      Brander C, Hartman KE, Trocha AK, et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998; 101:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/70\">",
"      Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/71\">",
"      Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/72\">",
"      Lathey JL, Tsou J, Brinker K, et al. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 1999; 180:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/73\">",
"      Ferrantelli F, Kitabwalla M, Rasmussen RA, et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2004; 189:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/74\">",
"      Lopalco L, Pastori C, Cosma A, et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/75\">",
"      Mazzoli S, Lopalco L, Salvi A, et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/76\">",
"      Mascola JR, Louder MK, VanCott TC, et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71:7198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/77\">",
"      Cecilia D, Kleeberger C, Mu&ntilde;oz A, et al. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 1999; 179:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/78\">",
"      Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/79\">",
"      Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/80\">",
"      Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/81\">",
"      Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/82\">",
"      Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/83\">",
"      Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/84\">",
"      Tsunemi S, Iwasaki T, Imado T, et al. Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005; 19:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/85\">",
"      Montes M, Lewis DE, Sanchez C, et al. Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. AIDS 2006; 20:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/86\">",
"      Gaardbo JC, Nielsen SD, Vedel SJ, et al. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy. Clin Exp Immunol 2008; 154:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/87\">",
"      Prendergast A, Prado JG, Kang YH, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/88\">",
"      Favre D, Lederer S, Kanwar B, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009; 5:e1000295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/89\">",
"      Ndhlovu LC, Loo CP, Spotts G, et al. FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 2008; 83:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/90\">",
"      Tenorio AR, Martinson J, Pollard D, et al. The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr 2008; 48:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/91\">",
"      Jiao Y, Fu J, Xing S, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology 2009; 128:e366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/92\">",
"      Kinter AL, Horak R, Sion M, et al. CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses 2007; 23:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/93\">",
"      Hunt PW. Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS 2010; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/94\">",
"      Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/95\">",
"      Walli R, Reinhart B, Luckow B, et al. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/96\">",
"      Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/97\">",
"      Pelak K, Goldstein DB, Walley NM, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010; 201:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/98\">",
"      Klein MR, van der Burg SH, Hovenkamp E, et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol 1998; 79 ( Pt 9):2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/99\">",
"      Kelleher AD, Long C, Holmes EC, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/100\">",
"      Bansal A, Yue L, Conway J, et al. Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. AIDS 2007; 21:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/101\">",
"      Streeck H, Lichterfeld M, Alter G, et al. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol 2007; 81:7725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/102\">",
"      Itescu S, Mathur-Wagh U, Skovron ML, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/103\">",
"      Klein MR, Keet IP, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994; 169:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/104\">",
"      Scorza Smeraldi R, Fabio G, Lazzarin A, et al. HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts. Hum Immunol 1988; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/105\">",
"      Itescu S, Rose S, Dwyer E, Winchester R. Grouping HLA-B locus serologic specificities according to shared structural motifs suggests that different peptide-anchoring pockets may have contrasting influences on the course of HIV-1 infection. Hum Immunol 1995; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/106\">",
"      Scherer A, Frater J, Oxenius A, et al. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci U S A 2004; 101:12266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/107\">",
"      Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/108\">",
"      Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/109\">",
"      Boulet S, Kleyman M, Kim JY, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/110\">",
"      Long BR, Ndhlovu LC, Oksenberg JR, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008; 82:4785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/111\">",
"      Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/112\">",
"      Lederman MM, Alter G, Daskalakis DC, et al. Determinants of protection among HIV���exposed seronegative persons: an overview. J Infect Dis 2010; 202 Suppl 3:S333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/113\">",
"      Pancino G, Saez-Cirion A, Scott-Algara D, Paul P. Natural resistance to HIV infection: lessons learned from HIV���exposed uninfected individuals. J Infect Dis 2010; 202 Suppl 3:S345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/114\">",
"      Malhotra U, Holte S, Dutta S, et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001; 107:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/115\">",
"      Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116:5571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/116\">",
"      Phillips AN, Lampe FC, Smith CJ, et al. Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. AIDS 2010; 24:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/117\">",
"      Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/118\">",
"      Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/119\">",
"      Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006; 8:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/120\">",
"      Massanella M, Negredo E, P&eacute;rez-Alvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010; 24:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/121\">",
"      Nies-Kraske E, Schacker TW, Condoluci D, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009; 199:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/122\">",
"      Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/123\">",
"      Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/124\">",
"      Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/125\">",
"      Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/126\">",
"      Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/127\">",
"      Blick G, Kagan RM, Coakley E, et al. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 2007; 195:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/128\">",
"      Jost S, Bernard MC, Kaiser L, et al. A patient with HIV-1 superinfection. N Engl J Med 2002; 347:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/129\">",
"      van der Kuyl AC, Kozaczynska K, van den Burg R, et al. Triple HIV-1 infection. N Engl J Med 2005; 352:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/130\">",
"      Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/131\">",
"      Gottlieb GS, Nickle DC, Jensen MA, et al. HIV type 1 superinfection with a dual-tropic virus and rapid progression to AIDS: a case report. Clin Infect Dis 2007; 45:501.",
"     </a>",
"    </li>",
"    <li>",
"     Chohan B, Lavreys L, Rainwater S, et al. The biology of HIV-1 transmission and re-infection. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/133\">",
"      Otten RA, Ellenberger DL, Adams DR, et al. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis 1999; 180:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/134\">",
"      Tsui R, Herring BL, Barbour JD, et al. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 2004; 78:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/135\">",
"      Johnston MI, Fauci AS. An HIV vaccine--challenges and prospects. N Engl J Med 2008; 359:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/136\">",
"      Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881.",
"     </a>",
"    </li>",
"    <li>",
"     Robertson M, Mehrotra D, Fitzgerald D, et al. Efficacy results from the STEP Study: A phase II Test of Concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #88LB.",
"    </li>",
"    <li>",
"     Robertson M, Casimiro D, De Rosa S, et al. Immunological characterization of subjects from the STEP Study: a phase IIB test of Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #89LB.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/139\">",
"      Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/34/5674/abstract/140\">",
"      Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3707 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5674=[""].join("\n");
var outline_f5_34_5674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOSSARY OF TERMS AND CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CCR5 and CXCR4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      R5 viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      X4 viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dual tropic viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Syncytia-formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-syncytia inducing virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Syncytium-inducing (SI) viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Macrophage inflammatory protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Regulated on activation, normal T cell expressed and secreted chemokine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stromal cell-derived factor type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Programmed death-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      T-cell anergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INNATE IMMUNE RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dendritic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Toll-like receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Natural killer cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADAPTIVE IMMUNE RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CD4 T-helper cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cytotoxic T lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Humoral immune responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immune activation and regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      HOST DETERMINANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Polymorphisms in chemokine receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      HLA background",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28456149\">",
"      NATURAL IMMUNITY TO HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      IMMUNOLOGIC BENEFITS OF ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9401250\">",
"      LATENT RESERVOIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      HIV SUPERINFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Implications for host immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HIV VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Obstacles to vaccine development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - STEP trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Thailand trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_34_5675="PCN skin test reagents";
var content_f5_34_5675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Penicillin skin test reagents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reagent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration used for skin testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicilloyl-polylysine (Pre-Pen)",
"       </td>",
"       <td>",
"        6 x 10",
"        <sup>",
"         -5",
"        </sup>",
"        M",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin G",
"       </td>",
"       <td>",
"        10,000 units/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicilloate",
"       </td>",
"       <td>",
"        0.01 M",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penilloate",
"       </td>",
"       <td>",
"        0.01 M",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin/amoxicillin",
"       </td>",
"       <td>",
"        3-25 mg/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Commonly used penicillin skin test reagents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5675=[""].join("\n");
var outline_f5_34_5675=null;
var title_f5_34_5676="Retiform purpura histopathology";
var content_f5_34_5676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinicopathological correlation for retiform purpura",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histopathological finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombi in vessels with no inflammation or minimal inflammation",
"       </td>",
"       <td>",
"        APS, DIC, WISN, TTP, HIT, cryofibrinogenemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prominent thrombosis with neutrophilic inflammation",
"       </td>",
"       <td>",
"        Septic emboli, bacterial endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory changes demonstrating:",
"        <br/>",
"        <ul>",
"         <li>",
"          Inflammatory invasion of vessel walls",
"         </li>",
"         <li>",
"          Fibrinoid necrosis",
"         </li>",
"         <li>",
"          Endothelial swelling",
"         </li>",
"         <li>",
"          Leukocytoclasis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Small and medium vessel vasculitides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic plugging of small vessels",
"       </td>",
"       <td>",
"        Type 1 cryoglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol clefts and fibrin clots in vessels",
"       </td>",
"       <td>",
"        Cholesterol emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vessel wall calcification",
"       </td>",
"       <td>",
"        Calciphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrin in vessel walls and vessel lumina",
"       </td>",
"       <td>",
"        Livedoid vasculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myxomatous tissue plugging of vessels",
"       </td>",
"       <td>",
"        Atrial myxoma embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium and crystal deposition in vessel walls",
"       </td>",
"       <td>",
"        Oxalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-specific inflammation with variable vascular involvement",
"       </td>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     APS: antiphospholipid syndrome; DIC: disseminated intravascular coagulation; WISN: warfarin-induced skin necrosis; TTP: thrombotic thrombocytopenic purpura; HIT: heparin-induced thrombocytopenia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5676=[""].join("\n");
var outline_f5_34_5676=null;
var title_f5_34_5677="Knodell score";
var content_f5_34_5677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Knodell score (HAI score) of liver biopsy specimens for necrosis, inflammation, and fibrosis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        I. Periportal &plusmn; bridging necrosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        II. Intralobular degeneration and focal necrosis&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        III. Portal inflammation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        IV. Fibrosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No portal inflammation",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No fibrosis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild piecemeal necrosis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Mild (acidophilic bodies, ballooning degeneration and/or scattered",
"foci of hepatocellular necrosis in &lt; 1/3 of lobules or nodules",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Mild (sprinkling of inflammatory cells in &lt;1/3 of portal tracts)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Fibrous portal expansion",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate piecemeal necrosis (involves less than 50 percent of the circumference of most portal tracts)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate (involvement of 1/3 to 2/3 of lobules or nodules)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate (increased inflammatory cells in 1/3 to 2/3 of portal tracts)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Bridging fiborisis (portal-portal or portal- central linkage)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked piecemeal necrosis (involves more than 50 percent of the circumference of most portal tracts)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Marked (involvement of &gt;2/3 of lobules or nodules)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Marked (dense packing of inflammatory cells in &gt;2/3 of portal tracts)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Cirrhosis&Delta;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate piecemeal necrosis plus bridging necrosis &loz;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked piecemeal necrosis plus bridging necrosis &loz;",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multilobular necrosis &sect;",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * HAI score is the combined scores for necrosis, inflammation, and fibrosis.",
"     <br>",
"      &bull; Degeneration-acidophilic bodies, ballooning; focal necrosis-scattered foci of hepatocellular necrosis.",
"      <br>",
"       &Delta; Loss of normal hepatic lobular architecture with fibrous septae separating and surrounding nodules.",
"       <br>",
"        &loz; Bridging is defined as &ge;2 bridges in the liver biopsy specimen; no distinction is made between portal-portal and portal-central linkage.",
"        <br>",
"         &sect; Two or more contiguous lobules with panlobular necrosis.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Knodell, RG, et al. Hepatology 1981; 1:431.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5677=[""].join("\n");
var outline_f5_34_5677=null;
var title_f5_34_5678="HR dobut rMPI";
var content_f5_34_5678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impact of achieved heart rate during dobutamine MPI upon outcomes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Navare SM, Katten D, Johnson LL, et al. Risk stratification with electrocardiographic-gated dobutamine stress technetium-99m sestamibi single-photon emission tomographic imaging: Value of heart rate response and assessment of left ventricular function. J Am Coll Cardiol 2006; 47:781. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5678=[""].join("\n");
var outline_f5_34_5678=null;
var title_f5_34_5679="Normal hematologic values";
var content_f5_34_5679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemoglobin, hematocrit, red blood cells, mean corpuscular volume, and white blood cells in children 1-14 years of age, by age group and sex: the Third National Health and Nutrition Examination Survey (1988-91)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Male* (n=5070)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Female* (n=5175)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle2\">",
"        SD",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        95% CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle2\">",
"        SD",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        95% CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Hemoglobin, g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-2 years",
"       </td>",
"       <td>",
"        12.01",
"       </td>",
"       <td>",
"        0.82",
"       </td>",
"       <td>",
"        10.37",
"       </td>",
"       <td>",
"        13.65",
"       </td>",
"       <td>",
"        12.02",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"       <td>",
"        10.42",
"       </td>",
"       <td>",
"        13.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-5 years",
"       </td>",
"       <td>",
"        12.35",
"       </td>",
"       <td>",
"        0.77",
"       </td>",
"       <td>",
"        10.81",
"       </td>",
"       <td>",
"        13.89",
"       </td>",
"       <td>",
"        12.39",
"       </td>",
"       <td>",
"        0.77",
"       </td>",
"       <td>",
"        10.85",
"       </td>",
"       <td>",
"        13.93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-8 years",
"       </td>",
"       <td>",
"        12.88",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"       <td>",
"        11.28",
"       </td>",
"       <td>",
"        14.48",
"       </td>",
"       <td>",
"        12.82",
"       </td>",
"       <td>",
"        0.77",
"       </td>",
"       <td>",
"        11.28",
"       </td>",
"       <td>",
"        14.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-11 years",
"       </td>",
"       <td>",
"        13.28",
"       </td>",
"       <td>",
"        0.84",
"       </td>",
"       <td>",
"        11.60",
"       </td>",
"       <td>",
"        14.96",
"       </td>",
"       <td>",
"        13.10",
"       </td>",
"       <td>",
"        0.78",
"       </td>",
"       <td>",
"        11.54",
"       </td>",
"       <td>",
"        14.66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12-14 years",
"       </td>",
"       <td>",
"        14.14",
"       </td>",
"       <td>",
"        1.08",
"       </td>",
"       <td>",
"        11.98",
"       </td>",
"       <td>",
"        16.30",
"       </td>",
"       <td>",
"        13.29",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        11.29",
"       </td>",
"       <td>",
"        15.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19 years",
"       </td>",
"       <td>",
"        15.07",
"       </td>",
"       <td>",
"        1.03",
"       </td>",
"       <td>",
"        13.01",
"       </td>",
"       <td>",
"        17.13",
"       </td>",
"       <td>",
"        13.15",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        11.15",
"       </td>",
"       <td>",
"        15.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Hematocrit, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-2 years",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-5 years",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-8 years",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-11 years",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12-14 years",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19 years",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Red blood cells, 10",
"        <sup>",
"         12",
"        </sup>",
"        cells per liter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-2 years",
"       </td>",
"       <td>",
"        4.55",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        3.87",
"       </td>",
"       <td>",
"        5.23",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        3.82",
"       </td>",
"       <td>",
"        5.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-5 years",
"       </td>",
"       <td>",
"        4.51",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        3.83",
"       </td>",
"       <td>",
"        5.19",
"       </td>",
"       <td>",
"        4.49",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"       <td>",
"        3.85",
"       </td>",
"       <td>",
"        5.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-8 years",
"       </td>",
"       <td>",
"        4.60",
"       </td>",
"       <td>",
"        0.29",
"       </td>",
"       <td>",
"        4.02",
"       </td>",
"       <td>",
"        5.18",
"       </td>",
"       <td>",
"        4.56",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        3.94",
"       </td>",
"       <td>",
"        5.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-11 years",
"       </td>",
"       <td>",
"        4.71",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"       <td>",
"        4.07",
"       </td>",
"       <td>",
"        5.35",
"       </td>",
"       <td>",
"        4.62",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        4.02",
"       </td>",
"       <td>",
"        5.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12-14 years",
"       </td>",
"       <td>",
"        4.93",
"       </td>",
"       <td>",
"        0.39",
"       </td>",
"       <td>",
"        4.15",
"       </td>",
"       <td>",
"        5.71",
"       </td>",
"       <td>",
"        4.59",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"       <td>",
"        3.95",
"       </td>",
"       <td>",
"        5.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19 years",
"       </td>",
"       <td>",
"        5.06",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"       <td>",
"        4.32",
"       </td>",
"       <td>",
"        5.80",
"       </td>",
"       <td>",
"        4.47",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        3.77",
"       </td>",
"       <td>",
"        5.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Mean corpuscular volume (femtoliters)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-2 years",
"       </td>",
"       <td>",
"        79.2",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        70.2",
"       </td>",
"       <td>",
"        88.2",
"       </td>",
"       <td>",
"        79.8",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        70.8",
"       </td>",
"       <td>",
"        88.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-5 years",
"       </td>",
"       <td>",
"        81.8",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        73.2",
"       </td>",
"       <td>",
"        90.4",
"       </td>",
"       <td>",
"        82.3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        74.3",
"       </td>",
"       <td>",
"        90.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-8 years",
"       </td>",
"       <td>",
"        83.2",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        75.2",
"       </td>",
"       <td>",
"        91.2",
"       </td>",
"       <td>",
"        83.6",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        76.4",
"       </td>",
"       <td>",
"        90.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-11 years",
"       </td>",
"       <td>",
"        83.9",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        76.5",
"       </td>",
"       <td>",
"        91.3",
"       </td>",
"       <td>",
"        84.2",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        76.4",
"       </td>",
"       <td>",
"        92.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12-14 years",
"       </td>",
"       <td>",
"        85.3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        77.3",
"       </td>",
"       <td>",
"        93.3",
"       </td>",
"       <td>",
"        86.2",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        77.8",
"       </td>",
"       <td>",
"        94.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19 years",
"       </td>",
"       <td>",
"        88.3",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        80.5",
"       </td>",
"       <td>",
"        96.1",
"       </td>",
"       <td>",
"        87.8",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"       <td>",
"        78.4",
"       </td>",
"       <td>",
"        97.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        White blood cells, 10",
"        <sup>",
"         9",
"        </sup>",
"        cells per liter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-2 years",
"       </td>",
"       <td>",
"        8.74",
"       </td>",
"       <td>",
"        2.53",
"       </td>",
"       <td>",
"        3.68",
"       </td>",
"       <td>",
"        13.80",
"       </td>",
"       <td>",
"        8.66",
"       </td>",
"       <td>",
"        2.41",
"       </td>",
"       <td>",
"        3.84",
"       </td>",
"       <td>",
"        13.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-5 years",
"       </td>",
"       <td>",
"        7.68",
"       </td>",
"       <td>",
"        2.26",
"       </td>",
"       <td>",
"        3.16",
"       </td>",
"       <td>",
"        12.20",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        2.12",
"       </td>",
"       <td>",
"        3.66",
"       </td>",
"       <td>",
"        12.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-8 years",
"       </td>",
"       <td>",
"        7.45",
"       </td>",
"       <td>",
"        2.02",
"       </td>",
"       <td>",
"        3.41",
"       </td>",
"       <td>",
"        11.49",
"       </td>",
"       <td>",
"        7.63",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"       <td>",
"        3.43",
"       </td>",
"       <td>",
"        11.83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-11 years",
"       </td>",
"       <td>",
"        7.01",
"       </td>",
"       <td>",
"        2.07",
"       </td>",
"       <td>",
"        2.87",
"       </td>",
"       <td>",
"        11.15",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"       <td>",
"        3.24",
"       </td>",
"       <td>",
"        11.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12-14 years",
"       </td>",
"       <td>",
"        7.02",
"       </td>",
"       <td>",
"        2.07",
"       </td>",
"       <td>",
"        2.88",
"       </td>",
"       <td>",
"        11.16",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        2.06",
"       </td>",
"       <td>",
"        3.18",
"       </td>",
"       <td>",
"        11.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19 years",
"       </td>",
"       <td>",
"        7.15",
"       </td>",
"       <td>",
"        2.11",
"       </td>",
"       <td>",
"        2.93",
"       </td>",
"       <td>",
"        11.37",
"       </td>",
"       <td>",
"        7.58",
"       </td>",
"       <td>",
"        2.18",
"       </td>",
"       <td>",
"        3.22",
"       </td>",
"       <td>",
"        11.94",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The 95% confidence interval (+/- 2 SD) defines the normal range, and corresponds to the 2.5th through 97.5th percentiles.",
"    <div class=\"footnotes\">",
"     SD: standard deviation; 95% CI: 95 percent confidence interval.",
"     <br>",
"      * Includes all race/ethnic groups.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hollowell JG, van Assendelft OW, Gunter EW, et al. Hematological and iron-related analytes-reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 2005; 11:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_34_5679=[""].join("\n");
var outline_f5_34_5679=null;
